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In vitro activities of six fluoroquinolone antimicrobials, flumequine,
sarafloxacin, PD127,391, PD117,596, enrofloxacin andRo 09-1690, against
Aeromonas salmonicida, isolated from outbreaks of furunculosis in farmed
and wild Atlantic salmon (salmo salar), were evaluated in terms of
minimum inhibitory concentration (MIC), bactericidal activity and the
frequency at which mutation to resistance developed to the drugs compared
to oxolinic acid, the4-quinolone antibiotic currently licensed for furunculosis
therapy in the UK. MICs were also determined for oxytetracycline and the
B-lactam amoxycillin.
In terms ofMIC, the fluoroquinolones were more active than oxolinic acid
with MICs reduced from 2- to 500-fold. Furthermore, the fluoroquinolones
were bactericidal against both oxolinic acid-resistant and -susceptible
isolates ofA.salmonicida whereas oxolinic acidwas notbactericidal against
any bacteria tested. In addition to the increased antimicrobial activity, the
frequency at which A.salmonicida mutated to resistance to the
fluoroquinolones was lower than the frequency for resistance to oxolinic
acid. Amoxycillin was active against all the A.salmonicida subsp.
salmonicida isolates tested; however, the atypical A.salmonicida subsp.
achromogenes isolates were resistant to amoxycillin with MICs in excess
of 500mg/l. Ion effects were noted for the quinolones and oxytetracycline.
For instance, the presence of 50mM MgCl2 resulted in a 20- to 60-fold
increase in theMICs of these drugs against the test strains. No ion effect was
identified for amoxycillin nor the components of Romet. The quinolones
were not affected by inoculum size but their efficacy, in terms ofMIC, was
reduced at the lower temperature of 10°C compared to 22°C.
Mechanisms of resistance to the fluoroquinolones, oxytetracycline and
amoxycillin were investigated. Low levels of resistance to the quinolones
and oxytetracycline could be induced with either oxolinic acid or
oxytetracycline, with each drug inducing cross resistance to the other. This
phenomenon was discovered to result from alterations in outer membrane
proteins, specifically the increase in expression of a 42kDa and a decrease
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in expression of a 37kDa protein. These two proteins were found to be non-
covalently associated with peptidoglycan suggesting they may function as
porins. It is suggested that high level resistance to quinolones inA.salmonicida
may be due to an alteration in the target enzyme,DNA gyrase. The high level
resistance to amoxycillin found in theA.salmonicida subsp. achromogenes
isolates resulted from the production of aB-lactamase enzyme. This enzyme
was inducible andprobably chromosomally expressed. Attempts tomobilise
the resistance gene were unsuccessful and plasmid curing experiments had
no effect on the amoxycillin MICs of the strains tested.
An experimental seawater infection challenge was developed that was
capable of inducing significant furunculosis mortalities in Atlantic salmon
smolts. The in vivo activity of the potentiated sulphonamide, Romet 30, was
investigated. Romet (15mg/kg/body wt/day) was effective in the control of
artificially induced outbreaks of furunculosis. Changes to the field unit at
Aultbeanecessitated aninvestigationinto disinfection ofundiluted seawater
with iodine. Iodine was bactericidal in undiluted seawater, killing 90% of
bacteria at normal pH (7.2), and 99% of bacteria at reduced pH (4.0).
However, this was insufficient to proceed with further in vivo infection
studies.
An alternative to efficacy studies requiring infection was developed. Fish
weremedicatedwith the quinolones oxolinic acid, flumequine, sarafloxacin,
enrofloxacin, and Ro 09-1168. Serum levels were determined, and the
bactericidal activities of these levels of antibiotic in serum were determined
against resistant and susceptible isolates of A.salmonicida. Levels of
antibiotic achieved in the fish were bacteriostatic against a resistant isolate
ofA.salmonicida, and, with the exception ofoxolinic acid, were bactericidal
against a susceptible isolate ofA.salmonicida.
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INTRODUCTION
1.1 FURUNCULOSIS IN SCOTLAND.
1.1.1. Atlantic Salmon Farming in Scotland. Commercial farming
ofAtlantic salmon (Salmo solar L.) in Scotland commenced in the early
1970s. Growth of the industry has been rapid, with 10,000 tonnes being
produced in 1985, increasing to 40,000 tonnes produced by around 360
registered sites in 1991 (SOAFD 1991).
The farming cycle ofAtlantic salmon varies considerably, but atypical cycle
may proceed as follows: Ova, from brood stock hen salmon, are collected
late in the year and fertilized. The eggs hatch in to alevins and develop into
FRESH r 1 SALT I HARVESTING
WATER hsillpl WATER ■ WINDOW
Figure 1. Farming Cycle of Atlantic Salmon in Scotland (source; SOAFD,
Aberdeen.)
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Figure 2. Outbreaks of Furunculosis in Farmed Salmonids Reported Between
1979 and 1989 (Source; SOAFD).
fry early the following spring. The parr are grown in fresh water tanks or
cages until they are ready for smolting. In most cases, this occurs in the late
spring of the following year when fish are one year of age (SI smolts),
although some fish may be ready for transfer to seawater within 6 months
(S1/2 smolts), while others do not smolt until the following year (S2 smolts).
During smoltification the fish undergo a series of physiological changes
which enable them to adapt to life in saltwater. Following transfer to sea, the
fish are grown in pens or cages. Typically, up to 60% of these fish may be
harvested and sold after one winter at sea. The remaining fish are kept at sea
for a further winter before harvesting. By this stage the mature salmon may
be 3-4 kilogrammes in weight (figure 1)
1.1.2. Scale of the Disease Problem. Farmed salmonids are susceptible to
a range of viral, bacterial and parasitic infections (Hastings 1988). Bacterial
diseases of fish have been reviewed in depth byAustin &Austin (1987). One
of themost economically damaging diseases to the Scottish salmon farming
industry in recent years, however, has been the bacterial disease, furunculosis.
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Number of Years % of Fish
Year Smolts Harvested Recovered
1984 3.6m 1985,1986 86.5
1985 5.6m 1986,1987 70.4
1986 6.6m 1987,1988 75.6
1987 12.9m 1988,1989 65.5
1988 20.9m 1989,1990 NA
Table 1. Survival of Smolts to Harvest (Source; SOAFD)
Over the last decade the prevalence ofthe furunculosis has increased rapidly,
with the number ofcases reported in farmed salmonids in seawaterescalating
from 11 in 1979 to 137 in 1989 (fig. 2). Furthermore, the percentage of
smolts recovered from production sites has decreased alarmingly over the
past 7 years, the losses resulting largely from disease mortalities (table 1).
1.1.3. Aeromonas salmonicida. Furunculosis is caused by the Gram-
negative, normally non-motile bacterium,Aeromonas salmonicida (Popoff,
1980) and has been reviewed by Austin & Austin, 1987. The species
A.salmonicida has been divided into 3 subspecies, namely; subsp.
achromogenes, subsp. masoucida and subsp. salmonicida (Popoff, 1980).
In addition to these subspecies, which can be differentiated by means of
biochemical and physiological characteristics, several unusual isolates have
been described (Austin & Austin, 1987). TypicalA.salmonicida produces a
water soluble brown diffusible pigment when grown on Tryptone Soy Agar
(TSA). Griffen et al. (1953) demonstrated that production of the pigment
was dependent upon the presence tyrosine and phenylanaline in the growth
medium, and this was confirmed by O'Leary (1956). Although the pigment
is similar in appearence to melanin, produced by several species of
Pseudomonas, Donlonera/. (1983) demonstrated thatpigment biosynthesis
from tyrosine differed substantially from from melanogenesis. Pigment
production provides a useful tool when identifying the organism; however,
non-pigmented strains of A.salmonicida occur. Furthermore, other
organisms produce similar brownpigments onTSA, includingA. hydrophila,
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A.media (Austin & Austin, 1987) and certain strains of Pseudomonas
fluorescens (Frerichs &Holliman, 1991). Interestingly, the brownpigmented
Ps.fluorescens also react with some commercially available antisera for
detection ofA.salmonicida. The two speciesmay, however, be distinguished
by incubation at 37°C (personal observations). Furunculosis in farmed
salmonids in Scotland is generally caused by typical A.salmonicida subsp.
salmonicida, although A.salmonicida subsp. achromogenes does cause
clinical outbreaks of the disease in wild fish in Scotland (T.Hastings
pers.comm), and has been reported to cause outbreaks in farmed salmon in
Finland (Rintamaki & Valtonen, 1991) and Canada (Harmon et al, 1991)
A variety of pathogenicity and virulence factors have been associated with
A.salmonicida. Munro (1984) divided these factors into two groups; cell-
associated components and extracellular components.
The most thoroughly studied cell-associated factor is an additional
proteinaceous layer surrounding the cell wall termed the A-layer (Udey &
Fryer, 1978). Sakai (1986) determined that theA-layerwas involved in auto-
agglutination, and adhesion to fish tissue culture cells. Sakai (1986) proposed
that the mechanism for auto-agglutination and adhesion was based on
electrical charge associated with the cell surface. Trust et al. (1980)
determined that theA-layer comprised a protein ofmolecular weight 50kDa
and Ishiguro et al. (1981) demonstrated that loss ofA-layer was associated
with reduced virulence. Ishigura et al. (1981) also provided evidence that
theA-layermay protectA.salmonicida from the action of bacteriophages by
shielding their binding sites. Further evidence for the role of theA-layerwas
provided by Munn & Trust (1984) who showed that virulent A.salmonicida
with A-layer was resistant to the bactericidal activity of both normal and
immune complement in rainbow trout (Oncorhynchusmykiss L.) serum. Trust
et al. (1983) reported that the A-layer also conferred hydrophobicity on the
organi sm, providing cellswith an enhanced ability to associate with rainbow
trout macrophages in the absence of opsonizing antibody. This increased
association with phagocytic monocytes may be advantageous to the cell as
Olivier et al., (1992) reported that A.salmonicida is cytotoxic to salmon
macrophages in ratios as low as <10:1. Although the authors were unable to
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correlate this with virulence, these observations coupled with resistance to
both immune and normal complement (Munn & Trust, 1984) leave the
salmon with few effective defences against furunculosis.
Extracellular virulence factors of A.salmonicida have recently been
reviewed by Ellis (1991). Many extracellular enzymes are produced by
A.salmonicida, two of which are known to be of prime importance in the
pathogenesis of the organism. The first, a 70KDa protease causes tissue
liquefaction and blood clotting, and has been demonstrated to have an LD50
of 2.4pg/g fish (Lee & Ellis, 1989). The second, a 25kDa phospholipase
(GCAT), is mainly present in a high molecular weight complex with
lipopolysaccharide (LPS), and the complex is haemolytic for fish erythrocytes
(Lee & Ellis, 1990). A further extracellular product (ECP) demonstrating
proteolytic activity was identified by Sheeran & Smith (1981). This protease
conferred casein hydrolysing activity, and activity against gelatin and
collagen.
1.1.5. Clinical Furunculosis. The disease is named after the raised
liquefactivemuscle lesions (furuncles)which sometimes occur inchronically
infected fish, though these lesions are rarely seen in acute infections which
are characterised by a rapid fatal septicaemia (McCarthy & Roberts, 1980).
Some devastating epizootics have been recorded in wild fish populations
(Mackieetal., 1930,1933, 1935) but the major impact in recent years has
been on farmed salmon (Hastings, 1988).
Most if not all species of salmonid fish may be affected by furunculosis,
though some species seem to bemore susceptible than others (Cipriano, 1983).
For example, Atlantic salmon and brown trout (Salrno trutta L.)are highly
susceptible whereas some strains of rainbow trout seem to be remarkably
resistant to the disease (Cipriano, 1983).
The clinical signs of furunculosis are somewhat variable depending on the
form of the disease, but affected fish often show lethargy, loss ofappetite and
darkening of the skin (Austin & Austin, 1987). Haemorrhaging may occur
at the base ofthe fins and in the abdominalwalls, heart and liver. Enlargement
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of the spleen and inflammation of the lower intestine are common features
of chronic infections, but in acute cases mortalities occur rapidly with few
external symptoms (McCarthy & Roberts, 1980; Austin & Austin, 1987).
Furunculosis is primarily adisease ofrising and elevatedwater temperatures,
nevertheless, mortalities can occur at temperatures as low as 4-6°C. The risk
of disease is especially high if fish are overcrowded, but outbreaks can
precipitate by the stressful nature of intensive fish rearing, particularly
during handling, grading, transporting or following transfer of smolts to salt
water (Hastings, 1988).
Transmission of furunculosis is normally lateral, via infected fish or
contaminated water (Austin & Austin, 1987). AlthoughA. salmonicida has
been isolated from the gonads of infected fish, attempts to demonstrate
vertical transmission have generally been unsuccessful (McCarthy, 1977).
Whether A. salmonicida is able to survive in the surface waters has been
argued formany years. Indeed, by definition, the organism is an obligate fish
pathogen, not surviving in the surface waters (Popoff, 1980). However,
alternative studies have revealed the contrary (Michel & Dubois-
Darnaudpeys, 1980; Allen-Austin et. al., 1984; Austin & Austin, 1987). The
length of time A.salmonicida resides in the water is likely to depend on
factors such as water temperature, nutrient levels and the presence of other
bacteria (Allen-Austin et al., 1984). Some studies have shown that the
organism may remain viable for several weeks in both fresh and salt water
(Austin & Austin, 1987), and for many months in river sediments (Michel
& Dubois-Darnaudpeys, 1980). The normal routes of infection into the fish
are also uncertain, infection through the gastrointestinal tract, skin or gills
being possible (Hodgkinson, Bucke & Austin, 1987).
1.1.5. Asymptomatic Furunculosis. A. salmonicida may be harboured in
the fish with no symptoms of disease being evident. These asymptomatic
carriers were first recognized by Plehn (1911) who demonstrated that
artificially infected carrier fish could be infective for healthy fish. Mackie
et al (1930) considered the carrier state to be incubatory and that the disease
would subsequently develop.
Introduction 7
Carrier fish, which may be present in both farmed and wild populations, can
transmit infection to other fish or succumb themselves to the disease when
stressed (Bullock & Stuckey, 1975; McCarthy, 1977). How the bacterium is
harboured in the fish during the carrier state is poorly understood.
Bacteriological sampling of various organs revealed that the organism was
most frequently isolated from the kidney of carrier fish (McDermott &
Berst, 1968).McCarthy (1977) investigated the site ofcarriage offurunculosis
and concluded that the kidney was the primary site, but that the organism
could also be detected in the gut. However, a recent report (Cipriano, 1992)
has demonstrated that A.salmonicida is more frequently isolated from the
mucus on the external surface of the fish than from the kidney. This is
supportedby the observations of the SOAFD staff (T. Hastings, pers.comm.).
Detection of carrier fish is problematic as bacterial numbers can be very low
and their presence is rarely revealed by conventional bacteriological
techniques (Hastings, 1988). It was not until 1975 that Bullock & Stuckey
reported more sensitive method of detecting carriers. This technique was
based on intramuscular (IM) injection ofa corticosteroid and thermal stress.
Fish were injected with triamcinolone acetonide and the water temperature
was raised form 12.5 to 18°C. McCarthy (1977), in a comparative study of
corticosteroids, found that prednisolone acetate was most effective at
activating asymptomatic furunculosis.
Further methods of detectingA.salmonicida have been investigated. Austin
et al. (1986) developed a monoclonal antibody-based enzyme-linked
immunosorbent assay (ELISA) for the detection of A.salmonicida.
However, this group found that their system could only detect >104 cfu.
Furthermore, this technique still required killing the fish. Further ELISA
systems have been investigated with similar observations (Bernoth, 1990).
More sensitive means of detection involve amplification of fragments of
A.salmonicida DNA using specific probes and polymerase chain reaction
(PCR) technology. Hiney et al. (1992) reported that their system could
detect two A.salmonicida cells. Although such technology may be difficult
to apply to carrier detection, it has ben used to characterize A.salmonicida
isolates (Henniganefa/., 1989), andmay prove useful in identifying habitats
and routes of transmission/infection ofA.salmonicida (Hiney et al., 1992).
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The only non-lethal mode of carrier detection would appear to be by
bacteriological sampling of external mucosa, based on the observations of
Cipriano et al. (1992). However, the detection rate of this method has yet to
be determined.
1.1.6. Control of Furunculosis. Furunculosis control has recently been
reviewed by Munro & Hastings (1992). Potential means of control may
include vaccination, improved husbandry, selection of resistant fish,
chemotherapy, management and, perhaps more realistically, a combination
of the above.
Vaccination against furunculosis has been reviewed by Munro (1984) and
Hastings (1988). Vaccines have been based on whole killed cells (bacterins)
(Olivier et al, 1985; McCarthy et al., 1983) of undefined antigenic
composition: Extracellular products (ECP) (Olivier et al., 1985; Cipriano,
1982; Shieh,1985) or ECP toxoids (Rodgers & Austin, 1985). Mixtures of
bacterins and ECP have also been tried (Cipriano et al, 1983). Live vaccines
have received little attention, perhaps through concern over safety in the
field. However, one live attenuated vaccine has been tested (Cipriano &
Starliper, 1982). Many of these vaccines have only beenmodestly successful
(Hastings, 1988). Thismay continue to be a problemwhen one considers the
success ofA.salmonicida in dealing with the fish immune system (Munn &
Tmst, 1984; Olivier et al., 1992).
There is little doubt that A.salmonicida is an opportunistic fish pathogen
awaiting periods of stress or trauma in the fish farming cycle; indeed, stress
forms the basis of asymptomatic carrier detection (Bullock & Stuckey,
1975). Thus,management of the fishes' environment throughout the farming
cycle to minimise stress would appear to be important. Management may
also play a role in avoidance of the pathogen through fallowing and single
year class policies. It has been suggested that lice infestations may provide
a route of infection for furunculosis, and may spread the disease through
transfer from fish to fish (Munro & Hastings, 1992). Indeed, McHenery et
al. (1991) have already highlighted the importance of controlling lice
infestations.
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Species of salmonid fish, namely rainbow trout, resistant to furunculosis
have been reported (Cipriano, 1983). Olivier etal (1988) determined a genetic
basis for furunculosis resistance inAtlantic salmon. Breeding programmes
which select formore resistant strains may be a practicalway ofreducing the
prevalence of furunculosis in future.
Chemotherapy can be an effective means of furunculosis control and this
will be reviewed at the end of this introduction. However, there is concern
over the use ofantibiotics in the environment (Lunestad, 1992). Investigations
have demonstrated that oxolinic acidmay be found inwild fauna (Samuelsen
etal, 1992), and sediments (Husevag et al., 1991; Samuelsen etal., 1991;
Hansen etal, 1992; Lunestad etal, 1992) associated with aquaculture sites
in Norway. Furthermore, fish pathogens and antibiotic resistant bacteria
have been recovered from sediments at abandoned fish farms (Husevag et
al, 1991), thus the removal of the site may not necessarily lead to recovery
of the natural flora. There is also concern that use of antibiotics may affect
bacterial diversity in marine sediments (Lunestad et al, 1992).
Currently, oxytetracycline, oxolinic acid, potentiated sulphonamides and
amoxycillin are licensed for use in Scottish aquaculture. The remaining part
of this Introduction will review three classes of antimicrobial studied in this
project: the quinolones, the potentiated sulphonamides, and the B-lactams.
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1.2 THE QUINOLONE ANTIMICROBIAL AGENTS
1.2.1 The Development of the Quinolones. The quinolones, also called
fluoroquinolones, 4-quinolones andquinolone carboxylic acids, are analogues
of the earlier developed agent nalidixic acid. Nalidixic acid was originally
isolated by Lesher and associates (1962) from a distillate during chloroquine
synthesis and thus was a by-product of antimalarial research. Additional
older analogues include pipemidic acid, cinoxacin and oxolinic acid which
is currently licensed for use in aquaculture in Scotland.
The newer quinolones are substantially more potent in vitro and broader in
antibacterial spectrum than nalidixic acid (Andriole, 1988). Furthermore,
they have relatively long half lives in serum, excellent penetration intomany
tissues and permeation into mammalian cells, resulting in antimicrobial
activity against intracellular pathogens.
Nalidixic acid and the newer quinolones have been reviewed (Crumplin,
1990; Andriole, 1988;Wolfson& Hooper, 1989). They arewholly synthetic
and structurally related compounds have not been identified as products of
living organisms. More than a thousand quinolones and analogues have
been synthesised and evaluated for antimicrobial activity, including
compounds with substitutions and additions to many parts of the molecule.
Moieties attached to N-l, a fluorine attached to C-6, and moieties such as a
piperazinyl or methylpiperazinyl group attached to C-7, seem to be
particularly important to increased antibacterial activity.
o
Figure 3. The Basic 4-Quinolone Skeleton.
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The favourable potency in vitro and the pharmacological properties of the
quinolones predictedpotential for treatmentofavariety ofbacterial infections,
and both clinical studies and medicinal use of these compounds have borne
out this promise (Norris & Mandell, 1988). However, oxolinic acid is
currently the only quinolone antimicrobial agent licensed foruse in veterinary
medicine in the United Kingdom.
1.2.2 DNAGyrase: Bacterial Topoisomerase II. The primary target of the
quinolone agents is DNA gyrase (bacterial topoisomerase II: EC number
5.99.1.3) (Gellert et al. 1976) and it is central to their mechanism of action.
Deoxyribonucleic acid (DNA) is a linear, double helical structure comprising
a sequence of the four nucleotide bases, adenine, thymine, cytosine and
guanine. This molecule encodes genetic information, allows mutation and
recombination, and serves as a template for semiconservative replication,
DNA repair and transcription.
The configuration of the DNA molecule leads to certain potential
conformational difficulties. The firstproblem occurs because the DNAmust
be condensed within the cell. For the bacterium Escherichia coli, the
chromosome is a circular DNA molecule 1,100pm in length (Cairns, 1963)
present in a cell of only 1 to 2 pm in length. This DNAmolecule, despite its
1000-fold condensed state, must be able to replicate, segregate into daughter
chromosomes, and allow transcriptionofindividual genes, withoutbecoming
lethally entangled.
A second problem is a result of the helical nature of the DNA duplex. For
the E.coli chromosome, which contains 4 x 106 base pairs, the strands are
intertwined about 400,000 times generating a linking number for E.coli of
400,000. To allow semiconservative replication to occur, therefore, the two
strandsmustunwind 400,000 times. Cairns (1963) recognised that, to permit
the unwinding of the DNA double helix during strand separation, a 'swivel'
mechanism would be required to prevent the molecule from becoming
tangled in front of the replication fork as it advanced.
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Figure 4. The a-subunits of DNAgyrase introduce nicks into the DNA strands at
specific sites 4 base pairs apart (Source; Bayer, UK).
A third problematic situation arises in prokaryotes. Their DNA double
helices containnegative supercoils which reduce the number ofhelical turns
thus facilitating strand separation (Wang, 1974). However, these supertwists
are energetically unfavourable thus an energy requiring process is needed
within the cell for their generation.
Forprokaryotic DNA, the problems ofentanglement, strand unwinding, and
negative supercoiling are solved, at least in part, by topoisomerases (Gellert,
1981;Wang, 1985). A topoisomerase is an enzyme that alters the number of
times one single strand of a DNA duplex winds around its complementary
strand; that is, a topoisomerase alters the linking number of a double
stranded DNA molecule. Such DNA molecules which differ in linking
number only are called topological isomers. Topoisomerases may be
categorised into three groups: type II topoisomerases (prokaryotic DNA
gyrase), type I topoisomerases, and special topoisomerases (Wang, 1985).
In 1976, Gellert and associates isolated the first topoisomerase II, DNA
gyrase, from E.coli. DNA gyrase is a tetramer containing two a subunits,
100 kilodaltons in mass and encoded by the gyrA gene located at 48 min.
on the E.coli map, and two (3 subunits, 90 kilodaltons in mass and encoded
by thegyri? gene located at 83 min. on theE.coli map. Thea subunits introduce
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nicks into each strand of the DNA helix at intervals of four base pairs. The
action of the (3 subunits of the gyrase enzyme is the ATP-dependent
introduction ofextra twists into both strands of the helix. Once this has been
affected, the a subunits reseal the 'nicked' strands, and stability and tension
in the DNA helix are restored (fig. 4)(Wang, 1985).
Reactions catalysedby purified DNA gyrase include introduction ofnegative
supercoils into DNA, catenation and decatenation of interlocked covalently
closed circular DNA molecules, and formation and resolution of knots
within the DNA duplex. These reactions require ATP and a divalent cation,
optimally magnesium, for activity (Wang, 1985).
DNA gyrase and topoisomerase I within the living bacterial cell set the net
level of negative supercoiling of DNA, with the introduction of negative
supercoils by DNA gyrase and their removal by topoisomerase I. The
amount of intracellular DNA gyrase and topoisomerase I is regulated at
transcription level in response to the superhelicity of DNA: decreasing the
negative supercoiled state of intracellular DNA stimulates transcription of
the gyrA and gyrB genes and suppresses the transcription of the topA gene;
increasing the superhelicity of intracellular DNA represses gyrA and gyrB
transcription whilst inducing transcription of topA (Wang, 1985).
1.2.3 Inhibition of Bacterial Topoisomerase II by the Quinolone
AntimicrobialAgents. Quinolone antimicrobial agents havemarked effects
on DNA gyrase and the bacterial cell. Many important consequences of
exposure ofbacteria to the quinolones nalidixic acid and oxolinic acid were
determinedprior to the discovery ofDNA gyrase. In the 1960s, Goss (1964,
1965) and his co-workers (Deitz etal., 1966; Cook etal., 1966) reported that
nalidixic acid selectively antagonised DNA synthesis, caused DNA
degradation and induced filamentation of bacteria.
In 1977 Gellert and associates and Sugino et al. reported experiments that
defined the a subunit of DNA gyrase as the primary target for oxolinic acid
and nalidixic acid. Quinolone resistance mutations affecting DNA gyrase
occur most frequently in the gyrA gene for E.coli, however two mutations
have also been identified in the gyrB gene (Inoue et a/., 1978; Yamagishi et
al. 1981, 1986). Thus the (3 subunit as well as the a subunit, is a target for
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quinolones, perhaps by direct interaction of the drug with the subunit or
alternatively by indirect action via the a subunit. As a result of this
interaction, nalidixic acid, oxolinic acid and other quinolones antagonise
almost all activities of purified DNA gyrase, including supercoiling,
catenation and decatenation, and unknotting (Crumplin et al. 1984;
Gellert, 1981).
1.2.4. Inhibition ofBacterial Growth in the Presence of the Quinolones.
Antagonism of bacteria by quinolones results in decreased introduction of
negative supercoils into DNA, decreased decatenation of interlocked DNA
circles, and damage toDNA (Cooked/., 1966; Crumpling? al., 1984; Deitz
etal., 1966; Drlica, 1984; Gellert, 1981;Gosse?a/., 1964;1965;Inouee?a/.,
1978; Smith, 1984;Wang, 1985;1987; Yamagishi, 1981). Induction of these
changes requires higher drug concentrations in gyrA mutants indicating that
gyrase is involved in these phenomena. The result of drug exposure is
interference with DNA synthesis, demonstrated by an immediate halt in the
uptake of DNA precursors. At high drug concentration, RNA and protein
synthesis are also impaired and filamentation occurs as a result of induction
of the SOS DNA repair system (Piddock and Wise, 1987).
In a review, Drlica (1984) hypothesised that the quinolones may complex
with both DNA and DNA gyrase, blocking the replication fork thereby
inducing the SOS DNA repair response. However, Lewin et al (1991)
demonstrated that SOS deficient mutants are still susceptible to the action
of the quinolones. They suggested that recombination repair played a
greater role in quinolone activity, as rec mutants were hypersensitive to
nalidixic acid, lexmutants, which are SOS deficient but have an operational
recombination repair system, are no more sensitive to nalidixic acid.
1.2.5. Killing of Bacteria by Quinolones. Most of the quinolone
antimicrobials, particularly the newer drugs, do not merely inhibit the
growth and division of susceptible bacterial strains. Exposure of most
susceptible bacterial species to these agents results in rapid cell death
(Smith, 1984a; Lewin & Hastings, 1989).
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At concentrations above the minimum inhibitory concentration (MIC), the
lethality of the drugs increases until a concentration known as the optimum
bactericidal concentration (OBC) is reached, beyond which the bactericidal
activity then declines. It has been suggested that this biphasic response
results from the inhibition of bacterial RNA synthesis by the 4-quinolones
at concentrations above the OBC (Smith, 1984; Smith & Lewin, 1988). It is
possible that this occurs because the inhibition ofDNA gyrase may cause
relaxation of chromosomal DNA to such an extent that it can no longer be
efficiently transcribed into RNA. Bacterial protein and RNA synthesis are
prerequisites for the full bactericidal activity of the 4-quinolones (Smith &
Lewin, 1988). For example, rifampicin, an inhibitor of bacterial RNA
synthesis, completely abolishes the bactericidal activity of nalidixic acid
against E.coli (Smith & Lewin, 1988).
Studying the bactericidal activity profiles of the quinolones has led to an
improved understanding of the killing mechanisms of these drugs. As
mentioned above, bacterial protein and RNA synthesis are essential for full
lethality ofthe 4-quinolones. However, while the additionofchloramphenicol,
an inhibitor of protein synthesis, or rifampicin, an inhibitor of RNA
synthesis, completely inhibited the bactericidal activity of nalidixic acid
against E.coli in nutrient broth they merely reduced, but did not completely
abolish, the bactericidal activity of ciprofloxacin or ofloxacin in nutrient
broth (Smith, 1984; Smith & Lewin, 1988). Furthermore, nalidixic acid was
not lethal in phosphate buffered saline where bacteria cannot divide, whilst
both ciprofloxacin and ofloxacin were active in this medium (Smith, 1984).
It was therefore proposed that nalidixic acid displayed a single bactericidal
mechanism, termedmechanismA,which requires protein andRNAsynthesis
as well as cell division for its activity, and that this is the principal
mechanism of action of all 4-quinolones. Furthermore, Smith (1984)
suggested that ciprofloxacin and ofloxacin possessed a second bactericidal
mechanism, mechanism B, which was not dependent upon protein or RNA
synthesis, and was active against non-dividing bacteria (table 2). Other
newer fluoroquinolones have also been shown to exert mechanism B in
addition to mechanism A. Although norfloxacin is unable to kill bacteria in
the absence of protein or RNA synthesis as rifampicin or chloramphenicol
completely abolish its bactericidal activity (Lewin, Amyes & Smith, 1989).
However, unlike nalidixic acid, norfloxacin is active against non-dividing
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Mechanism A Mechanism B Mechanism C
All 4-quinolones Ciprofloxacin Enoxacin
(only mechanism Ofloxacin Norfloxacin




Table 2. Categorisation of 4-quinolones by bactericidal mechanism. All
fluoroquinolones so far tested display an additional mechanism of action, in
addition to mechanism A, against Escherichia coli.
cells. It has therefore been proposed that it displays a third mechanism,
termed C, in addition to mechanismA (Ratcliffe & Smith, 1985). It has also
been shown that enoxacin exerts mechanism C (Lewin et al, 1989). Thus,
many of the fluoroquinolones appear to exert a second mechanism of action
in addition to mechanismA, the principal bactericidal mechanism of all 4-
quinolones (table 2).
Although the precise molecular events leading to the death of bacteria
exposed to the 4-quinolones are not clear, several proposals have beenmade.
The SOS genes are a set of genes encoding DNA repair enzymes which are
induced by the 4-quinolones (Piddock & Wise, 1987) and it has been
proposed that one of the SOS genes may code for a lethal protein (Philips et
al, 1987). Indeed, Walters and co-workers (1989) have implicated the SOS
gene, sfiA, in the lethality of the 4-quinolones. However, mutations that
disable the SOS response either have no effect or increase the susceptibility
of bacteria to nalidixic acid (Lewin et al, 1989a). These results would not
be expected if an SOS gene encodes the lethal protein, and it has been
suggested that the hyper-susceptibility of some SOS deficient mutants is a
result of deficient recombination repair rather than SOS repair (Lewin etal,
1989a). Thus recombination repair appears to play a role in restoring DNA
damaged by the 4-quinolones.
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Cook et al. (1966) suggested that, since DNA breakdown occurred in
bacteria treatedwith nalidixic acid, the lethal proteinmight be an exonuclease
and that bacterial deathmay result from degradation of chromosomal DNA.
However, recent studies have demonstrated that this is not the case as DNA
breakdown was shown to occur under conditions where nalidixic acid was
notbactericidal (Lewin &Smith, 1990). Furthermore therewas no correlation
betweenDNAbreakdown and the rate ofcell death caused by the quinolones.
Lewin and Smith (1990) have suggested that DNA breakdown occurs as a
result of exonuclease V involvement and may merely serve as a signal for
the induction of the SOS response, since exonuclease V activity is required
for the quinolones to induce this response.
Protein andRNA synthesis, as well as bacterial cell division, are not the only
factorswhich can affect the bactericidal activity ofthe quinolones. Multivalent
metal ions have also been shown to affect the lethality of these drugs (Smith
& Lewin, 1988). Varying the inoculum size has little or no effect on the MICs
of the quinolones (Smith, 1984a), however an inoculum size effect is
exhibited at theOBCwithE.coli andStaphylococcus aureus (Smith & Lewin,
1988). Bactericidal activities are normally determined with a starting
inoculumof 106 colony forming units permillilitre (cfu/ml), but itwas found
that if the initial inoculum size was increased to 108 cfu/ml, a reduction in
bactericidal activity ofciprofloxacin and ofloxacin occurred at their respective
OBCs. Furthermore, when the initial inoculumwas increased to 1010 cfu/ml,
the activity of both quinolones was reduced to mere bacteriostasis. The
inoculum size effect could not be attributed to pH or multivalent ion
concentration, or indeed to any destruction of the antibiotics at the higher
initial inoculum sizes (Smith & Lewin, 1988). Aeration of cultures of high
initial inoculum did, however, restore some of the bactericidal activity,
suggesting that lack of oxygen may be the cause of the inoculum size effect
(Smith & Lewin, 1988;Morrissey etal. 1990). This explanation seems valid
as both ofloxacin andciprofloxacin are bacteriostatic againstA.coli andStaph,
aureus under anaerobic conditions (Smith & Lewin, 1988; Lewin, Morrissey
& Smith, 1989; Morrissey et al., 1990).
As the 4-quinolones affect DNA gyrase, DNA supercoilingmay account for
the lackofbactericidal activity under anaerobic conditions. DNA superhelicity
has been implicated in the control of expression of certain genes involved
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in anaerobicity in both E.coli and Salmonella typhimurium (Yamamoto &
Droffler, 1985; Dorman et al, 1988). Obligate aerobic mutants of S.
typhimurium have been found to be DNA gyrase deficient, implying that
gyrase activity is essential for anaerobic growth. Furthermore, there is
evidence linking anaerobic conditions with DNA supercoiling and with 4-
quinolone uptake. Anaerobicity can influence the supercoiling of cellular
DNA (Dorman et al., 1988), which is subsequently responsible for the
regulation of a number of specific genes. The ompC porin genes are among
those genes induced by anaerobicity via a supercoiling regulated system
(Bhriain et al. 1989). As the quinolones are known to enterE.coli via ompF
and ompC (Hirai etal., 1986a, 1986b; Hooper etal, 1986), it is interesting
to postulate that some form of altered porin configuration under anaerobic
conditions may decrease quinolone uptake and thus bactericidal activity.
In summary, the bactericidal activity of all 4-quinolones is biphasic owing
to a requirement forRNA and protein synthesis for full bactericidal activity.
This biphasic response is less pronounced with the newer fluoroquinolones
due to the possession of an additional mechanism of action, termed either
B or C. All of the newer fluoroquinolones are active against non-dividing
cells whereas the older drugs such as oxolinic, nalidixic, pipedimic acids
require cell division for their activity. Bacterial cell division, protein and
RNA synthesis do not appear to be the sole requisites for full activity of these
drugs as oxygen has been shown to be essential for the drugs currently
available to kill bacteria.
1.2.6. Mechanisms of Resistance to the Quinolone Antibacterials.
Resistance to quinolones has been reviewed by Wolfson et al. (1989). A
number of genes that can mutate to cause bacterial resistance to the
quinolones have been identified. These genes inE.coli include gyrA (nalA,
njxA, norA, cfxA and ofxA) and gyrB (Yamagishi et al. 1981,1986) encoding
DNA gyrase (table 3). Othermutant loci (table 4), include nfxB, cfxB, norB,
norC and marA, which appear to result in altered drug permeation.
The majority of DNA gyrase alterations so far identified occur in the gyrA
gene encoding theA subunits of the enzyme. Recently, nucleotide sequences
have been determined for gyrA genes isolated from two strains of E.coli
selected for spontaneous resistance to nalidixic acid and two strains selected
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DNA gyrase gene Resistance mutations
gyrA nalA, nfxA, ofxA, norA, cfxA; cause resistance
to quinolones only.
gyrB nalO, resistance to nalidixic acid and
hypersusceptibility to certain fluoroquinolones;
nalD; resistance to nalidixic acid and
fluoroquinolones.
Table 3. Quinolone resistance mutations in genes encoding DNA gyrase in
Escherichia coli.
for resistance to pipemidic acid (Yoshida et al., 1988). In each mutant gene
a single base pair was changed. The four mutations were located in close
proximity in a sequence near the N-terminus of the gyrA polypeptide. The
four sites were located in hydrophilic regions of the peptide, suggesting they
reside near the surface of the a subunit protein. The mutations were also
found at ser 83, close to the codon for tyrosine 122, which has been shown
to be the site of covalent attachment of the a subunit to DNA when the
enzyme cleaves DNA in the presence of quinolones (Horowitz & Wang,
1987). Nucleotide sequences have also been determined for the two gyrB
mutations, nalC and nalD (Yamagishi et al., 1981,1986). Mutations at the
nalD locus cause increased resistance to the newer quinolones, particularly
those with piperazinyl substitutions, while nalC mutants exhibit increased
susceptibility to new quinolones. Eachmutation results in a single nucleotide
change in the midportion of the coding sequence. These alterations encode
single amino acid changes which alter the protein charge in opposite
directions, suggesting that charge is in some way related to drug-enzyme
interaction (Yamagishi et al, 1986).
The second class of mutations is characterised by low level resistance to
quinolones and structurally unrelated drugs. The pleiotropic nature of these
mutations suggest that they are a result of alterations in drug uptake or
permeability. This hypothesis is supported by the observations ofCohen and
co-workers (1989). In their study, it was found that resistance to
fluoroquinolones could be selected with tetracycline or chloramphenicol.
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nalB, nalD, crp, cya,
icd, purB, ctr.
nfxB, norB, norC Likely permeation mutants;
cfxB
marA









Table 4. Quinolone resistance in Escherichia coli as a result of mutations in
genes other than gyrA and gyrB.
This cross resistance was a result of two changes in outermembrane proteins
(OMPs), namely the porins OmpC and OmpF. The alterations resulted in a
change in outer membrane permeability as a result of increased expression
of the narrow channelled porin OmpC, coupled with decreased expression
of thewider channelledporin OmpF. norB and norC, two additionalmutants
selectedwith norfloxacin inE.coli, also appear to result fromdecreased drug
permeation (Hirai et al., 1987). norC causes hypersusceptibility to
hydrophobic quinolones such as nalidixic and oxolinic acids, detergents and
dyes, and exhibits both decreased OmpF expression and altered
lipopolysaccharides in the outer membrane (Hirai et al., 1987).
Formost classes ofantibiotic, resistance genesmay be carried chromosomally
ormay be encoded on extrachromosomal portions of DNA, plasmids. With
a single, as yet unconfirmed, apparent exception (Munshi et al. 1987),
mutations causing quinolone resistance are located exclusively on the
bacterial chromosome, despite an extensive search (Courvalin, 1990). This
apparent absence ofplasmidmediated quinolone resistance has an important

















Figure 5. Transfer of genetic material encoding antibiotic resistance.
are generally restricted to vertical transmission, i.e. frommother to daughter
cells at cell division (fig. 5). On the other hand, plasmids are frequently
transferred laterally between bacteria of the same, or even different, species
or genera (fig. 5). The result of this is that resistance carried on plasmids
tends to spread significantlymore rapidly than chromosomally determined
resistance. Four attributes of quinolones and quinolone resistance may
contribute to the scarcity of plasmid mediated resistance (Wolfson et al.
1989):
1). Wild type susceptible genes are dominant to many gyrA mutations
encoding quinolone resistance (Hane & Wood, 1969; Lampe & Bott, 1984;
Robillard, 1990; Swanberg & Wang, 1987; Yoshida et al., 1988). This
dominance pattern suggests that transfer of a mutant gyrA gene into a
susceptible cell would not be likely to generate a resistant phenotype in the
absence of gene conversion by recombination with a wild-type allele.
2). Expression of mutations which decrease outer membrane permeability
is delayed when introduced into wild-type cells (Foulds, 1976). It seems fair
to assume, therefore, thatquinolone resistance determinedby Omp alterations
may also be delayed.
3). Plasmid conjugation is inhibited by quinolones (Burman, 1977a, 1977b;
Nakamura et al., 1976).
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4). Some plasmids are eliminated from bacteria by sub-inhibitory
concentrations of quinolones (Piatt & Black, 1987; Weisser &Wiedemann,
1985).
For these reasons, the spread of quinolone resistance by plasmid mediated
transfer seems unlikely, particularly in the presence of a quinolone agent. It
must be stressed, however, that, in spite of the absence of plasmid mediated
resistance to this class of compounds, there are therapeutic difficulties in
certain bacterial species, notably Pseudomonas aeruginosa and
Staphylococcus aureus. The difficulties in Ps.aeruginosa can be explained
by the poor uptake of the antibiotics by these bacteria, thus therapeutically
effective levels of antibiotic are difficult to achieve, and are maintained for
shorter periods. Staph.aureus, although occasionally treated with
quinolones, is hardly an appropriate target as these drugs generally have
poor anti Gram-positive activity (Norris & Mandell, 1988).
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1.3. THE POTENTIATED SULPHONAMIDES.
The sulphonamideswere the earliestwholly synthetic antibacterials, Prontosil
being discovered by Domagk in 1935 for which he received the Nobel prize.
The selective antimicrobial activity ofProntosil was attributed to the release
of sulphonilamide which inhibits dihydropteroate synthetase. This enzyme
exists only in bacteria but not in animals hence the drug is selective.
(Trefouel et al., 1935; Colebrook et al., 1936).
In all areas of antibacterial chemotherapy, resistance to the sulphonamides
is widespread (Lacey etal, 1972). Thus the efficacy of these compounds has
been greatly enhanced by active potentiation with 2,4-diaminopyrimidines
such as trimethoprim, and potentiated sulphonamides have now almost
entirely replaced the sulphonamides in clinical use.
1.3.1. Folic Acid Biosynthesis. Trimethoprim and sulphonamides inhibit
successive steps in the bacterial synthesis of tetrahydrofolic acid, a co-factor
essential in many of the metabolic processes of the living cell (Bushby &
Hitchings, 1968)(fig 6.). Folic acid or folate, is usually synthesised de novo
as it may not be supplied exogenously. Brown (1959) found enzymes in
Escherichia coli that used substituted pteridines for the formation ofpteroic
acid in the presence ofp-amino benzoate (PABA). Brown etal. (1959)found
that pteroic acid could only be formed from certain substituted pteridines
and that PABA was a more efficient substrate for pteroate synthesis thanp-
aminobenzyl glutamate was for folate synthesis. This suggested thatpteroate
was an intermediate of folate synthesis. In a subsequent study, Brown et al.
(1961) found that that dihydropteroate was a more effective precursor than
the unreduced compound and proposed apathway whereby PABAcombined
with dihydropteridine to form dihydropteroate (fig 6). This reaction had a
requirement for ATP and magnesium ions, suggesting a phosphorylated
pteridine intermediate may be involved (Jaenicke and Chan, 1960). Brown
et al. (1961) proposed that condensing enzymes formed dihydrofolate from
dihydropteroate and glutamic acid. Dihydrofolate was then reduced to




















Figure 6. Pathway for the biosynthesis of reduced folate compounds in bacteria.
1.3.2.MechanismofAction ofFolate Inhibitors. Sulphonamideswere noted
to inhibit the production of folic acid (Nimmo-Smith et al., 1948). Bacteria
which were able to utilise exogenous folic acid were not affected by
sulphonamide antimicrobials (Woods, 1954). However itwas only when the
pathway describing the synthesis of folic acid was deduced that their
mechanismofactionwas determined (Brown, 1962). Brown (1962) deduced
that sulphonamides inhibited the incorporation of PABA into folates by
competitionwith thePABAcondensing enzyme, dihydropteroate synthetase.
The 2,4-diaminopyrimidines, such as trimethoprim and ormetoprim, inhibit
bacterial dihydrofolate reductase, an enzyme that converts dihydrofolate
into an active reduced form, tetrahydrofolate (Hitchings & Burchall, 1965).
2,4-diaminopyrimidines are folate analogues which bind competetively
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with dihydrofolate reductase (DHFR)(Hitchings &Burchall, 1965). Hitchings
and Burchall (1965) also demonstrated that these folate analogues were
more effective at binding bacterial DHFR than themammalian counterpart.
Burchall (1971) suggested that the mammalian enzyme had evolved further
than the bacterial DHFR, enabling it to distinguish between the pteridine
substrate and thediaminopyrimidine analogue. Thus abasis for chemotherapy
was established.
As sulphonamides and 2,4-diamino pyrimidines act in the same biochemical
pathway, their combined effect can sometimes be greater than the expected
additive interaction. This is known as synergy (Bushby & Hitchings, 1968).
Synergy between 2,4-diaminopyrimidines and sulphonamides is generally
measured by the effect of each drug on the level of inhibition of the other.
That is, the effect each drug has on the MIC of the other. Therefore, it is
bacteriostatic synergy that is measured and this can be quantified by a
'checker-board' titration (Bushby, 1973). This synergystic effectis exploited
in the potentiated sulphonamides.
1.3.3. Resistance to Potentiated Sulphonamides. Resistance to the
potentiated sulphonamides is frequently plasmid-mediated. The biochemical
mechanism of plasmid-mediated resistance to both sulphonamides and the
dihydrofolate reductase inhibitors involves target enzymes resistant to the
action of the antimicrobial. In the case of the sulphonamides, this is a drug
resistant dihydropteroate synthetase, while for trimethoprim and ormetoprim
it is a drug-resistant dihydrofolate reductase (Amyes & Towner, 1990;
Skold, 1976; Wise & Abou-Donia, 1975). There are two known genes
coding for plasmid-borne sulphonamide-resistant dihydropteroate synthetase
and these have been termed sul-I and sul-II (Radstrom & Swedberg, 1988).
There are over ten different plasmid-borne trimethoprim-resistant
dihydrofolate reductases which can be differentiated by DNA:DNA
hybridisation and biochemical characteristics (Amyes & Towner, 1990).
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1.4. THE p-LACTAM ANTIMICROBIAL AGENTS.
1.4.1. The Development of the p-Lactams. The early success ofpenicillin
prompted large scale research programmes in the pharmaceutical industry
resulting in the development of the semisynthetic antimicrobials penicilllins
G and V. Penicillin G was unstable at low pH and had no activity against
Gram negative pathogens. Penicillin V, whilst being more stable at low pH,
and thus suitable for oral administraion, was still poorly active against the
Gram negatives.
The first semisynthetic penicillin to show significant activity against Gram-
negative as well as Gram-positive pathogens was ampicillin. Ampicillin,
however, was found to be poorly taken up into the serum of the patient
resulting in high residues in the gut and thus potential for the development
of a reservoir of resistant commensal flora. A slight modification to the side
chain ofampicillin, however, gave rise to amolecule with similarantibacterial
properties but with greatly improved pharmacokinetics. This molecule was
named amoxycillin (fig. 7).
1.4.2. Mechanism ofAction ofAmoxycillin. P-lactam antimicrobials act
by inhibiting the synthesis of peptidoglycan. Peptidoglycan is a complex,
regular matrix which gives rigidity to the bacterial cell envelope, enabling
the cell to withstand the relatively high internal osmotic pressure.
Peptidoglycan is a highly ordered structure consisting of amino sugars and
amino acids. The repeating units, N-acetyl muramic acid and N-acetyl
glucosamine, coupled to their pentapeptide side chains, are synthesised
within the cytoplasm while bound to the nucleotide UDP; they are then
transferred to lipid carrier molecules that facilitate their movement across
the hydrophobic membrane. Finally they are polymerised into peptidoglycan
on the outside of the membrane by enzymes located on the membranes outer
surface (Rogers et al., 1980). It is during this cross linking, or
transpeptidation reaction that the synthesis pathway is susceptible to attack
by penicillins (Fig. 8). The P-lactam antibiotics appear to be able to bind to
the cross-linking enzyme, alanine transpeptidase resulting in its inactivation.
Penicillins are thought to be structural analogues ofD-alanyl-D-alanine, the




Figure 7. Amoxycillin, a derivative of ampicillin with improved
pharmacokinetics and now licensed for aquaculture.
normal substrate of alanine transpeptidase (Waxman & Strominger, 1983).
Thus the p-lactam is drawn to the active site of the transpeptidase normally
occupied by the D-alanyl-D-alanine part of the pentapeptide side chain
attached to the N-acetylmuramic acid. It seems that the antibiotic forms an
irreversible bond with the enzyme preventing it from catalysing the cross-
linking reaction by permanently occupying the active site. This appears to
be the primary mechanism of action of the P-lactam antibiotics. However,
the cross-linking of peptidoglycan occurs at multiple sites in the cell each
catalysed by distinct enzymes.
Furthermore, the P-lactams have been shown to inhibit biochemical reactions
which are not transpeptidations, specifically the actions of endopeptidases
(Waxman & Strominger, 1983). These enzymes catalyse the hydrolysis of
the peptidoglycan structure into different subunits. Thus it appears that the
P-lactams have several biochemical reactions as their targets in the bacterial
cell.
1.4.3. Resistance to the P-Lactams. There are several biochemical
mechanisms by which an organism may resist p-lactam antibiotics: 1)
decreased intracellular drug level, i.e modification of the cell envelope
reducing the permeability to the drug; 2) destruction of the drug by P-
lactamase enzymes; 3) an increase in target enzyme concentration; 4) repair
or by-passing of the drug sensitive reaction and 5) decreased affinity of the
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Figure 8. Action of penicillin on cross-linking of peptidoglycan.
Reduced permeability of the outer membrane of Gram negative pathogens
can lead to resistance to most classes of (3-lactam antibiotic, and cross
resistance to unrelated classes of drug (Rella & Haas, 1982; Goldstein etal.,
1983; Bush et al., 1988; Cohen et al., 1989). The targets of the (3-lactam
antibiotics are a series ofenzymes involved in cell wall synthesis in bacteria
and are known collectively as penicillin binding proteins (PBPs). Clinical
strains of pathogens with reduced or modified affinity for the penicillin
binding proteins (PBPs), are being isolated with increasing frequency
(Bryan, 1988).
(3-lactamases, enzymes that bind and destroy (3-lactam antibiotics, are the
main cause of resistance to this class of antibiotics. They act by cleaving the
lactam ring between C6 and the adjacent nitrogenmoiety (fig. 9). It has been
suggested that p-lactamase enzymes may have evolved from the penicillin
sensitive enzymes of cell wall synthesis (Tipper & Strominger, 1965).
Indeed, several PBPs have been found to exhibit p-lactamase activity and,
furthermore, some homology has been demonstrated between the low
molecular weight PBPs and p-lactamases (Waxman & Strominger, 1983).
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Figure 9. Action of (3-lactamase on amoxycillin.
(3-lactamases are identified on the basis of their subtrate hydrolysis profiles,
molecularweight, and the point atwhich they focus on polyacrylamide gels
containing carrier ampholines of various pH ranges, i.e. their isoelectric
point (pi) (Matthew, 1976).
In Gram negative pathogens, (3-lactamase productionmay be either plasmid
mediated, or encoded on the chromosome.More than sixty plasmid encoded
[3-lactamases have been identified in Gram negative bacteria (Weidemann,
1989). Themost prevalent of these enzymes is TEM-1. For example inE.coli
of which almost 25% of isolates are ampicillin resistant (Kresken &
Wiedemann, 1987), 70-100% of the resistance is due to TEM-1 or TEM-2.
Furthermore, TEM-1 is responsible for most of the ampicillin resistance in
Salmonella (Roy etal, 1983,1985; Simpson et al, 1986). Indeed, TEM-1
has been found in all Enterobacteria so far examined along with strains of
Vibrio, Acinetobacter, Haemophilus, and Neisseria (Roberts et al., 1977;
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Matthew, 1979; Dillon et al, 1983; Joly-Guillon etal., 1988).
Chromosomally determined (3-lactamases are readily detected in Gram-
negative bacteria such as the Enterobacteriaceae, Ps. aeruginosa (Sykes &
Matthew, 1976), Campylobacter (Fleming etal., 1982) andAeromonas spp.
(Bakken et al., 1988; Hedges et al., 1989; Iaconis & Sanders, 1990).
Chromosomally mediated (3-lactamases are generally species-specific
enzymes (Matthew et al., 1975). However, it has been demonstrated that
some chromosomally determined enzymes can be mobilised and thus
transferred to other bacterial species (Hedges et al, 1985). A further
characteristic of chromosomal (3-lactamases is their inducibility. That is,
different (3-lactam antibiotics can stimulate the production of (3-lactamases
to varying extents (Minami et al., 1980; Sanders et al., 1982; Gootz &
Sanders, 1983). It has been reported that new forms of (3-lactamase
occasionally arise after induction, though it is unclear whether these are new
enzymes or merely a modification of the original (3-lactamase (Sanders et
al, 1982).
(3-lactamases of Aeromonas spp. have been widely identified and
characterized (Hedges etal., 1985; Bakken etal., 1988; Iaconis & Sanders,
1990). These enzymes are mostly chromosomal, inducible, and active
against penicillins, cephalosporins and carbapenems (Hedges et al, 1985;
Bakken etal., 1988; Iaconis & Sanders, 1990). When analysed by isoelectric
focusing (IEF) the enzymes so far identified in strains of A.hydrophila,
A.caviae andA.sobria have pis ranging between 5.9 (AER-1, Hedges etal,
1985) and 8.4 (A2s, Iaconis & Sanders, 1990). Interestingly,AER-1 resembles
plasmid determined carbenicillinases in substrate profile but differs in pi
(5.9) and molecular weight (22,000) (Hedges etal., 1989). No evidence for
a plasmid locus has been found in A.hydrophila, but the AER-1 gene and
resistance to chloramphenicol, streptomycin, and sulphonamide can be
transferred to E.coli with IncP plasmids (Hedges et al, 1985). The linked
resistances are similar to those found on multi-resistant (3-lactamase
transposons. However the insertion of theA.hydrophila gene is site specific
and recA dependent, suggesting that this is not a functioning transposon
(Hedges et al, 1985). In spite of the plethora of papers puplished on
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Aeromonas (3-lactamases, none of these studies have included Aeromonas
salmonicida. Thus, the investigation of (3-lactam resistance in this species
will be included in this study.
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1.5. CONTROL OF FURUNCULOSIS BY ANTIMICROBIAL
CHEMOTHERAPY.
The use of chemicals in fish culture for the control of fungal, bacterial and
parasitic infections has a long history and has been reviewed extensively
(Meyer & Schnick, 1978; Meyer, 1989; Alderman, 1988; Alderman &
Michel, 1991).
Antibiotics from the three classes described in this introduction are licensed
for use in aquaculture in Scotland.
1.5.1. Folate Inhibitors in Aquaculture. Use of the sulphonamides in
aquaculture has been reviewed by Alderman (1988). The sulphonamides
were some of the first antibiotics made available for aquaculture use. The
first sulphonamide, sulphanilamide, was tested on fish in 1937 (Tunison &
McCay, 1937), andGutsell (1948) demonstrated the efficacy ofsulfamerazine
and sulfathiazole in controlling furunculosis in brook trout (Salvelinus
fontinalis). In his study, Gutsell demonstrated that oral administration of 8g
per 1001b fish per day of sulfamerazine was sufficient to control an outbreak
of furunculosis in brook trout. In a similar study, Snieszko and Bullock
(1957) found that 200mg/kg fish/day sulfamerazine could significantly
reduce furunculosis mortalities in brook trout. Allison (1956) demonstrated
that combinations of sulphaguanidine and sulphadiazine were equally
effective in brook trout. Studies inAtlantic salmon demonstrated that intra¬
peritoneal (IP) injection of sulphisoxazole and sulphadimethoxine could
effectively control furunculosis. However, sulphadimethoxine was found to
cause abscesses at the injection site (Amend & Fryer, 1968). Amend et al.
(1969) also found that sulphisoxazole was better absorbed from the feed by
chinook salmon than sulphametazine and was more active against
A.salmonicida in vitro.
More recent studies found that A.salmonicida was becoming resistant to
sulphonamide antimicrobials when used alone (McCarthy et al., 1974a).
Indeed Aoki et al. (1983) found that 54 out of 129 A.salmonicida isolates
recovered from culture ponds had MICs of 100mg/l or greater, and only 12
out of 46 isolates recovered from rivers had MICs below 25 mg/1. Aoki
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(1988) reported that between 70 and 100 per cent of Vibrio anguillarum
strains isolated in Japan between 1973 and 1977 were resistant to
sulphonamides. However, the percentage of resistance decreased between
1978 and 1983, ranging between 6 and 20%, depending on year.
Although trimethoprim has been marketed for use on its own in human
medicine since its patent expired in 1979, it tends to be used in aquaculture
in combination with a sulphonamide. Nevertheless, several authors have
examined the in vitro activity of ormetoprim and trimethoprim against
A.salmonicida. Aoki et al. (1983) found that trimethoprim MICs ranged
between 1.6 and >1000mg/l against A.salmonicida isolated from culture
ponds in Japan, although the highest MIC found in A.salmonicida isolated
from rivers was 3. lmg/1. In the same study, Aoki reported that ormetoprim
MICs rangedbetween 0.1 and400mg/1 in culture pond isolates, and between
1.6 and 12.5 mg/1 in river isolates.
In humanmedicine, the effective life of sulphonamides has been increased
by potentiation with a 2,4-diaminopyrimidine, trimethoprim. Potentiated
sulphonamides are available for aquaculture use. In the US, Romet 30, a 1:5
combination of ormetoprim and sulphadimethoxine was licensed in 1984
(Maestrone, 1984; Meyer, 1988), and Tribrissen (1:4 combination of
trimethoprim and sulphadiazine) was licensed in the UK in 1987 (K.
Treeves-Brown, Pers.Comm). There are numerous reports of in vitro
activity of potentiated sulphonamides againstA.salmonicida (McCarthy et
al., 1974a,b,c; Inglisetal., 1991a,b;Toranzoeta/. 1991;Gilesetal., 1991).
With the exception of the studies by McCarthy etal,. (1974a,b,c)most of the
studies may be questioned due to the experimental techniques employed.
Maestrone (1984), Inglis et al., (1991a,b), Toranzo etal., (1991) and Giles
et al., (1991), evaluated Romet 30, Co-trimoxazole, Tribrissen, or
combinations of Sulphadiazine and trimethoprim in the ratios in which the
drugs are supplied by the manufacturers. The ratios which are achieved in
vivo rarely reflect the ratios in which the drugs are supplied due to the
varying pharmacokinetic properties of the antibiotics (McCarthy, 1977b;
D.Love, Pers.Comm.). Pharmacokinetics are of vital importance to the
activity of potentiated sulphonamides as active potentiationmay only occur
in a very narrow range of ratios. Indeed, the optimum ratio of trimethoprim
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to sulphadiazine is 1:20 (McCarthy et al (1974b), however the two
components are presented in a 1:4 ratio in Tribrissen (1:4). In the case of
Romet 30, which is supplied as 1:5 ormetoprim to sulphadimethoxine, the
optimum ratio appears to be 1:20 (D.Love, Pers.Comm). The ratio of the
components of Romet achieved in vivo has not yet been reported. Toranzo
et al., (1991) determined MICs for Romet and Tribrissen on Brain Heart
Infusion Agar (BHIA) containing 1% NaCl. Use of BHIA may lead to
erroneous results as the presence of thymine in the medium antagonises
folate inhibitors and can, in the presence ofamino acids and purines, reverse
trimethoprim induced death (Amyes and Smith, 1974). McCarthy et al.
(1974a,b,c) conducted a series of studies into the potentiation of a variety of
sulphonamides with trimethoprim in fish. In these studies, seven
sulphonamides were tested. Little difference between them was observed in
vitro, however sulphamethylphenazole (SMP) had the most favourable
pharmacokinetic properties. McCarthy et al. (1974b) found that the ratio of
SMP to trimethoprim achieved in rainbow trout by admixture with feed
(200mg sulphonamide:20mg trimethoprim:!kg fish) was approximately
20:0.75, close to the optimum ratio formaximum antibacterial effect of these
two drugs against A.salmonicida in vitro. However, these favourable
pharmacokinetics may not necessarily apply to Atlantic salmon. Indeed
there are few published data on the pharmacokinetics of potentiated
sulphonamides in Atlantic salmon. Since the ratio of the levels of the two
components of these drugs achieved in vivo is essential for active
potentiation, this dearth of information may be a serious failing.
In the present study, the optimum concentrations of the components of
Romet 30 in vitro againstA.salmonicida will be investigated. The efficacy
of the combination as supplied by the manufacturer will be evaluated for the
control of furunculosis in Atlantic salmon.
1.5.2. Quinolones in Aquaculture. The earliest application of quinolone
antibiotics to fish pathogens was reported by Endo et al., (1973) who tested
nalidixic acid and oxolinic acid againstA.salmonicida, both in vitro and in
vivo. In 1983, Aoki et al., also reported favourable results with oxolinic acid
in vitro, demonstrating that over 90% of isolates from a culture pond were
susceptible to oxolinic acid at 0.8mg/l. The results for A.salmonicida
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isolated from riverswere more impressive, with all but one isolate susceptible
to 0.4 mg/1. The first reports of successful control of furunculosis by a
quinolone in Britain were made by Austin et al. (1983), who found that
oxolinic acid administered orally at 1 Omg/kg/day could significantly reduce
mortalities in brown and rainbow trout. Oxolinic acid was subsequently
licensed for aquaculture use in the UK (K. Treeves-Brown, Pers.Comm.),
however resistance to the drug was soon reported (Hastings & McKay,
1987; O,Grady et al., 1987). In human medicine, the quinolones such as
nalidixic and oxolinic acid have been superceded by the fluoroquinolones
(Andriole, 1988). Several fluoroquinolones have been investigated in vitro
and in vivo for use in aquaculture.
Flumequine, one ofthe earliest fluorinated4-quinolones, has been investigated
as a potential fish chemotherapeutant. In 1980, Michel et al. reported that
oral administration of flumequinewas successful in the control offurunculosis
in salmonids. Chevalier et al. (1981) reported favourable pharmacokinetics
and acceptable withdrawal periods (ie rapid absorption and elimination in
rainbow trout at 12°C). Chevalier et al. (1981) employed two dose rates,
6mg/kg and 12mg/kg, and found that both dosing regimens resulted in
elimination to the limit of detection within 72hours. O'Grady et al. (1988)
reported that elimination of flumequine following bath administration of the
antibiotic (50ppm in distilled water) was slower, with lmg/1 still present
14days following treatment. However, the levels of flumequine achieved in
serum by bathing were very much higher than those determined by the oral
route of Chevalier et al (1980). Elimination of flumequine following IP
injection was slower than following bath administration, with 3mg/l being
recorded 14 days afteradministration (O'Grady etal, 1988). Scallan & Smith
(1985) demonstrated that the carrier state ofA.salmonicida infection could
be successfully eliminated by bathing in a flumequine bath.
The fluoroquinolone enrofloxacin has been investigated for both in vitro and
in vivo activity against A.salmonicida (Bragg & Todd, 1988; Tsoumas et
al., 1989; Bowser & House, 1990; Bowser et al. 1990; Inglis etal., 1991;
Bowser & Babish, 1991; Bowser et al., 1992). Favourable MIC data were
obtained; Tsoumas et al. (1989) reported MICs ranging between 0.00024
and 0.5 mg/1. Similar results were reported by Bowser & House (1990), and
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Inglis et al. (1991). In spite of these favourable in vitro results, Bowser et
al. (1990) reported a failure to control furunculosis inAtlantic salmon with
enrofloxacin. This was attributed to low temperature and poor feeding
leading to low drug levels in the treated fish. It is interesting to speculate that
adequate levels of antibiotic may have been achievable by ultra-fine
preparation of the drug prior to administration, as increased bioavailability
has been reported with ultra-fine size reduction ofoxolinic acid in yellowtail
(Takahashi & Endo, 1987; Endo etal., 1987a) and in sea bream (Endo etal.,
1987b). In a subsequent study Bowser & Babish (1992) concluded that
treatment of furunculosis in brook trout (Salvelinusfontalis, L.) x lake trout
(Salvelinus namaycush, L.) hybrids with enrofloxacin was successful.
However, the mortality data presented in this paper were ambiguous and
inconclusive. The pharmacokinetic data, however, were clearer, and levels
in excess of8mg/l antimicrobial activity were detected in liver and skin, and
3.37 mg/1 in muscle (Bowser & Babish, 1992).
Stammeral, (1986) reported favourable in vitro activity ofsarafloxacin against
a range of human pathogens, and a low potential to induce resistance
(Fernandes et al, 1987). Markwardt & Klontz (1989) claimed that
sarafloxacin was capable of eliminating an artificially induced "carrier
state" of furunculosis in salmonids. The first report of in vitro activity of
sarafloxacin against A.salmonicida was published by Stamm (1989) who
reported an MIC of 0.06mg/l. However, only one isolate was used in this
study, thus the significance of the results is limited. In a more recent survey,
Stamm (1991) investigated the in vitro activity of sarafloxacin against 47
isolates of A.salmonicida. In this study, he reported that MICs ranged
between 0.008 and 2.00mg/l. The only pharmacokinetic data available on
sarafloxacin have been provided by Markwardt & Klontz (1989) who found
that the maximum levels were attained in serum when Tween 80 was added
to a 50mg/l bath treatment of sarafloxacin. However the data presented in
this study were for a 10 minute treatment only and the levels attained were
low (0.09mg/l).
A search of the literature has failed to provide any published information on
the other fluoroquinolones investigatedin this study (PD127,391, PD117,596,
















Figure 10. Fluoroquinolones investigated in this study (NB. Structure for Ro 09
1168 not available).
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1.5.3.Amoxycillin inAquaculture.Amoxycillin is a recent addition to the
antibiotics licensed for use in aquaculture in Scotland. Inglis & Richards
(1991) found MICs ranging between 0.16 and 0.3 mg/1, however their study
only included seven isolates ofA.salmonicida. They also reported a limited
temperature effect with 7% of isolates requiring a higher concentration of
amoxycillin to inhibit their growth at 10 °C compared to 22°C. Inglis and
Richards (1991) found that amoxycillin was poorly bactericidal, with 30%
ofbacteria surviving 3h exposure to 5mg/l of the antibiotic, a concentration
of 9 x MIC. There appear to be no published pharmacokinetic data relating
to the use of amoxycillin in fish.
1.5.4. Bacterial Resistance inAquaculture. Despite the long history of the
use ofmedicines in aquaculture, it was only in the late 1960s, when the rapid
expansion of fish farming coincided with increasingly widespread use of
antibiotics, that some observers remarked on the potential hazards of drug
use in the aquatic environment. As in the case of other farmed animals,
attention was drawn to the increasing occurrence of drug resistance.
Drug resistance problems have become increasingly evident over the past
ten years (Hastings & Mackay, 1987; O'Grady et al., 1987; Richards et al.,
1990) possibly due to the availability ofonly a limited numberofcompounds
really suited to the control ofaquatic pathogens, and their repeated therapeutic
use (Aoki et al, 1981; Aoki et al., 1983; Tsoumas et al., 1989).
One of the most serious examples of this problem has occurred recently in
marine salmon farms in Scotland. Only two antimicrobials were available
foruse on these sites in themid 1980s, oxytetracycline, forwhich transmissible
plasmid-mediated resistance has been well documented (Aoki, 1988), and
oxolinic acid. Both were used extensively during the rapid expansion of the
salmon farming industry at this time and, as a result, resistance to these
compounds became well established (Hastings & Mackay, 1987; O'Grady
et al., 1987; Tsoumas etal., 1989; SOAFD, 1990).
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With the exception ofamoxycillin, which has only been available for use for
a limited period of time, resistance to all aquaculture antibacterials is
widespread in Scotland (Richards et al, 1991; Inglis et al, 1991). This
observation, coupled with the prevalence of furunculosis in Scottish
aquaculture emphasises the need fornew antibiotics.Against this background,
the fluoroquinolone antibacterials, amoxycillin and the potentiated
sulphonamide Romet 30, have been examined.
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1.6. AIMS OF THIS THESIS.
1. Fluoroquinolones which have potential for use in aquaculture will be
investigated in vitro againstA.salmonicida, and the bactericidal activity of
the fluoroquinolones under study will be investigated.
2. Inhibitory and bactericidal concentrations of the quinolones in vitro will
be compared with the levels which may be achieved in Atlantic salmon in
vivo.
3. Potential mechanisms of resistance to the fluoroquinolone antibacterial
agents in Aeromonas salmonicida will be studied.
4. The in vitro activity of the two components, individually and in
combination, against A.salmonicida will be examined. The efficacy of
Romet 30 in controlling a laboratory induced outbreak of furunculosis in
Atlantic salmon will also be investigated.
5. The prevalence and mechanisms of resistance to the B-lactam antibiotic
amoxycillin in Scottish islolates of A.salmonicida will be investigated.
6. A sea water infection challenge model will be developed and methods of
disinfecting effluent seawater so that clinical studies can be undertaken
without risk of releasing A.salmonicida into the aquatic environment.
MATERIALS & METHODS
2.1. BACTERIAL STRAINS.
One hundred and thirty-seven isolates ofAeromonas salmonicida subsp.
salmonicida, recoveredpredominantly fromnatural outbreaks of furunculosis
in farmed salmonids in Scotland, between 1986 and 1989, were used in this
study. A further nine isolates of A.salmonicida subsp. achromogenes
isolated from wild salmonids over the same period were also obtained
(AppendixA). All isolates were received from the Scottish OfficeAgriculture
and Fisheries Department (SOAFD) Marine Laboratory, Aberdeen. The
bacterial isolates were stored at ~70°C in Tryptic Soy Broth (TSB, Oxoid,
UK) containing glycerol (10%).Working cultures were stored on Tryptone
Soya Agar (TSA, Oxoid, UK) plates at 4°C.
2.2. ANTIBIOTICS.
The fluorinated 4-quinolones enrofloxacin (Bayer, UK), PD127,391,
PD117,596, CI934 (Parke-Davis, UK), Ro 09-1168 (F. Hoffman-la Roche,
Switzerland),as well as amoxycillin (Amoxil®, Bencard, UK), Augmentin
(SmithKline-Beecham,UK) andOxytetracycline (Sigma,UK)wereweighed
aseptically and dissolved in sterile distilled water. Oxolinic acid (Sigma,
UK), Sarafloxacin (A-56620, Abbott, Nth. Chic. 111.) and flumequine
(Apoflu®, Apothokernes Laboratorium A.S., Norway) were dissolved in
0.5N NaOH (0.02ml/mg) and diluted to the required concentration in sterile
distilledwater. Romet 30, ormetoprimand sulphadimethoxinewere supplied
by F. Hoffmann La-Roche, Basle, Switzerland. For in vitro studies,
ormetoprim was dissolved in 1.0N lactic acid; sulphadimethoxine was
dissolved in 0.5N NaOH. All drug solutions were prepared fresh on the day
of use. Drugs were stored as dry powders in darkness at 4°C.
2.3. MEDIA.
2.3.1. Complex media. The following complex media were used; Tryptic
soy broth (TSB), Tryptone SoyaAgar (TSA) IsoSensitest Broth, Diagnostic
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Sensitivity Test Agar (DSTA), Brain Heart Infusion Broth (BHIB), all
supplied by Oxoid, Basingstoke, UK. Bacto Marine Agar (BMA) was
supplied by Difco, UK.
Chemicals were supplied by Sigma Chemical Co Ltd., Poole, UK, unless
otherwise stated.
2.3.2. DMMinimal Salts Medium. Double strength minimal saltsmedium
was prepared as described by Davis & Mingioli (1950).
2.4. IN VITRO ACTIVITIES OFANTIBACTERIAL AGENTS.
The in vitro activity of a range of antibacterials against the fish pathogen
A.salmonicidawas determined in terms ofminimum inhibitory concentration,
bactericidal activity, and the frequency atwhich mutation to resistance to the
drugs occurred.
2.4.1 Determination of Minimum Inhibitory Concentrations (MICs).
MICs were determined against 38 oxolinic acid-resistant and 45 oxolinic
acid-susceptible isolates ofA.salmonicida. Employing the criteria proposed
by Tsoumas etal. (1989), strains for which theMIC of oxolinic acid was less
than 1.0 mg/1 were deemed oxolinic acid susceptible, whereas strains for
which the MIC was equal to or greater than 1.0 mg/1 were deemed oxolinic
acid resistant. MICs were determined onTSAby an agar dilution technique.
The dilution scheme followed either the arithmetic schedule 0.5, 1.0, 1.5,
2.0, 3.0, 4.0, 5.0, 7.5; or a doubling dilution schedule where stated. The
antibiotic plates were inoculated with amultipoint inoculator (Denley, UK)
delivering approximately 105 cfu/spot and were incubated aerobically
overnight at 22°C in a cooled incubator (Gallenkamp, UK) unless otherwise
stated. The MIC was defined as the lowest concentration of antibiotic at
which all visible growth was completely inhibited. The technique was
validated using type strains ofEscherichia coli and Staphylococcus aureus.
Consistency of results was ensured by including Aeromonas salmonicida
MT363 as a standard on every plate.
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2.4.2. Effect of Inoculum Size onAntibacterialActivity of the Quinolones.
Antibacterial activities, in terms of MIC, of oxolinic acid, sarafloxacin,
enrofloxacin, PD117,596, PD127,391, and CI934 were determined against
20 isolates of A.salmonicida essentially as described above except that
initial inocula of 102, 104 and 106 cfu per spot were employed.
2.4.3. Effects of Environmental Conditions on Antimicrobial Activity.
The effects of temperature on the 4-quinolones was examined by determining
MICs as described above (2.3.1) except that the plates were incubated at
10°C for 48hrs before calculating the inhibitory concentration. The
antibacterial activities against A.salmonicida, of oxytetracycline,
amoxycillin, oxolinic acid, sarafloxacin, and flumequine were determined
on TSA, Bacto Marine Agar 2216 (Difco, UK) and TSA supplemented with
50mM MgCl0 or 340mM NaCl, to elucidate the effect of these seawater
cations on the antibacterials. Plates were incubated at 22°C for 24 hrs and
MICs were calculated as described above.
2.4.4. Estimation of Bactericidal Activity of the Quinolone
Antimicrobials. The bactericidal activities of the quinoloneswere estimated
essentially as described by Lewin et al. (1989a), employing two oxolinic
acid resistant isolates, MT364 andMT472, and two oxolinic acid susceptible
isolates, MT363 and MT736 (Table 5). An overnight culture of the isolates
containing approximately 108 cfu/ml was diluted 1 in 50 in fresh tryptic soy
broth containing the various antibacterial agents. The antibacterial
concentrations followed the arithmetic progression 1.5, 3, 5, and 9. One
hundred microlitre samples were taken after lh incubation at 22°C in the
case of the newer fluoroquinolones, and after 1, 3 and 6h incubation at 22°C
in the case ofoxolinic acid and flumequine, andwere serially diluted inTSB.
Percentage survival was estimated by viable counting on TSA plates.
Experiments were performed in triplicate and mean values calculated.





Sarafloxacin Enrofloxacin CI934 PD117,596 PD127,391
MT363 0.03 0.2 0.05 0.015 0.4 0.015 0.0075
MT364 7.5 0.3 3.0 1.0 3.0 0.3 0.1
MT472 3.0 0.3 2.0 1.0 2.0 0.2 0.1
MT490 0.03 0.2 0.05 0.02 0.4 0.015 0.0075
MT494 0.03 0.2 0.04 0.02 0.4 0.015 0.0075
MT736 0.015 100.0 0.04 0.04 0.3 0.015 0.01
MT744 0.03 0.2 0.05 0.015 0.4 0.015 0.0075
MT747 0.03 0.2 0.03 0.02 0.4 0.015 0.0075
Table 5. MICs (mg/1) of strains used in mutation frequency and bactericidal
activity experiments
2.4.5.Mechanisms ofBactericidalAction of theVeterinary Quinolones.
The mechanisms ofaction ofthe fluoroquinolones enrofloxacin, sarafloxacin
andRo 09-1168were investigated as describedbySmith (1984a). Bactericidal
activity was estimated, as described above, in PBS pH7.0, to assess the
activity of the agents against non-dividing bacteria. To determine the action
of these drugs whenRNA or protein synthesis was inhibited, the bactericidal
activities were determined in the presence of4.0mg/l rifampicin and 2.0mg/
1 chloramphenicol respectively. Briefly, overnight cultures ofA.salmonicida
MT363 were diluted 1 in 50 into universals of fresh TSB containing the
either rifampicin or chloramphenicol at the appropriate concentration, plus
a series ofdilutions of the quinolone under investigation as described above.
After 1 hour of incubation at 22°C, samples (0.1ml) were taken and serially
diluted into fresh TSB before estimation of survival by viable counting on
TSA plates.
2.5. MECHANISMS OF QUINOLONE RESISTANCE.
2.5.1. Stability of Quinolone Resistance in A.salmonicida. MICs of
oxolinic acid, sarafloxacin, enrofloxacin, PD127,391, PD117,596 andCI934
were determined for 20 oxolinic acid-resistant isolates of A.salmonicida
after 10 successive passages of the strains on drug free TSA plates.
2.5.2. Frequency of Mutation to Resistance to the Quinolones and
Oxytetracycline.Mutation frequencieswere determined for five quinolone-
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susceptible isolates ofAeromonas salmonicida MT363, MT490, MT494,
MT744, MT747 (table 5) according to the method of Smith (1986).
Conical flasks containing 250ml drug-free TSB were inoculated with 4.5ml
overnight starter cultures ofA.salmonicida and incubated at 22°C overnight
with shaking. The resulting cultures were harvested by centrifugation at
11,500 x g and resuspended in 2 ml fresh TSB to give cell concentrations in
excess of 1010 cfu/ml. Aliquots (0.1 ml) of undiluted, 10"1, 10~2, 10 3 & 10~4
dilutionswere then spread ontoTSAplates containing the various antibiotics
at 5, 10, and 20 times their respective MICs. The plates were incubated at
22°C for 7 days and examined daily for the presence of resistant colonies.
Resistant colonies were subcultured onto TSA plates containing antibiotic
at the same concentration to verify resistance and the colonies were
identified to species level with a latex bead agglutination kit (Aquaculture
Vaccines Ltd., UK).
2.5.3. Preparation ofOuterMembrane Proteins (OMPs). Quinolone and
oxytetracycline resistant mutants isolated from mutation frequency
experiments, along with wild type A.salmonicida isolates exhibiting low
level resistance to the fluoroquinolones, were investigated for outermembrane
alterations.
Outer membrane proteins were prepared from 1 litre TSB cultures shaken
for 48 hours at 22°C. Cells were harvested by centrifugation at 10,000 x g
for 15 minutes and lysed by sonication at 8pm for 30 second bursts totalling
3 minutes with an ultrasonic disrupter (MSE soniprep, MSE instruments,
UK). The lysate was then centrifuged twice at 15,000 x g to remove whole
cells and the inner membranes were solubilised by addition of lauryl
sarcosinate (Sarkosyl) to a concentration of 0.7 %. The outer membranes
were then precipitated byultracentrifugation at 100,000 x g for Ih at 4°C. The
membranes were then washed with approximately 7 ml pyrogen-free water
(Milli-Q, Millipore, UK) and harvested by centrifugation at 100,000 x g for
lh at 4°C. The precipitated membranes were finally resuspended in 1 ml
Milli-Q water.
2.5.4. Analysis of Outer Membranes by Sodium Dodecyl Sulphate
Polyacrylamide Gel Electrophoresis (SDS-PAGE). Outer membrane
proteins were resolubilised prior to electrophoresis by boiling in sodium
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MICs (mg/1)
Oxolinic Enro- Sara-
Isolate acid floxacin floxacin Ro 09-1168
MT438 1.50 0.20 1.00 0.20
MT362 5.00 0.75 2.00 0.40
MT487 5.00 1.00 2.00 0.10
Table 6. Quinolone resistant isolates ofA.salmonicida employed in
transformation experiments
dodecyl sulphate (SDS) for 5 min. The OMPs were analysed on gel gradient
of 10-15% polyacrylamide using the PhastSystem® (Pharmacia LKB,
Sweden). A coomassie brilliant blue R (Sigma) staining technique was
employed to visualise the separated protein bands.
2.5.5. Examination of OMPs for Non-Covalent Association with
Peptidoglycan. To determine whether the OMPs were non-covalently
associated with peptidoglycan, the method of Darveau et al. (1983) was
followed. Briefly, cell envelopes, isolated as described above, were solubilised
in buffer containing 2% (w/v) SDS, 10% (w/v) glycerol, and lOmM Tris-
HC1 (pH 7.4) at 37°C for 30 min. The pellet obtained after centrifugation at
100,000 x g for 1 h was resuspended in the same buffer containing 0.1M
NaCl. The resulting suspension was analysed by SDS-PAGE as described
above.
2.5.6. Probing for DNA gyrase mutations. Genetic studies have shown
that aquinolone sensitive gyrA gene is dominant over the quinolone resistant
allele (Hane &Wood, 1969; Nakamura et al. 1989). Two gene probes have
been made to screen bacteria for gyrA mediated quinolone resistance; a
broad host range probe containing quinolone sensitive gyrA from E.coli,
pNJR3-2, using acosmid vector (Robilllard, 1990) and a probe, pBP513, on
a high copy number plasmid (Heisig & Wiedemann, 1991).
pNJR3.2 was supplied by Bayer, UK, andpBP513 was supplied by DrEddie
Power, UMDS, London, UK with the kind permission of Dr Peter Heisig.
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The two plasmids, carrying the wild type E.coli gyrA gene were used to
probe high level quinolone resistant isolates of A.salmonicida (table 6).
L-F Base L-F Broth L-F Recovery Agar SMM SMMB
BHI (1%) L-F Base L-F Base Sucrose 0.5M SMM
Sucrose (10%) + + Maleate 0.02M mixed
Yeast Extract Horse serum Agar No. 3 MgCl 0.02M with an
(0.5%) (deactivated & (1%) (pH6.5, adjusted equal
added when with NaOH) volume of
cool) (1%) 4x BHIB
Table 7. Media used in protoplast transformation experiments.
pUC19, a high copy number plasmid, was used as a negative control to
ensure that transformation per se did not alter quinolone resistance.
Minipreparations of plasmid DNA were obtained by the alkaline lysis
method of Takahashi & Nagano (1984).
Competent cells for transformationwere prepared as follows; fiftymillilitres
of brain heart infusion broth (BHIB, Oxoid) at 22°C was inoculated with
0.5ml overnight culture of the requiredA.salmonicida isolate and incubated
at 22°C to give a culture of OD66o= 0.15-0.2. Cultures were chilled on ice
and cells harvested by centrifugation at 4°C. Pellets were resuspended in
12.5 ml ice-cold calcium chloride (lOmM) and left on ice for 15min. The
suspensions were centrifuged, resuspended in 75mM calcium chloride and
kept at 4°C for 24 hours.
Transformations were carried out based on the methods of Saunders &
Saunders (1988). Briefly, 0.2ml competent cells were mixed in Eppendorf
tubes with plasmid DNA (30pl) and made up to 0.5ml with ice-cold 75mM
calcium chloride. The transformationmixture was kept on ice for 30 minutes
and then transferred to a 40°C water-bath for 2 min. BHIB (0.5ml) was then
added and incubation continued at 22°C for 4h to allow expression of the
plasmid. Dilutions of the transformationmixture were then plated onto DST
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agar plates containing the appropriate antibiotics (20 or 40mg/l tetracycline
for pNJR3-2; 20mg/l kanamycin for pBP513; 20 mg/1 ampicillin for
pUC19) and transformants selected after 48h at 22°C.
The presence of the relevant plasmid in the transformants was determined
by agarose gel electrophoresis. Plasmids, prepared as described previously
(Takahashi&Nagano, 1984)were electrophoresed in 0.7% agaroseminigels
in buffer A (40mM Tris-acetic acid, 2mM EDTA (pH8.0)) at 100V for 2h.
Plasmid DNA was stained with ethidium bromide and visualized with
ultraviolet light (330nm).
2.5.7. Transformation of Protoplasts. A.salmonicida protoplasts were
prepared according to the method of Dr D I Mcintosh (personal
communication), based on the technique ofWyrick and Rodgers (1973). L-
F broth (10ml)( Mcintosh & Austin, 1988) (table 7) was inoculated with
A.salmonicida and incubated overnight at 22°C. The resulting cultures were
transferred to 50ml fresh L-F broth and incubated with shaking for 4 hours.
Benzyl penicillin was added to a concentration of 50mg/1 and the incubation
continued statically overnight. The cultures were then examined by phase
contrastmicroscopy to determinewhetherprotoplasts hadbeen formed. The
protoplasts were harvestedby centrifugation at3500 xg for 15minandwashed
in 10ml fresh L-F base (table 7). The washed protoplasts were reharvested
and suspended in 10ml SMMB (table 7) before dilution to one tenth of the
concentration of the starting culture (approx. 107 cfu/ml).
Protoplasts were transformed by a method adapted from that of Chang &
Cohen (1979). Serial dilutions of plasmid pNJR 3,2 in TE buffer (lOmM
Tris.HCl, ImM EDTA, pH8.0) were mixed with an equal volume of double
strength SMM (table 7). To this mixture was added protoplast solution
(0.5ml) followed by immediate addition of 40% w/v Polyethyleneglycol
(PEG) (1.5ml). After 2min, 5ml L-F Base was added to dilute the PEG and
the protoplasts were recovered by centrifugation at 3500 x g for 15min. The
pellets were resuspended in 1 ml L-F base and incubated for 6hours to allow
expression of the plasmid. Transformants were selected on L-F recovery
agar containing tetracycline (40mg/l) and incubated at 22°C for up to 5 days.
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2.6. IN VITRO ASSESSMENT OF ROMET.
This work was carried out in collaboration with C.J.Thomson in our
laboratory.
2.6.1. Minimum Inhibitory Concentrations (MICs). The minimum
inhibitory concentrations of ormetoprim and sulphadimethoxine, the
components of Romet, were determined. In addition to this, the 2,4-
diaminopyrimidine trimethoprimwas included in this study for comparison.
MICs of the antifolate inhibitors were determined on Oxoid DSTA plates
incorporating the various chemotherapeutants according to a doubling
dilution schedule. Overnight cultures of the bacteria in nutrient broth were
centrifuged andwashed inDMminimalmedium. Theywere thenresuspended
to their original cell density in fresh DM medium. The viable count of the
cell densities was established such that they could be diluted sufficiently in
order that 2pl would give approximately 105cfu. The antibiotic plates were
inoculated with a multipoint inoculator (Denley, UK) delivering 2pl/spot
(105 cfu) and incubated for 48h at 22°C. Results were read at both 24h and
48h, though the results at 48h were recorded as they were poorly defined
after 24h.
2.6.2. Fractional Inhibitory Concentrations (FICs). FIC Indices were
determined by the two dimensional serial dilution procedure devised by
Bushby (1973). Twenty strains were selected for further study. The MICs of
ormetoprimand sulphadimethoxine were repeated; however, on this occasion
the determination was performed on agar plates containing the various
antibiotics at concentrations following an arithmetic dilution schedule. This
progression gives a closer determination of their true MIC values. To
determine the fractional inhibitory concentrations, the inhibitory
concentrations of ormetoprim and sulphadimethoxine were determined in
the presence of sub-inhibitory concentrations of the other drug. An
isobologram was constructed for each test organism and the FIC of each
drug at the point ofmaximum interaction was determined. The sum of these
two FICs, the FIC index, gives a quantifiable determination of the drugs'
interaction. A value of <0.7 indicates synergy, 0.7-1.0 indicates an additive
effect, >1.0-2.0 indicates indifference and >2.0 indicates antagonism.
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2.7. RESISTANCE TO AMOXYCILLIN.
Amoxycillin resistant isolates ofA.salmonicida were selected to determine
the mechanisms of resistance to this class of antibiotics.
Substrate










Table 8. (3-lactam substrates used in hydrolysis assays.
2.7.1. Preparation of Crude (3-Lactamase Enzyme Extracts. Resistant
isolates were grown overnight in 10mlTSB at 22°Cwith shaking. Cells were
harvested by centrifugation at 3500 x g for 15 minutes. The pellet was
resuspended in 3 ml 25mM sodium phosphate buffer (pH7.0) and cells were
lysed by sonication at 8 pm for4 bursts of 30 seconds each with anultrasonic
disruptor (MSE Soniprep, MSE Instruments, UK). Whole cells were then
removed by centrifugation at 32,000 x g for 10 minutes. The supernatant
containing the crude enzyme preparation was stored at -20°C until required.
2.7.2. Confirmation of (3-Lactamase Activity. Crude cell extract (30pl)
was mixed with lOOpl of nitrocefin solution (500mg/l) in a microtitre well
and the time taken for the colour of the mixture to change fromyellow to red
was measured.
2.7.3. Determination of Spectrum of Activity of the p-Lactamase by
Hydrolysis Assay. Into a 3ml cuvette was added 2.6ml 25mM sodium
phosphate buffer (pH7.0) and 0.3ml substrate antibiotic solution at the
appropriate concentration (table 8) which were then allowed to equilibrate
at 37°C. Enzyme (0.1ml) was added and the change in optical density (OD)
at the A, for the particular substrate (table 8) was measured against a blank
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Material Supplier Final Cone.
5% tetramethylethylenediamine









Acrylamide (lOOg) + methylene
bisacrylamide (2.7g) in distilled
water (300ml)









Table 9. Composition of IEF gels
containing 2.9ml 25mM sodium phosphate buffer and 0.1ml enzyme.
Optical densitieswere determinedwith aPerkin-Elmer Lambda 2 dual beam
UV/Vis spectrophotometer with a thermostatically controlled cuvette
carriage.The rate of substrate hydrolysis was determined according to the
equation;
R=AOD x C x 10 x d
Initial OD x t
where; AOD = Decrease in OD at X over reaction time t.7 max
C = Concentration of substrate at tO (0.3 pinoles for
penicillins, 0.03 pmoles for cephalosporins)
10 = Correction for enzyme (0.1 ml) to 1ml.
d = Dilution factor (if required),
t = Time (mins) during which reaction is linear.
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The rates were then expressed in terms of initial rate of hydrolysis of
substrate relative to that of hydrolysis of benzylpenicillin (Vmax).
2.7.4. Analytical Isoelectric Focusing of (^-Lactamase Enzymes. The
method used for isoelectric focusing (IEF) was described by Matthew et al.
(1975). The crude |3-lactamase enzyme preparations were focused on a glass
plate supporting a thin layer polyaery lamide gel containing carrier ampholines
of pH range 3.5-10.0. The composition of the gel mixture is given in table
9. (3-lactamase activitywas detected with nitrocefin; a sheet ofWhatmanNo.
54 paper dipped in nitrocefin solution (500mg/l) was laid over the gel
surface. Focused bands of (3-lactamase activity appeared red on a yellow
background. Gels were photographed onPolaroid 655 filmusing transmitted
light and a Wratten 58 green filter.
2.7.5. Plasmid Curing with Ethidium Bromide. Ethidiumbromide (EtBr)
is a known plasmid curing agent (Bouanchaud et al. 1969). MICs of EtBr
were determined by serial doubling dilutions in TSB. The MIC was taken as
the lowest concentration at which visible growth was completely inhibited
after 24h incubation at 22°C. One hundred microlitre samples were taken
from the broth containing the MIC ofEtBr and from two dilutions on either
side. These aliquots were washed in fresh TSB prior to plating onto TSA and
replica plating onto TSA containing amoxycillin (100mg/l) to identify any
cells which may have become sensitive. Plates were incubated at 22°C for
48 h.
2.7.6. Induction of (3-Lactamase Production. Overnight cultures (10ml)
ofA.salmonicida were inoculated into 90 ml fresh TSB containing 10mg/l
(1/4 of the MIC) of cefoxitin, a potent inducer of (3-lactamase production
(Minami et al. 1980).
The cultures were then incubated at 22°C with shaking for 4 h. The cells
were harvested by centrifugation at 3500 x g and resuspended in 10ml 25mM
sodium phosphate buffer (pH7.0) prior to lysing by sonication as described
above. The protein concentration in the induced and uninduced enzyme
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preparations was then assayed by the method of Waddell (1956) and the
activity of the enzymes was determined in terms of rate of hydrolysis of
nitrocefin.
2.7.7. Estimation of Rate of Hydrolysis of Nitrocefin by a
Spectrophotometric Technique. The rate of hydrolysis of nitrocefin was
determined per milligramme of protein for both induced and uninduced
enzyme by the spectophotometric technique described above (2.7.3.).
2.7.8.MobilisationofResistance Genes fromA.salmonicida toE.coliK.12.
In attempts to mobilise resistance genes from A.salmonicida subsp.
achromogenes to E.coli K12 (KT106. K.Towner, University of
Nottingham) containing the Inc P plasmid R702, equal volumes of
overnight cultures of donor and recipient were mixed gently and incubated
statically overnight at 25°C. Themixturewas then filtered through a0.45|im
membrane filter (Millipore, UK), which was placed on a nutrient agar plate
and incubated for a further 4h at 25°C. The cells were dislodged from the
filter by gentle shaking in 10ml Davis and Mingioli (DM) minimal broth
then harvested by centrifugation at 3500 x g prior to washing in a further
10mlDM and finally resuspended in 1ml DM broth. One hundredmicrolitre
samples were then spread onto TSA plates containing 50mg/l amoxycillin
and incubated at 37°C for 24h. The incubation temperature of 37°C was
sufficiently high to prevent any growth ofA.salmonicida and thus acted to
select in favour of amoxycillin resistant E.coli K12.
2.8. AN INFECTION CHALLENGE MODEL.
2.8.1. Experimental animals. Atlantic salmon S1 post smolts,meanweight
120g, were held in lm circular tanks supplied with pumped sea water (151/
min) and were fed commercial pelleted diet (BP S2). These fish had no
previous history ofA.salmonicida infection nor of any antibiotic treatment.
Effluent water, diluted 1:10 with fresh water, was disinfected with iodine
(5ppm, holding time 30 minutes).
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2.8.2. The challenge. The challenge model was developed with a virulent
Scottish isolate ofA.salmonicida (MT879). Seed cultures were transferred
from liquid nitrogen to tryptone soya agar (TSA, Oxoid) plates and incubated
at 15°C for 72 hours. The resulting cultures were used as inocula for further
TSA plates which in turn were incubated at 15°C for 48 hours. Bacterial cells
were removed from the plates and suspended in phosphate buffered saline
(PBS) pH7.0 immediately prior to commencement of the challenge.
The preliminary infection challenges were performed on fish of mean
weight 120g. Fish were starved for 24hours prior to commencement of
infection challenge. Noon seawater temperatures were between 13°C and
15°C during the period of the experiment.
Suspensions of A.salmonicida were added to tanks containing 50 post-
smolts in static aerated water to give bacterial densities of 1 x 104, 1 x 105
or 1 x 106 cfu/ml. After six hours, running sea water supplies were resumed
to each tank and maintained, thereafter, at normal flow rates.
Mortalities were removed daily during the ensuing challenge period of 22
days. Bacteriological samples were taken from all dead fish: kidney samples
were inoculated onto TSA plates and incubated at 22°C for up to seven days.




Sea water temperatures were approximately 2°C lower during the period of
the efficacy study than during the development of the infection challenge
model. As lower sea water temperatures tend to reduce both the occurence
and severity of furunculosis outbreaks inAtlantic salmon, it was decided to
use the highest challenge dose of A.salmonicida tested in the infection
challenge model (ie. 106cfu/ml) and subject both treated and control
populations to handling stress 5 days and 16 days post infection.
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Three replicate efficacy trials were performed with approximately 50
control and 50 treated fish in each trial. Each trial was performed in two
phases: phase 1 examined efficacy of a single 5 day oral treatment with
Romet in preventing mortalities due to furunculosis. In phase 2, the fish were
administered a second five day treatment with Romet and subsequently
examined for evidence ofA.salmonicida infection.
2.9.1. Phase One. Two groups of fish (mean weight 177g), held in separate
tanks in seawater, were exposed to waterborne infection withA.salmonicida
(106cfu/ml for six hours). Noon sea water temperatures were between 11°C
and 13°C during the period of the experiment.
Commencing one day after exposure to infection, one group of fish (group
1) was fed amedicated diet (50mg Romet 30/kg body weight/day; i.e. 15mg
active drug/kg/day) for five days. The feeding rate to fish was 0.5% of body
weight per day. The second group of fish (group 2) received a normal
unmedicated diet at 0.5% of body weight per day.
Five days following exposure to infection, six fish from each tank were
removed with a hand net and then immediately returned to the water. A
second stress event was initiated 11 days later. The sea water supply to all
six groups of fish was interrupted for one hour; during this time, six fish were
briefly removed from each tank with a hand net.
Mortalities were removed from tanks daily. Bacteriological samples were
taken from all fish, and mortalities caused by furunculosis confirmed as
described above.
2.9.2. Phase Two. Commencing 24 days after initial infection, group 1 was
administered a five day oral treatment with Romet, similar to the first
treatment. Group 2 continued to receive an unmedicated diet.
Thirty days following initial infection, all surviving fish were sacrificed and
examined bacteriologically for evidence of asymptomatic A.salmonicida
infection: kidney and lower intestine samples were inoculated onto TSA
plates and incubated at 22°C for up to 10 days. Asymptomatic infection was
confirmed by isolation ofone ormore colonies ofA.salmonicida either from
kidney or lower intestine.
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Relative percentage survival (RPS) values were calculated according to the
equation:
% mortalities in treated fish
RPS = 1 - x 100
% mortalities in control fish
2.10. SUITABILITY OF IODINEASASEAWATER DISINFECTANT.
The suitability of iodine for disinfection of effluent water was determined
in terms of bactericidal activity in seawater, seawater at reduced pH and
artificial seawater (table 10,DrB.Austin, personal communication). Seawater
was obtained from the effluent sump of the Marine Laboratory Fish
Cultivation Unit, Aultbea, Rosshire.





Table 10. Composition of artificial seawater.
Bactericidal activity was assayed essentially as described in section 2.4.4.
Briefly, an overnight culture (10ml TSB) of A.salmonicida MT879 was
harvested by centrifugation and resuspended in 10ml PBS pH7.0. The
culture was then diluted 1 in 50 into seawater (pH7.2, unadjusted), seawater
pH 4.0 (pH adjusted with HC1), or artificial seawater, containing iodine at
various concentrations. The iodine concentrations followed a doubling
dilution schedule from 0.25parts per million (ppm) to 32ppm. Aliquots
(0. lml)were takenimmediately after, and 20minutes following inoculation,
and serially diluted in 0.5M thiosulphate to inactivate the iodine. Percentage
survival was estimated by viable counting on TSA.
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2.11.ANALTERNATIVETO INFECTIONMODELS FORSTUDYING
ANTIMICROBIAL EFFICACY IN FISH.
2.11.1. Selection and maintenance of fish. Eight circular sea water tanks,
lm in diameter, were each stocked with 25 Atlantic salmon post smolts,
which were acclimatised for 2 weeks prior to commencing the study. Eight
fish from each group were netted, anaesthetised and weighed to determine
a mean weight for each tank (table 11). Having been maintained at a feeding
rate of 2% body weight per day, the fish were starved for 48 hours prior to
commencement ofmedication.
Weight of Fish (grammes)
Dose
Tank No. Medication (mg/kg/day) Mean Range
93 Flumequine 10 417.7 319-525
94 Enrofloxacin 5 488.7 301-633
95 Sarafloxacin 10 392.4 235-498
96 Ro 09-1168 2 390.3 259-565
97 Oxolinic acid 10 460.4 232-618
98 Oxolinic acid 10 419.4 280-582
99 Controls - 362.0 319-490
100 (Unmedicated) - 374.8 173-492
Table 11. Mean fish weights and medication dose rates.
2.11.2. Preparation and Administration of Medicated Feed. Medicated
feed was prepared as follows: the appropriate weight of BP S2 feed pellets
was mixed with preweighed drug (table 11) by hand to give an even surface
coating. Fish feeding oil (6ml/kg feed) was added to assist binding of the
antibiotics and as an appetiser. The fish were fed to appetite, by hand, at a
rate of 0.5% body wt / day, for three days.
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MIC (mg/1)
Oxolinic
Strain acid Sarafloxacin Enrofloxacin Flumequine Ro 09-1168
MT363 0.03 0.05 0.02 0.10 0.01
MT477 1.50 0.75 0.20 1.50 0.10
Table 12. MICs of quinolones against A.salmonicida MT363 & MT477.
2.11.3. Sampling of Serum. Eight fish were netted from each tank and
anaesthetised 3h, 8h and 24h following the administration of the final dose
of medicated feed. The fish were bled from the caudal vein using 10ml
Vacutainers® (Becton-Dickinson, France). The blood was allowed to clot at
room temperature and then cooled. The samples were transported on ice and
centrifuged at 4500rpm in a Heraeus Labofuge to remove blood cells.
Aliquots (0.5ml) of serum were removed from each sample and pooled into
two groups from four fish each, for each of the drugs and sampling times.




Acid Flumequine Sarafloxacin Enrofloxacin Ro 09-1168
50 90 50 50 50
15 50 15 30 15
5 15 9 15 5
3 5 5 5 1.5
0 3 1.5 1.5 0.5
0.9 0.5 0.5 0.15
0 0 0 0
Table 13. Standard antibiotic concentrations used in bioassays.
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2.11.4. Determination of Antibiotic Levels in Serum by Bioassay.
Antibiotic levels in the serum samples were determined by microbiological
assay using aquinolone sensitive isolate ofAeromonas salmonicida (MT363,
table 12) as the detection organism. Bioassays were performed according to
the method of Reeves and Wise (1978). Briefly, square bioassay plates
(Nunc, UK) were levelled and poured with 100ml cooled DST agar (Oxoid,
UK). The agar was allowed to set and the plates were dried at 37°C for 1 h.
Plates were cooled to 20°C before inoculation.
Well Number
Standard 1 7 19 27
Standard 2 4 15 22
Standard 3 5 12 23
Standard 4 3 20 29
Standard 5 1 13 25
Standard 6 6 17 28
Standard 7 2 14 24
Test 1 8 11 30
Test 2 9 16 26
Test 3 10 18 21
Table 14. Codes for Latin square 7,3.
Standard inocula of A.salmonicida MT363 were prepared as follows.
Overnight IsoSensitestbroth cultures (10ml) ofMT363 were diluted fourfold
in fresh IsoSensitest broth. This culture (20ml) was then poured onto the
surface dried bioassay plate. The culture was drained from each of the four
corners of the plates and the plates were surface dried at 20°C for 2 h. Thirty
sample wells (9mm) were then cut in the inoculated agar using a sterile No.
4 cork borer.
Antibiotic standards were prepared in fish serum isolated from the control
fish according to an arithmetic dilution schedule following the progression
1.5, 3, 5, 9. With the exception of oxolinic acid, sample wells were
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inoculated with 7 selected standards (table 13) and 3 test samples, each in
triplicate, according to an encrypted latin square 7,3 technique (table 14). In
the case of oxolinic acid, a 5,5 latin square pattern was employed.
2.11.5. Bactericidal activity of antibiotics in serum. To samples (0.9ml)
of serum isolated from the various medicated fish, was added 0.1ml of a
logarithmic phase culture ofA.salmonicida MT477 orMT363 (MICs shown
in table 12). Aliquots (0.1ml) were taken at 20,40,60,120 and 180 minutes
and diluted in fresh TSB before spreading onto TSA plates to estimate
percentage survival by viable counting.
RESULTS
3.1 MINIMUM INHIBITORY CONCENTRATIONS
Minimum inhibitory concentrations (MICs) give a comparative estimation
of the amounts of various antibiotics required to inhibit completely the
growth of the targetorganism.With the quinolones,MICsmust be determined
by agar dilution as opposed to the broth dilution technique, as filamentation
of bacteria caused by the quinolones can lead to erroneous MIC values
determined by the latter method (Smith, 1984b).
3.1.1. Survey ofMICs of Quinolones Against Aeromonas salmonicida.
MICs of enrofloxacin, flumequine, sarafloxacin, oxolinic acid, PD127,391,
PD117,596, CI934 andRo 09-1168were determined, employing an arithmetic
dilution schedule, against 38 oxolinic acid-resistant and 45 oxolinic acid
susceptible isolates ofAeromonas salmonicida (Appendix B).
The fluoroquinolones, PD 117,596 andPD127,391 were, on average, at least
15 times more active, in terms of MIC, than oxolinic acid against oxolinic
acid-resistant isolates and 10 times more active against oxolinic acid-
susceptible isolates (table 15). Enrofloxacin was slightly more active than
oxolinic acid against both oxolinic acid-susceptible and oxolinic acid-
resistant isolates. Sarafloxacin was also slightly more active than oxolinic
acid against both susceptible and resistant isolates (table 15). CI934 was as
active as oxolinic acid against resistant isolates but less active against
oxolinic acid susceptible isolates. Flumequine, on the other hand, was more
active than oxolinic acid against both susceptible and resistant isolates.
Interestingly, the range offlumequineMICs was broader than those recorded
for oxolinic acid (table 15). In terms of MIC, the most active of the
compounds tested was the Roche quinolone Ro 09-1168. This drug had very
low MICs when tested against both oxolinic acid-susceptible and -resistant
isolates, with MIC90s of 0.015 and 0.2 respectively (table 15).
3.1.2. Effect of Inoculum Size on the Fluoroquinolones. MICs of five
fluoroquinolones and oxolinic acid (figure 11) were determined, employing
an arithmetic dilution schedule, against three oxolinic acid-susceptible and
three oxolinic acid-resistant isolates ofA.salmonicida by the agar dilution
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MIC at 22 C (mg/1)
Test agent 50% 90% Range
Oxolinic acid 3.00 7.50 1.00-15.00
Sarafloxacin 1.50 4.00 0.20-4.00
Enrofloxacin 0.50 1.00 0.05-5.00
Flumequine 2.00 4.00 0.10-20.00
CI934 3.00 7.50 0.30-10.00
PD127,391 0.10 0.15 0.015-0.30
PD117,596 0.15 0.50 0.075-0.75
Ro 09-1168 0.20 0.20 0.075-0.50
Oxolinic acid resistant (38)
Oxolinic acid 0.03 0.40 0.01-0.75
Sarafloxacin 0.05 0.20 0.0075-1.00
Enrofloxacin 0.02 0.15 0.004-0.75
Flumequinc 0.075 0.10 0.075-0.50
CI934 0.40 1.00 0.04-3.00
PD127,391 0.0075 0.03 0.002-0.10
PD 117,596 0.015 0.05 0.003-0.50
Ro 09-1168 0.01 0.015 0.01-0.10
Table 15. In vitro activities of 4-quinolones against 83 isolates of A.salmonicida.
technique as described previously. Plates were inoculated with 102,104and
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Figure 12. Effect of temperature on MICs of 4-quinolones. (Results shown
recorded after 7 days incubation at 22°C).
The maximum change in MIC with inoculum size was found to be
approximately threefold (1.5mg/l to 5.0 mg/1). However, considering the
10,000 fold increase in cell concentration, a threefold increase inMIC seems
insignificant.
3.1.3 Temperature Effect and the 4-Quinolones. The MIC of each of the
five fluoroquinolones (above) and oxolinic acidwere determined against 18
oxolinic acid-susceptible isolates ofA.salmonicida at 10°C, a temperature
which more closely reflects those at which outbreaks of furunculosis may
occur. Results were read after 5 and 7 days incubation at this temperature.
With the exception of sarafloxacin, the quinolones exhibited a two- to five¬
fold increase after both 5 and 7 days incubation, compared with the MICs
at 22°C (figure 12). Interestingly, sarafloxacin did not appear to be affected
significantly by the reduction in temperature.
3.1.4. Effects of Seawater Cations on Antibacterial Agents. Treatment
regimens for furunculosis are normally based on disc susceptibility testing
on commercial media of A.salmonicida, isolated from fish mortalities.
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Range of MICs Determined on
Strain type Test Agent TSA TSA TSA Bacto
(No. of isolates) (IsoSensitest) (IsoSensitest) (IsoSensitest) + Marine
+340mM NaCl 50mM MgC12 Agar
Oxolinic Acid Oxolinic Acid 0.03-0.50 0.03-0.50 0.50-32.0 0.25-16.0
Susceptible (10) Flumequine 0.06 0.06-0.50 2.00-64.0 1.00-16.0
Sarafloxacin 0.03-0.50 0.03-0.50 1.00-2.00 0.50-1.00
Oxytetracycline 0.50 0.25 16.0-32.0 8.00
Amoxycillin 0.50 0.50 0.50-1.00 0.50-1.00
Ormetoprim (0.50-1.00) (0.50-1.00) (0.50-1.00) NT
Sulfadimethoxine (16.0->128) (16.0->128) (16.0->128) NT
Oxolinic Acid Oxolinic Acid 1.00-4.00 1.00-2.00 32.0->128 16.0->128
Resistant (10) Flumequine 2.00 1.00-2.00 64.0->128 64.0->128
Sarafloxacin 0.50-2.00 0.50-2.00 16.0-128 8.00-128
Oxytetracycline 0.50 0.25 16.0-32.0 8.00
Amoxycillin 0.50 0.50 0.50-1.00 0.50-1.00
Ormetoprim (0.50-1.00) (0.50-1.00) (0.50-1.00) NT
Sulfadimethoxine (16.0->128) (16.0->128) (16.0->128) NT
Table 16. Antagonism of aquaculture antibacterials by sea water cations.
(Figures in parentheses indicate MICs determined on IsoSensitest Agar).
However, these media do not take into account the ion balance of the salt
water environment in which the drugs are used. MICs of oxolinic acid,
sarafloxacin, flumequine, oxytetracycline and amoxycillinwere determined
on Bacto marine agar (BMA) and TSA. A 40 to 60 fold increase in the MICs
of the quinolones and oxytetracycline, but not amoxycillin, was observed on
BMA. This antagonism appeared to be due to Mg2+ in the BMA, as addition
of 50mM MgCl0 but not 340mM NaCl (the ion concentrations in BMA) to
TSA resulted in similar antagonism (table 16). Furthemore, the activities of
the two components of the potentiated sulphonamideRomet 30, ormetoprim
and sulphadimethoxine, against the same isolates of A.salmonicida were
unaffected by the addition of 50mM MgCl2 to IsoSensitest agar (table 16).
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3.2. KILLING OF AEROMONAS SALMON1C1DA BY THE
QUINOLONES.
Minimum inhibitory concentrations of the 4-quinolones provide information
about the inhibition of bacterialmultiplication by these antibiotics. They do
not, however, give any indication ofthe ability of these drugs to kill the target
organism (Smith & Lewin, 1988). In order to determine the potency and
mechanism of bactericidal activity of the quinolones, a further series of
experiments was undertaken.
3.2.1. BactericidalActivity of the Quinolones. Lewin & Hastings (1990)
demonstrated that two fluoroquinolones in clinical use in humans,
ciprofloxacin and norfloxacin, were bactericidal against both oxolinic acid-
resistant and -susceptible isolates of A.salmonicida after 3h exposure. In
contrast, oxolinic acid was merely bacteriostatic under these conditions.
Therefore, the bactericidal activities of oxolinic acid and the seven
fluoroquinolones, sarafloxacin, enrofloxacin, CI934, PD127,391,
PD 117,596, Ro 09-1168 and flumequine, were examined against oxolinic
acid-susceptible and -resistant isolates ofA.salmonicida.
Isolate Oxolinic
acid
Sarafloxacin Enrofloxacin CI934 PD117,596 PD127,391 Ro 09-1168
MT363 0.03 0.05 0.015 0.40 0.015 0.0075 0.01
MT736 0.015 0.04 0.04 0.40 0.015 0.010 0.01
MT364 7.50 3.00 1.00 3.00 0.30 0.10 0.10
MT472 3.00 2.00 1.00 2.00 0.20 0.10 0.20
Table 17. MICs of the test 4-quinolones against A.salmonicida isolates used in
bactericidal activity experiments.
After lh exposure, neither oxolinic acid nor flumequine were bactericidal
with approximately 100% of the bacteria surviving at concentrations of up
to 100 times theMIC for the isolate. Furthermore, oxolinic acid was merely
bacteriostatic even after 6h exposure, with approximately 100% of the
bacteria surviving (figs. 13,14 & 15). In contrast, flumequinewasbactericidal,
killing 90% and >99% of the bacteria after 3h and 6h exposure respectively,
at concentrations above five times the MIC at 22°C (figs. 14 & 15).
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Figure 13. Bactericidal activity of oxolinic acid against A.salmonicida MT363
(left) and MT736 (right). Both isolates were oxolinic acid-susceptible.
Figure 14. Bactericidal activity of oxolinic acid (left) and flumequine (right)
against A.almonicida MT472 (oxolinic acid-resistant).
With the exception of CI934, the remaining fluoroquinolones were rapidly
bactericidal against oxolinic acid-susceptible isolates of A.salmonicida
MT363 (fig. 16) and MT736 (fig. 17). Less than 1% of the bacteria survived
at concentrations just above theMIC after lh exposure (table 17, figs. 16 &
17). CI934 was less bactericidal than the other fluoroquinolones as 90% of
the bacteria survived lh exposure to the drug. Sarafloxacin andenrofloxacin
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Figure 15. Bactericidal activity of flumequine against A.salmonicida MT363
(left) and MT736 (right). Both isolates are oxolinic acid-susceptible.
Figure 16. Bactericidal activity of fluoroquinolones against A.salmonicida
MT363 (oxolinic acid-susceptible).
appeared to be less active against oxolinic acid-resistant isolates MT364
(fig. 19) and MT472 (fig. 18), with 10% of the bacteria surviving after lh
exposure. However, PD 127,391, PD117,596 and Ro 09-1168 were as active
against the resistant isolate MT472 as they were against the two susceptible
isolates, killing > 99% of the bacteria (fig 18).
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Figure 17. Bactericidal acivity of fluoroquinolones against A.salmonicidu MT736
(oxolinic acid-susceptible).
Figure 18. Bactericidal activity of fluoroquinolones against A.salmonicida
MT472 (oxolinic acid-resistant).
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Figure 19. Bactericidal activity of fluoroquinolones against A.salmonicida
MT364 (oxolinic acid-resistant).
3.2.2. Optimum Bactericidal Concentrations (OBCs). One of the
characteristics ofthe fluoroquinolone antibiotics is theirbiphasic antibacterial
activity. The killing efficacy increases to a point known as the OBC after
which it decreases (refer to page 13).
OBCs Determined after 1 hour
Oxolinic acid Oxolinic acid
Susceptible Resistant
Drug MT363 MT736 MT472 MT364
CI934 1.50 0.90 ND ND
PD127,391 0.03 ND 1.00 ND
PD117,596 0.05 ND 1.50 ND
Enrofloxacin 0.90 0.90 5.00 ND
Sarafloxacin 1.50 1.50 5.00 ND
Ro 09-1168 0.30 ND ND ND
Table 18. Optimum Bactericidal Concentrations (OBCs, mg/1) of
fluoroquinolones. (ND = not determined).
OBCs were determined, where possible, for the quinolones from their
bactericidal curves (figures 13-19). The OBCs are presented in table 18. As
flumequine and oxolinic acidwere not bactericidal after lh their OBCs were
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not determined. The OBC ofenrofloxacin against the quinolone susceptible
isolates ofA.salmonicida, MT363 and MT736, and the quinolone resistant
isolate MT472, was approximately 5 times the respective MICs. On the
other hand, sarafloxacin had an OBC 30 times its MIC against MT363,
whereas the OBC of sarafloxacin against the resistant isolate MT472 was
merely 2.5 times its MIC. The three Parke-Davis compounds, PD127,391,
PD117,596 and CI934 had OBCs approximately 3 times their respective
MICs against the oxolinic acid-susceptible isolates (tables 17 & 18),
However, against the oxolinic acid-resistant isolate MT472, the OBCs of
PD 127,391 and PD117,596 were almost 10 times the MIC. The OBC ofRo
09-1168 was 30 times its MIC against the quinolone susceptible isolate
MT363.
3.2.3. Mechanism ofBactericidalAction ofThree Fluoroquinolones. All
4-quinolones, including the older examples oxolinic acid and nalidixic acid,
possess one mechanism of bactericidal action, termed mechanism A. The
fluoroquinolones, however, generally possess an additional mechanism of
action termed B or C (refer to page 13).
Figure 20. Bactericidal acivity of sarafloxacin, enrofloxacin and Ro 09-1168
against non-dividing A.salmonicida MT363 in PBS.
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Drug concentration mg/1 Drug concentration mg/1
Figure 21. Bactericidal activity of enrofloxacin in the absence of protein
synthesis (left) and RNA synthesis (right).
Drug Concentration mg/1 Concentration mg/1
Figure 22. Bactericidal activity of sarafloxacin in the absence of protein
synthesis (left) and RNA synthesis (right).
The previous experiments have demonstrated that the fluoroquinolones
enrofloxacin, sarafloxacin and Ro 09-1168 are rapidly bactericidal, killing
90->99% of oxolinic acid sensitive bacteria after lh exposure. In this study,
the antibacterial action of these quinolones against a) non-dividing bacteria,
b) bacteria where protein synthesis is prevented by chloramphenicol, and c)
bacteria in which the RNA synthesis has been terminated with rifampicin,



































Figure 23. Bactericidal activity of Ro 09-1168 in the absence of protein synthesis
(left) and RNA synthesis (right).
Sarafloxacin, enrofloxacin and Ro 09-1168 were all active against non
dividing bacteria (fig. 20) demonstrating that these drugs possess a second
mechanism ofbactericidal action in addition tomechanismA. Furthermore,
all three antibiotics showed only slightly reduced bactericidal activity in the
presence of either rifampicin or chloramphenicol (figs. 21, 22 & 23). This
suggests that the secondarymechanismofactionutilisedby these compounds
is mechanism B. Thus sarafloxacin, enrofloxacin and Ro09-1168 possess
both mechanisms A and B.
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3.3 MECHANISMS OF QUINOLONE RESISTANCE.
Almost half of the A.salmonicida isolates tested in this study were resistant
to oxolinic acid (table 15), according to the criteria proposed by Tsoumas et
al. (1989). It was, therefore, considered important to investigate resistance
to the 4-quinolones further in this species.
Oxolinic CI934 Saraflox Enroflox PD 117,596 PD 127,391
acid -acin -acin
Figure 24. Stability of resistance to 4-quinolones.
3.3.1.Stability ofquinolone resistance. It has been reported that resistance
of A.salmonicida to oxolinic acid is reduced after repeated passage on
tryptone soy agar medium (Tsoumas et al., 1989). After 10 successive
passages of 20 oxolinic acid resistant strains ofA.salmonicida on drug-free
TSA, there was a mean threefold decrease in the MIC of oxolinic acid.
However, no such decrease was observed for PD117,596, PD127,391 or
sarafloxacin, whereas a twofold decrease inMIC was noted for enrofloxacin
and CI934 (fig. 24). Despite the threefold decrease in MIC observed for
oxolinic acid, all strains are still classified as resistant by the criteria of
Tsoumas et al. (1989), thus the significance of such a small change must be
questioned.
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Range of mutation frequencies at:
Drug 5 x MIC 10 x MIC 20 x MIC
Oxolinic acid 3.3 x 10"9- 3.64 x 10"8 1.7 x 10~9- 6.5 x 10~8 <1.1 x 10"9- 3.2 x 10"8
Sarafloxacin <8.3 x 10"1-1.76x 10"8 <5.0 x 10"10 <5.0 x 1040
Enrofloxacin <5.0 x Iff10 <5.0 x 10"10 <5.0 x l0-t°
CI934 <6.7 x 10"1- 8.5 x 10"9 <5.0 x 10"10 <5.0 x lO40
PD117,596 <5.0 x 10"1-1.6 x 10 7 <5.0 x 10"10 <5.0 x 10"10
PD127,391 <5.0 x 10 2.9 x 10"7 <5.0 x 10'10 <5.0 x 10-1°
Flumequine 1.5 x 109- 2.0 x 108 <3.3 x lO10 <3.3 x 10-to
Oxytetracycline 1.27 x 10 -6.82 x 10"7 <6.7 x 10"1-7.8 x 10"8 <5.0 x 10"10
Table 19. Frequency of chromosomal mutation to resistance to the 4-quinolones
and oxytetracycline.
3.3.2. Frequency of Mutational Resistance to the 4-Quinolones and
Oxytetracycline. Mutation frequencies give some idea of the rate at which
resistance to a quinolone will develop during therapy as plasmid mediated
resistance to these drugs has not yet been identified (Lewin, Allen &Amyes,
1990; Courvalin, 1990). The frequencies at which five oxolinic acid-
susceptible strains of A.salmonicida mutated to develop resistance when
exposed to oxolinic acid, oxytetracycline and 6 fluoroquinolones were
determined at drug concentrations of 5, 10 and 20 times their respective
MICs (table 19). Mutants resistant to oxolinic acidwere isolated at 5,10 and
20 times the MIC at frequencies ranging from 109 to 10"8 (table 19).
Oxytetracycline resistant mutants were isolated at similar frequencies at 5
and 10 times the MIC. However, at 20 times the MIC, the mutation
frequency was less than 10"10, which was the limit of detection for this
experiment. For the 6 fluoroquinolones tested, the frequency at which
resistance developed at 10 and 20 times their respective MICs in all five test
strains was less than 1010(table 19). When enrofloxacin was used as the test
agent, no mutants were obtained at 5 times the MIC (table 19). Mutation
frequencies for the remaining fluoroquinolones varied between isolates
exposed to the drug at five times their MICs. Resistant mutants were
detected for three of the five isolates tested with sarafloxacin, one of the five
isolates with CI934, four of the five isolates with PD127,391, two of the five
isolates with PD117,596 and two of the five isolates with flumequine (table
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MT494 MT363 MT744 MT747 MT490
Oxolinic acid <3.3 x 10"8 3.64 x 10"8 1.05 x 10 s 3.33 x 10"9 2.19 x 10"8
Sarafloxacin <8.3 x 10~10 1.76 x 10 8 7.38 x 10"9 2.20 x 10"9 <1.25 x 10"9
PD117.596 <8.3 x 1040 <6.6 x 1040 <5.0 xlO40 1.63 x 10"7 3.75 x 104
CI934 <8.3 x 1040 <6.67 x 1040 8.5 x 10"9 <1.1 x 10"9 <1.25 x 10"9
PD127,391 <8.3 x 1040 3.42 x 10"7 1.83 x 10"8 1.31 x 10"7 2.93 x 10 "7
Enrofloxacin <8.3 x 1040 <6.67 x 1040 <5.0 x 1040 <1.1 x 10"9 <1.25 xlO"9
Flumequine 2.0 x 10~8 3.75 x 10"9 1.5 x 10'9 NT 1.0 x 10'9
Table 20. Mutation frequencies ofA.salmonicida isolates to 4-quinolones at 5x
their respective MICs
20). Resistantmutantswere selected only with flumequine forA.salmonicida
MT494 but notwith any of the fluoroquinolones tested.With the other four
strains tested, resistance was selected with one or more of the quinolones at
5 times their MIC (table 20).
The susceptibility of some of the quinolone resistant mutants isolated from
the mutation frequency experiments was examined.All of the isolates tested
were cross-resistant to the other quinolones, with an increase in MIC of
approximately 10 fold (table 21). Two of the oxolinic acid resistant isolates
selected from the mutation frequency experiments, AB174 & AB176
derived fromMT363 and MT744 respectively, were also cross-resistant to
oxytetracycline (table 21). These isolates were investigated further to
determine the reason for this.
3.3.3. Alterations in Outer Membrane Proteins Associated with Cross
Resistance BetweenOxytetracycline and OxolinicAcid. Previous work
has shown that low level resistance to antibiotics inA.salmonicida may be
associated with changes in outer membrane proteins (Wood et al., 1986;
Griffiths & Lynch, 1989). Wood et al. (1986) found that resistance to a wide
range of antibiotics including 4-quinolones, p-lactams and tetracycline was
associated with the appearance of a 37 kDa protein in the outer membrane.
Cross-resistance between oxolinic acid and oxytetracycline could have
serious implications for the aquaculture industry. Therefore, the cross
resistance between these two compounds in A.salmonicida observed in the




















































































Table 21. MICs of resistant mutants isolated during mutation frequency studies.
(Figures in parentheses indicate MICs of parent isolates).
Oxytetracycline resistant mutants were isolated on TSA containing
oxytetracycline at 5 times the MIC. The MICs of oxytetracycline for both
resistantmutants,AB174 andAB176, increased approximately 5-fold (table
21). Resistance was stable as ten repeated passages on drug free TSAhad no
effect on the MICs. When the susceptibility of these mutants to oxolinic acid
was examined, both were less susceptible to the 4-quinolone than their
respective parents (table 21). The MIC ofAB174 was increased by 30-fold
compared to its parent strainMT363, while the MIC ofAB 176 was increased
only threefold compared to its parentMT744 (table 21). Bothmutant strains
were also less susceptible to enrofloxacin and sarafloxacin, and the other
fluoroquinolones.
Outer membranes were prepared and the proteins were analysed by SDS-
PAGEonthePhastSystem®.ThePhastSystem®was calibrated for coomassie
staining by running a series of dilutions of a preparation of the OMPs of
A.salmonicida MT363 on a 12% polyacrylamide PhastGel®. It was found
that the optimum protein concentration for giving clear bands on this system
was 0.86 -1.30g/l (figure 25). Proteins were run against molecular mass
standards, the sizes of which are given in table 22.
Prior to analysing the resistant mutants, it was necessary to investigate both
quinolone sensitive isolates, and isolates bearing high level resistance to the
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Figure 25. Effect of protein concentration (g/1) on detection of OMPs of
A.salmonicida separated by SDS-PAGE using the PhastSystem®.
A.salmonicida (MICs given in table 23)were separated by the PhastSystem®
and are shown in figure 26. No differences in major proteins were observed
in the sensitive isolates examined. Furthermore, when the outer membrane
protein profiles of four A.salmonicida isolates exhibiting high level
resistance to the quinolones (MICs given in table 23) were analysed, no
differences between the major proteins were observed (figure 27)
Molecular Mass Standards (Da)
Phosphorylase B 94,000
Bovine Serum Albumin 67,000
Ovalbumin 43,000
Carbonic Anhydrase 30,000
Soybean Trypsin Inhibitor 20,100
a-Lactalbumin 14,400
Table 22. Molecular masses of standards run on PhastGels®.
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MICs (mg/1)
Isolate Oxolinic acid Sarafloxacin Enrofloxacin Oxytetracycline
MT363 0.03 0.05 0.015 0.20
MT199 0.20 0.15 0.15 0.30
MT350 0.04 0.05 0.02 40.00
MT736 0.015 0.04 0.04 100.00
MT494 0.03 0.05 0.02 30.00
MT744 0.03 0.05 0.015 0.30
MT491 0.04 0.075 0.05 0.30
MT340 0.75 0.50 0.15 NT
MT458 1.00 0.75 0.30 50.00
MT438 1.50 1.00 0.20 0.30
MT464 1.50 1.00 0.20 40.00
MT740 1.50 1.00 0.20 NT
MT475 3.00 2.00 0.75 NT
MT472 3.00 2.00 1.00 0.30
MT335 5.00 4.00 1.50 50.00
MT364 7.50 3.00 1.00 0.30
*NT = not tested.
Table 23. MICs of quinolone sensitive and resistant isolates ofA.salmonicida
used in OMP studies.
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Figure 27. OMP profiles ofA.salmonicida isolates with high level quinolone
resistance.
The outer membrane proteins of the resistant mutants and their respective
parents were then analysed by SDS-PAGE. Both mutants were found to
express an additional protein, molecularmass approximately 37 kDa, which
was not present in the parent strain (figure 28), or indeed, in any of the
sensitive isolates examined (figure 28). However, differenceswere observed
in the OMP profiles ofmutants AB174 and AB176. A 43 kDa protein which
was present inAB 176 as well as both wild-type strains could not be detected
in AB 174. The complete absence of this proteinmay explain why resistance
to oxytetracycline and oxolinic acid was higher in AB174 compared to
AB176.
It may be that the single OMP change observed in AB176, namely the
increased expression of the 37 kDa protein, is merely a single step towards
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Figure 30. PhastGel® showing proteins from AB176 which are non-covalently
associated with peptidoglycan (see text).
changes in the outer membrane profiles. In order to determine whether this
was the case, AB176 (1010 cfu/ml) was lawned onto TSA plates containing
oxolinic acid at 5 x the MIC. The plates were incubated for 7 days and
examined daily for the presence of resistant colonies. A resistant mutant
(AB202) was isolated and identified as described for the mutation frequency
experiments (section 2.5.2). The mutant isolate (AB202) was found to have
elevated MICs to the fluoroquinolones and oxytetracycline (table 24).
Furthermore, on analysis of the outer membrane proteins ofAB202, the 43
kDa protein, which was expressed in its parent, AB176, was not expressed
in AB202 (figure 29). This supports the idea that there may be two stages to
OMP associated fluoroquinolone resistance. A single change, the increase
in expression of a 37 kDa protein, which results in low level resistance to
quinolones and oxytetracycline. This change may be followed by a second

















MT363 0.03 0.20 0.04 0.02 0.30 0.20
AB174 1.50 40.00 0.30 0.10 0.75 1.00
MT744 0.03 0.20 0.04 0.02 0.30 0.20
AB176 0.10 0.75 0.20 0.10 0.75 1.00
AB202 1.50 40.00 0.30 0.10 0.75 1.00
Table 24. MICs of quinolones and unrelated antibacterials against A.salmonicida
OMP mutants.
Both the 37- and the 43-kDa proteins appeared to be non-covalently
associated with peptidoglycan as they both remained with the insoluble
peptidoglycan fraction after solubilisation with 2% (w/v) SDS at 37°C (fig
30). These proteins were, however, released from the peptidoglycan by
heating in 2% SDS at 100°C for 5 minutes. This suggests that these two
proteins may function as porins.
This proposal is supported by the observation that hydrophilic quinolones
such as nalidixic acid and oxolinic acid are affected more significantly by
these changes than the more hydrophobic fluoroquinolones such as
sarafloxacin, enrofloxacin, PD127,391 and PD117,596 (table 24). This is a
result of the reliance ofhydrophilic antibiotics on the porins for uptake into
the bacterial cell. Hydrophobic compounds can be taken up by other routes.
These phenomena are not solely laboratory artefacts. A number of
A.salmonicida isolates exhibiting low level resistance to quinolones were
screened for alterations associated with multiple antibiotic resistance. The
outermembranes are shown in figure 31 .A.salmonicidaMT464 (fig. 31, lane
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Figure 31. PhastGel® showing OMP changes in a wild-type isolate of
A.salmonicida exhibiting low level quinolone resistance.
6), an isolate exhibiting low-level resistance to oxolinic acid (MIC 1.00mg/
1), isolated from an outbreak of furunculosis at a Scottish salmon farm in
1989, demonstrated increased expression of a 37kDa protein. As discussed
previously, this protein is associated with decreased permeability to
antibacterials.
3.3.4 Probing for gyrA Mutations. High level quinolone resistance in
many pathogens is due predominantly to alterations in the a-subunit of the
target enzyme DNA gyrase, encoded by the gentgyrA (Lewin et al. 1991).
Two probes, pNJR 3,2 and pBP513 were used to determine whether gyrA
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mutations are prevalent in A.salmonicida isolates exhibiting high level
resistance to the quinolones.
Transformation was used as the method of introducing the probes into
A.salmonicida as the difficulty in separating the recipient A.salmonicida
isolates from a donor E.coli deemed conjugation unsuitable.
Parent Oxolinic Acid Kanamycin resistant
Isolate MIC (mg/1) isolate (MIC >20.0mg/l)
MT438 1.50 265, 266, 267
268
MT362 5.00 269, 270, 271
272, 273
MT487 5.00 274, 275, 277
279, 280, 281
Table 25. Kanamycin resistant isolates recovered from transformation
experiments.
In spite of numerous attempts, transformants were not obtained using
plasmid pNJR 3,2, either by the ice-cold calcium chloride technique of
Saunders & Saunders (1988), or by the protoplast transformation technique
ofChang and Cohen (1979). Indeed, no colonies resistant to the tetracycline
marker on the probewere isolated on the selective plates after 48h incubation.
Plasmid pNJR3,2 is quite large (23kb). Thus a smaller probe, pBP513, of
only lOkb was obtained. Using the ice cold calcium chloride technique of
Saunders & Saunders (1988), colonies resistant to kanamycin (the marker
on pBP513) were isolated after 48h incubation. The colonies were speciated
with a Bionor Mono AS latex bead agglutination kit and found to be
A.salmonicida. Minipreparations of plasmid DNA from these resistant
colonies was analysed on a 0.7% agarose gel. However, pBP513 was not
present in any of the resistant isolates (fig. 32 & table 25).
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Figure 32. Agarose gel electrophoresis of plasmid DNA from transformants.
Also shown is purified pBP513.
Furthermore, transformation of protoplasts by the method of Chang and
Cohen (1979) with pBP513 was also unsuccessful, as no kanamycin
resistant colonies were recovered.
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3.4. IN VITRO ACTIVITY OF THE POTENTIATED
SULPHONAMIDE ROMET.
Romet 30 is a potentiated sulphonamide comprising two antibiotics,
ormetoprim and sulphadimethoxine. Romet has been used for a number of
years in aquaculture and agriculture in the USA. It is now being considered
for use in aquaculture in the UK, thus the efficacy ofRomet was investigated
in vitro against Scottish isolates ofA.salmonicida.
3.4.1. Minimum Inhibitory Concentrations (MICs). The MICs of
ormetoprim and sulphadimethoxine were estimated in parallel with
trimethoprim, the prototype 2,4-diaminopyrimidine considered to be the
standard dihydrofolate reductase inhibitor. The results show that all of the
isolates were susceptible to ormetoprim at lmg/1 (table 26). Approximately
75% of the Scottish isolates of A.salmonicida were susceptible to
sulphadimethoxine at 16mg/l. Generally speaking, the trimethoprim
concentrations required to inhibit the bacteria were half that required by
ormetoprim. Examination of the MICs suggested that two main phenotypes
were prevalent, based on their resistance levels to ormethoprim and
sulphadimethoxine; a) Sensitivity to ormetoprim and sulphadimethoxine;




Ormetoprim 0.5 1.0 0.5 - 1.0
Sulphadimethoxine 16.0 >64.0 8.0 - >64.0
Trimethoprim 0.25 0.5 0.0625 - 0.5
Table 26. Range of MICs (mg/1) of dihydrofolate reductase inhibitors
3.4.2. Fractional Inhibitory Concentrations of Ormetoprim and
Sulphadimethoxine. Isolates of both phenotypes were taken for further
examination of the fractional inhibitory concentrations (FIC), 10 from
phenotype a, and 10 from phenotype b. The isolates within each group were
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distinct, based on their resistance profiles of oxytetracyline and oxolinic
acid. The FICs were determined at their points ofmaximum interaction (for
examples see figures 33 & 34) and the FIC index determined (table 27).
Isolate
MIC (mg/1) FIC FIC
IndexOrm Su Orm Su
MT491 0.75 12 0.083 0.166 0.25
MT199 1.00 12 0.125 0.166 0.29
MT328 0.75 6 0.083 0.33 0.41
MT495 0.50 6 0.125 0.33 0.46
MT489 0.75 12 0.083 0.166 0.25
MT736 1.00 12 0.062 0.166 0.23
MT494 0.75 8 0.083 0.25 0.33
MT321 1.00 16 0.125 0.125 0.25
MT496 0.75 6 0.083 0.33 0.41
MT350 1.00 8 0.062 0.25 0.31
MT320 0.75 >2048 0.5 <0.125 <0.625
MT427 0.75 2048 0.5 0.125 0.625
MT674 1.0 2048 0.5 0.187 0.687
MT448 0.75 2048 0.33 0.125 0.45
MT464 0.75 2048 0.5 0.187 0.687
MT757 0.75 2048 0.5 0.187 0.687
MT740 0.75 2048 0.33 0.125 0.45
MT741 1.00 768 0.187 0.33 0.52
MT350 1.00 2048 0.375 0.125 0.5
MT487 1.00 2048 0.25 0.125 0.375
Table 27. Fractional inhibitory concentrations of the component antibiotics of
Romet 30.
Amongst the 12 isolates which were sensitive to both ormetoprim and
sulphadimethoxine, the highestFIC indexwas 0.46. This value is considerably
lower than the value of 0.7, which is the accepted value associated with the
upper limit of synergy. In otherwords, the two drugs are actively interacting
with one another to produce potentiation. The highest FIC index for the eight
sulphadimethoxine resistant strains was 0.687. Although close to the upper
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Figure 33. Isobologram from which fractional inhibitory concentrations of
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Figure 34. Isobologram from which FICs of ormetoprim and sulphadimethoxine
were determined against A.salmonicida MT320 (Su-resistant).
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3.5 RESISTANCE OF AEROMONAS SALMONICIDA TO
AMOXYCILLIN.
Amoxycillin was licensed foruse inAtlantic salmon inScotland in September
1990. Potential resistance to this compound was therefore investigated.
3.5.1. In Vitro Activity of Amoxycillin Against Scottish Isolates of
A.salmonicida. In vitro activitywas assessed in terms ofminimuminhibitory
concentration against 80 isolates ofA.salmonicida. The isolates could be
divided into two phenotypes on the basis of their amoxycillin susceptibility;
thosewhichwere amoxycillin susceptible and thosewhichwere amoxycillin
resistant (table 28). MICs ofamoxycillin ranged between 0.30mg/l and 1.50
mg/1 against all of theA.salmonicida subsp. salmonicida tested. On the other
hand, all of the A.salmonicida. subsp. achromogenes isolates tested were
resistant to amoxycillin, having MICs in excess of 500mg/l.
A.salmonicida No. of Range of MICs MICso MIC90
subspecies isolates (mg/1) (mg/1) (mg/1)
salmonicida 71 0.30-1.50 0.30 0.50
achromogenes 9 >500.00 >500.00 >500.00
Table 27. Range of MICs of amoxycillin against A.salmonicida subspecies.
3.5.2. Mechanism ofAmoxycillin Resistance. The nine resistant isolates
were investigated further to characterize the nature ofthe observed resistance.
Crude extracts prepared from amoxycillin resistant isolates were examined
for p-lactamase activity by a nitrocefin spot test. All of the amoxycillin
resistant isolates produced a (3-lactamase enzyme (designatedASE-1).When
focused according to its isoelectric point, the enzyme focused into multiple
bands with the main band having a pi of approximately 8.0 (fig. 35).
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Figure 35. Polyacrylamide gel showing focused bands of ^-lactamases, including
ASE-1.
3.5.3. Spectrum of p-lactamaseActivity. The rate ofhydrolysis of a range
of (3-lactams was determined and compared to that of penicillin G. ASE-1
was found to hydrolyse ampicillin very rapidly, but had little activity against
either carbenicillin or cefotaxime (table 29).
3.5.4. Susceptibility to Augmentin. Clavulanic acid is a (3-lactamase
inhibitor frequently administered with amoxycillin in humanmedicine. The
combination (4:1 amoxycillin: clavulanate) is marketed as Augmentin. The
susceptibility of the achromogenes isolates to Augmentin was therefore
investigated. The MICs of the resistant isolates were significantly lower to
Augmentin than to amoxycillin. All the isolates hadMICs of amoxycillin in
excess of 500mg/l, whereas MICs ofAugmentin were 16.0 mg/1 (table 30).
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Relative rate of hydrolysis*
Enzyme pi Amp Carb CTX Reference
TEM-1 5.4 106 10 <1 Hedges et al. (1974)
SHV-1 7.6 212 8 0 Petroceilou et al. (1974)
LCR-1 6.5 145 4 Simpson et al. (1983)
NPS-1 6.5 223 18 <1 Livermore & Jones (1986)
PSE-2 6.1 267 121 16 Matthew (1978)
AER-1 5.9 38 98 20 Hedges et al. (1985)
ASE-1 8.0 182 3 0 This study
Amp, ampicillin; Carb, carbenicillin; CTX, cefotaxime.
*The rate of hydrolysis for Penicillin G = 100.
Table 29. Relative initial rates of hydrolysis of (3-lactamases.
3.5.5. Genetic Basis for Amoxycillin Resistance. During the plasmid
curing experiments, no matter what concentration of ethidium bromide
(EtBr) was used, the replica plates showed that there was never any loss of
resistance to amoxycillin. This strongly suggests that the (3-lactamaseASE-
1 is encoded on the bacterial chromosome. ASE-1 was inducible with 10mg/
1 cefoxitin, the induced form hydrolysing nitrocefin at a rate of0.227/pmole/
min/g ofprotein compared to 0.0017/pmole/min/g protein for the uninduced
form, a 163-fold increase in activity.
Range of MICs (mg/1)
No. of isolates Amoxycillin Augmentin
9 >500.0 16.0
Table 30. Range ofMICs of amoxycillin and Augmentin against A.salmonicida
subsp. achromogenes.
3.5.6. Conjugation with E.coli K12. Attempts to mobilise the gene(s)
expressing P-lactamase ASE-1 fromA.salmonicida were unsuccessful.
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3.6. A SEAWATER INFECTION CHALLENGE MODEL.
Groups of50Atlantic salmon post smolts were infectedwith a virulent Scottish
isolate ofA.salmonicida (MT879). Inocula of 1 x 104, 1 x 105 and 1 x 106 cfu/
ml were employed. Mortalities were removed daily andbacteriological samples














2 4 6 8 10 12 14 16 18 20 22
Days post infection
Figure 36. Cumulative mortalities resulting from furunculosis at three levels of
infection challenge: Curve 1 shows challenge with 106 cfu/ml A.salmonicida
MT879; curve 2 shows challenge with 10s cfu/ml; curve 3 shows challenge with
104 cfu/ml. Sea water temperatures over the challenge period are also shown.
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At seawater temperatures of around 14°C (fig. 36), fish challenged with the
highest concentration of A.salmonicida MT879 (106 cfu/ml) began dying 5
days post infection. Fish exposed to 105 or 104 cfu/ml began to die one day later.
Therewas a close relationship between infection challenge dose andmortalities:
mortality rates and total mortalities increased with exposure to increasing
numbers of A.salmonicida (fig. 36). At the end of the challenge period (22
days), cumulative mortalities reached 31.9%, 66.7% and 87.9% in populations
exposed to 1 x 104, 1 x 105 and 1 x 106 cfu/ml respectively. Pure cultures of
A.salmonicidawere reisolated fromall fish which died, confirming allmortalities
resulted from furunculosis.
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3.7. A PILOT IN VIVO EFFICACY STUDY ON ROMET 30.
A study into the in vitro efficacy of the potentiated sulphonamide Romet 30
(refer to chapter 3.4), suggested that this compound was active against
Scottish isolates of A.salmonicida. Previous work has demonstrated that
Romet is effective in trout in freshwater (Maestrone, 1984), but, as yet, no
data are available on the control of furunculosis in salmon with Romet.
These in vivo experiments were performed in a quarantined part of the
SOAFD facility at Aultbea, Wester Ross, containing predominantly fresh
water tanks but also some capable of being supplied with salt water. To
achieve disinfection during live disease agent trials, iodine is added to the
effluent water at a rate necessary to achieve a final concentration in the
settlement sump of 5ppm. The residence time in the sump is flow dependent
but not less than 30minutes. Granular iodine is contained in 15cm diameter,
1 metre long perspex columns connected to a freshwater supply. Iodine
concentration in the effluent of the columns has, at 100-150ppm, been
measured to be relatively independent of flow rate through the column in the
range 1-10 L/min (R. Johnstone, personal communication) as long as the
height of the column is maintained by frequent addition ofiodine. The output
of the column is matched to the outflow of the tanks requiring disinfection
in order to effect the required concentration. Previous experimentation by
the SOAFD staff had verified the efficacy of these disinfection procedures
under freshwater conditions only andunder themaximumpossible admixture
of salt to fresh water conditions (ca 1:10).
3.7.1. Efficacy Study; Phase 1. Three replicate efficacy trials were
performed.
Trial 1. Twenty-three days following exposure to A.salmonicida infection,
cumulative mortalities in the control (untreated) population reached 29.4%.
Bacteriological examination of dead fish indicated that 86.7% of the
mortalities (ie. 25.5% of the total untreated population) resulted from
furunculosis. During the same period, 2% of the fish in the populationwhich
had received a single five day oral treatment with Romet 30 died of
furunculosis (figure 37). However, 22 fish in the Romet treated group died
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from anoxia on day 18 when a sand-eel blocked the water supply inlet and
cut off the water supply to the tank.A.salmonicida was not isolated from any
of these fish, nor from one further fish found dead the next day.
Trial 2.Mortalities in the untreated population reached 32.6% after 23 days.
In the population which had received a single five day oral treatment with
Romet, 4% of the fish died during the same period (figure 38). Pure cultures
ofA.salmonicida were isolated from all fish which died.
Trial 3. A total of 39.6% of the control population died from furunculosis
within the 23 day period following exposure to water-borne A.salmonicida
infection. A further 3.9% mortality in this population was not attributable to
A.salmonicida infection. A total of 3.9% of the fish which received a single
treatment of Romet died within the same period (figure 39).
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Figure 37. Efficacy of Romet in controlling furunculosis in Atlantic salmon held
in sea water. Trial 1.
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Taking trials 1,2 and 3 together, 32.7% of fish in the untreated populations
died from furunculosis infection within the 23 day trial period. Cumulative
furunculosis mortalities in the populations which had been administered a
single five day oral treatmentwithRometwere 3.3% during the sameperiod.
The relative percentage survival of Romet treated fish compared with




Figure 38. Efficacy of Romet in controlling furunculosis in Atlantic salmon held
in sea water. Trial 2.
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3.7.2. Efficacy Study; Phase 2. During the following period in which trials
1,2 and 3 received a second five day oral treatment with Romet, the treated
populations suffered a total of 3.9% mortalities from furunculosis (an
additional 0.6% was not attributable to furunculosis). During the same
period, the corresponding control (untreated) populations suffered 9.3%
mortalities caused by furunculosis. The results of trials 1,2 and 3 are
summarised in figure 40.
Days post infection
Figure 39. Efficacy of Romet in controlling furunculosis in Atlantic salmon held
in sea water. Trial 3.
When surviving fish were sacrificed 30 days post initial infection,
A.salmonicida was isolated from7.7% of theRomet treated fish as compared
with 6.0% of the control fish (table 31). Thus the prevalence of detected
asymptomatic carriage of A.salmonicida amongst the surviving fish was




Figure 40. Cumulative mortalities due to furunculosis in Atlantic salmon held in
sea water following two 5-day oral treatments with Romet. Combined results of
trials 1,2 and 3.
Control
Trial 1 Trial 2 Trial 3 Total
Romet Control Romet Control Romet Control Romet Control
No. of survivors 27 33 45 28 45 22 117 83
No. of survivors in which 00 72 23 95
A.salmonicida detected
Percentage of survivors in 0 0 15.5 7.1 4.4 13.6 7.7 6.0
which A.salmonicida detected
Table 31. Detection of asymptomaticA.salmonicida infection in surviving fish.
3.7.3. Observations on the Palatability ofRomet. The feeding response of
the fishwas closelymonitored during oral administration ofRometmedicated
feed. Most, if not all, of the fish appeared to participate in feeding activity.
There was no evidence of spitting out or regurgitation of feed pellets, and all
of the medicated feed appeared to be taken each day.
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3.8. EFFICACY OF IODINE AS A SEAWATER DISINFECTANT.
The previously reported in vivo experiments were performed in a
quarantined part of the SOAFD experimental facility at Aultbea that
contained fresh and salt water tanks. Iodine (final sump concentration
5ppm) was added to the effluent during the experiment to effect disinfection
and the efficacy of this procedure has been verified by experiment. Site
modifications and improvements dictated that an additional and extended
series of seawater in vivo trials planned to be carried out towards the end of
this project be conducted in a new seawater only quarantine facility. During
its commissioning, however, the efficacy of iodine at the concentrations
previously used in fresh water, as a disinfectant in undiluted sea water, or sea
water/fresh water mixtures of around 1:10, was called into question. As a
result, the planned in vivo studies were not performed. Instead, some
preliminary investigations into the efficacy of iodine under sea water
conditions were undertaken.
3.8.1. Bactericidal Activity of Iodine in Sump Seawater. Iodine was
bactericidal in sump water, killing 99% of the bacteria after 20mins exposure
at a concentration of 8ppm (fig. 41). However at 4ppm, close to the iodine
concentration whichmay be achieved using a single column atAultbea, 10%
of the bacteria survived after 20 min (fig. 41).
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Figure 42. Bactericidal activity of iodine in artificial sea water.
3.8.2. Effect of Organic Load on Bactericidal Activity of Iodine. To
determine whether the bacterial survival was due to organic loading or
presence of free ions, the bactericidal acivity of iodine was investigated in
artificial seawater (i.e. same ion balance as seawater, but no organic








Figure 43. Bactericidal activity of iodine in effluent sea water with reduced
organic load.
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effluent seawater from Aultbea, with approximately 1% of the bacteria
surviving 20 mins exposure to iodine at 8ppm (fig. 42). This suggests that
any organic material in the seawater samples played little part in inhibiting
the efficacy ofiodine. To confirm this, the antibacterial activity ofiodine was
investigated in sump water with half the number of fish at half the normal
feed rate to decrease the organic loading. This seemed to reduce further the
bactericidal activity of iodine, with 10% of the organisms surviving even
after 20mins at 16ppm (fig. 43).
3.8.3. Effect of pH on Killing Efficacy of Iodine. It has been reported that
reduced pH can increase the disinfectant qualities of iodine. Thus the
bactericidal activity of iodine in seawater at normal pH (which was found
to be 7.20 on that day) was compared to activity in seawater with the pH
corrected to 4.00 with HC1. At pH 7.20, Iodine was able to kill 99% of the
initial inoculum (105 cfu/ml) after 20 mins exposure at 8ppm (fig. 44). At
pH4.00, less than 0.01% of the bacteria survived after 20 mins at 8ppm (fig
44).
Concentration (PPM)
Figure 44. Effect of reduced pH on the bactericidal activity of iodine.
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3.9. A POTENTIAL ALTERNATIVE TO INFECTION
CHALLENGES.
In light of the results of the study into the bactericidal efficacy of iodine in
undiluted seawater (section 3.8), in vivo efficacy studies involving infection
could no longer be undertaken safely atAultbea. Thus an alternative means
of evaluating the quinolones in Atlantic salmon was developed. Fish were
medicated and serum samples taken to determine the level of antibiotic in
the fish serum. These serum samples were then used in a bactericidal assay
against sensitive and resistant isolates of A.salmonicida to determine
whether the achieved antibacterial levels were sufficient to inhibit or kill
bacteria in the serum.
3.9.1. Serum Levels of Oxolinic Acid and Fluoroquinolones inAtlantic
Salmon. The concentrationofantibiotic required to inhibit themultiplication
of, or to kill, bacteria in vitro is a useful means of comparing antibiotics in
the laboratory. However, these results have little real meaning unless these
levels can be achieved in fish during therapy. The attainable serum levels of
oxolinic acid and four fluoroquinolones were therefore investigated in
Atlantic salmon smolts.
Serum samples, taken frommedicated fish, were analysed by bioassay with
seven standards for each three samples, in triplicate. Inhibition zone sizes for
samples and standards were read after 24 hours incubation at 22°C, and the
logarithm of the standard sample concentration was plotted against zone
diameter to give standard curves for each equation. Best fit polynomials
(logarithmic) were calculated for each plate using Cricket Graph ™ vl.3
(Cricket Software Inc., USA), and the concentrations of antibiotic in the
unknown serum samples were determined from these expressions (figs. 45-
49, tables 32 & 33).
Serum levels of oxolinic acid ranged between 0.47 and 1.04 mg/1. There did
not appear to be any particular pattern of serum level over the sampling
period (ie. 25 hours). Similar serum levels were achieved with flumequine,
and again, these were reasonably consistent over the sampling period. The
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Figure 45. Graphs (a) and (b). Oxolinic acid standards from which equations (a)
and (b) were derived.
Drug Concentration (mg/1) Drug Concentration (mg/1)
Figure 46. Graphs (c) and (d). Flumequine standards from which equations (c)
and (d) were determined.
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Figure 47. Graphs (e) and (f). Enrofloxacin standards from which equations (e)
and (f) were determined.
Figure 48. Graphs (g) and (h). Sarafloxacin standards from which equations (g)
and (h) were determined.
of 2.22 mg/1 observed 4 hours after the final feed. The level of enrofloxacin
appeared to fall over the 24 hour sampling period reaching approximately
0.5 mg/1 after 24h 45 min. Sarafloxacin was only detected in one of the
pooled serum samples. The serum levels of Ro 09-1168 were low, with a
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Drug Concentration (mg/1) Drug Concentration (mg/1)
Figure 49. Graphs (j) and (k). Ro 09-1168 standards from which equations (j)
and (k) were determined.
maximum level of 0.242 mg/1 recorded 24h 15min after the final feed. This
level, however, is in excess of theMICs recorded for all but themost resistant




Oxolinic acid 97 (a) y=16.263 + 13.856Log(x)
98 (b) y=16.708 + 15.676Log(x)
Flumequine 93 (c) y=10.867 + 12.495Log(x)
(d) y=9.1694+ 12.973Log(x)
Enrofloxacin 94 (e) y=12.901 + 12.756Log(x)
(f) y=15.073 + 12.653Log(x)
Sarafloxacin 95 (g) y=13.955 + 12.173Log(x)
(h) y=14.186 + 12.314Log(x)
Ro 09-1168 96 (j) y=23.490 + 12.464Log(x)
(k) y=21.626+ 12.91 lLog(x)






Mean Zone Size (mm)
Serum Level (mg/1)
(calculated from equation)
Pooll Pool 2 Pooll Pool 2
Oxolinic 97 4.40 12.33 15.00 0.520 (a) 0.811 (a)
acid 8.05 14.00 11.67 0.687 (a) 0.466 (a)
25.10 11.33 NT 0.466 (a) NT
98 3.05 NT 17.00 NT 1.044 (b)
7.50 13.33 15.66 0.609 (b) 0.857 (b)
24.05 12.33 14.00 0.526 (b) 0.672 (b)
Flumequine 93 4.25 10.67 10.00 0.964 (c) 0.852 (c)
8.55 10.00 10.33 0.852 (c) 1.229 (d)
25.00 10.00 11.33 1.467 (d) 1.159 (d)
Enrofloxacin 94 4.05 17.33 12.33 2.224 (e) 0.902 (e)
8.40 15.00 12.33 1.469 (e) 0.607 (f)
24.45 10.33 11.67 0.422 (f) 0.538 (f)
Sarafloxacin 95 3.45 9.00 10.67 ND (g) 0.537 (g)
8.30 9.00 9.00 ND (g) ND (h)
24.35 9.00 9.00 ND (h) ND (h)
Ro 09-1168 96 3.30 12.00 11.67 0.120 (j) 0.113 (j)
8.20 11.00 12.67 0.100 (j) 0.202 (k)
24.15 12.67 13.67 0.202 (k) 0.242 (k)
Table 33. Serum levels of antibiotics from pooled serum samples. Also shown
are sampling times and code letters for equations from which levels were
derived.
The pooled serum samples taken from fish medicatedwith Ro 09-1168 were
sent to Dr Theodore Graser of F Hoffman la-Roche, Basle, Switzerland for
analysis by High Pressure LiquidChromatography (HPLC). This assay was
performedwith 0.4ml sample aliquots. The limit ofquantificationwas 0.005
Serum Cone, (mg/1)
Sample Identification HPLC Bioassay
Tank 96 3h30min Pool 1 0.105 0.120
(Ro 09-1168) Pool 2 0.072 0.113
8h20min Pool 1 0.091 0.100
Pool 2 0.215 0.202
24hl5min Pool 1 0.123 0.202
Pool 2 0.115 0.242
Table 34. HPLC results determined for quinolone Ro 09-1168.
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mg/1. The results for serum levels of this drug were, in general, close to those
recorded by our bioassay technique (table 34). The exceptions were the
samples taken after 24.25h, forwhich the levels determined by HPLC were
approximately 50 % of the values determined by bioassay. The relatively
close correlation between the levels recorded by HPLC and by bioassay of
the other two groups of samples, however, suggests that these results are
acceptable.
Oxolinic
acid Sarafloxacin Enrofloxacin Flumequine Ro 09-1168
MT363 MIC (mg/1) 0.03 0.05 0.02 0.10 0.01
MT477 MIC (mg/1) 1.50 0.75 0.20 1.50 0.10
Concentration in 1.04 0.54 2.22 1.47 0.24
serum determined
by bioassay (mg/1)
Table 35. Concentration of quinolones in serum, and their respective MICs
against two isolates of A.salmonicida.
3.9.2. Bactericidal Activity of Quinolones in Fish Serum. The
bactericidal activity of the quinolones in the fish semm obtained from the
pharmacokinetic studies was investigated against A.salmonicida MT363
(oxolinic acid-susceptible) and MT477 (oxolinic acid-resistant).
Figure 50. Bactericidal activity of quinolones in fish serum against
A.salmonicida MT363 (oxolinic acid-susceptible).
Results 108
When the antibacterial activity of the quinolones was assayed against
MT363 (oxolinic acid-susceptible), the newer fluoroquinolones were rapidly
bactericidal (fig. 50). Ro 09-1168, enrofloxacin and sarafloxacin all reduced
the viable count to the limit of detection for this experiment (<10 cfu/ml for
sarafloxacin and enrofloxacin; <100 cfu/ml for Ro 09-1168) within the 6
hour period of the experiment at the concentrations attained in vivo in the
serum. Flumequine was less bactericidal, killing 90% of the bacteria after 6h
exposure, whereas oxolinic acid was merely bacteriostatic (fig. 50).
Time (hours) Time (hours)
Figure 51. Bactericidal activity of quinolones in fish serum against
A.salmonicida MT477 (oxolinic acid-resistant).
All the quinolones inhibited the growth of MT477 in serum (fig. 51).
Sarafloxacin appeared to inhibit the growth of the bacteria in spite of the fact
that the level of the drug in the serumwas lower than theMIC againstMT477
(table 35). Similarly the level of oxolinic acid in serum was lower than the
MIC against MT477 yet the antibiotic still inhibited growth to a degree,
(table 35, fig.51). The level of flumequine in serum was similar to the MIC
against this isolate and the drug was able to inhibit growth.
In contrast, the MIC of enrofloxacin was ten times the MIC against MT477,
yet the killing activity of the drug was very slight, even after 6 hours
exposure (table 35, fig.51). In a similarmanner, the concentration ofRo 09-
1168 in serum was 20 times the MIC, yet the bactericidal activity was
insignificant after 6 hours.
DISCUSSION
4.1. IN VITRO ACTIVITIES OF THE QUINOLONES.
Several quinolones have been evaluated as potential antibacterials for the
control of furunculosis in terms of minimum inhibitory concentration
(MIC), bactericidal activity and optimum bactericidal concentration (OBC).
4.1.1. Minimum Inhibitory Concentrations. The MICs of oxolinic acid
ranged between 0.01 and 15.0 mg/1. This range differed somewhat from that
reported by Tsoumas et al. (1989). In their study, oxolinic acid
susceptibilities ranged between 0.00012mg/l and 4.0 mg/1. Tsoumas et al.,
however, determined their MICs by a broth technique in microtitre wells.
This technique can lead to erroneous results as the quinolones cause
filamentation ofbacteria. The filamentation results in increased light scattering
by the cultures, normally associated with bacterial growth; however, the
viability of the culture, when determined on solid media, decreasesmarkedly
(Smith, 1984a). This phenomenon tends to lead to over-estimated MICs
rather than the low values determined by Tsoumas et al. (1989).
In a study in 1989, Tsoumas et al. divided their isolates into theree
categories, based on their oxolinic acid MICs. Those with an oxolinic acid
MIC > 1.0mg/l were deemed oxolinic acid resistant; those with an MIC
between 0.125 and 0.5 were deemed moderately susceptible; whilst those
with MICs < 0.0625 were deemed susceptible to oxolinic acid.
The isolates investigated in this study could be divided into two phenotypes
based on their oxolinic acid MICs: according to a simplified adaptation of
the criteria proposed by Tsoumas et al., (1989), those isolates with an MIC
less than 1.0mg/1were deemed oxolinic acid susceptible, those isolates with
MICs greater than or equal to 1.0 mg/1 were deemed oxolinic acid-resistant.
In our survey, 38 of the 83 isolates tested were resistant to oxolinic acid, that
is over 45% of these randomly selected isolates recovered predominantly in
1989. This is a higher percentage than that reported by Inglis et al. (1991),
who reported that 36.5% of their survey strains were oxolinic acid resistant.
However, their isolates were obtained from a limited number of sites with
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a narrow geographical distribution in Scotland. Furthermore, their survey
relied upon disc susceptibility testing as opposed to determination ofMICs,
and little indication of the criteria they used to define resistance to oxolinic
acid is given in their paper. This is particularly important as the relationship
between zone size and MIC is notwell defined. In a study in 1987, Hastings
& McKay related zones of inhibition to MICs of oxolinic acid resistant
isolates of A.salmonicida. They demonstrated that isolates with MICs
ranging between 1.25 and 5.0mg/l each gave a zone of inhibition of 15mm
around a 2pg oxolinic acid disk. Furthermore, 3 distinct isolates, each with
an MIC of 1.25mg/l gave inhibition zone diameters of 15, 20 and 22mm.
Thus it can be seen that disc susceptibility testing results do not necessarily
correlate precisely with MIC. In a study in 1987,0'Grady etal. found MICs
of oxolinic acid ranging between 0.012mg/l and 2.0mg/l in Irish isolates of
A.salmonicida. In contrast to the findings of Hastings and McKay (1987),
O'Grady et al. (1987) found reasonable correlation between MIC and Disc
susceptibility results when the semi-quantitativeKirby-Bauer disc technique
was employed.
In this study, the MICs of sarafloxacin related closely to those reported by
Stamm (1989). Sarafloxacin was slightly more active than oxolinic acid in
terms ofMIC against both oxolinic acid susceptible and resistant isolates of
A.salmonicida.
Enrofloxacin was also more active than oxolinic acid against susceptible
isolates, and was very much more active than oxolinic acid against oxolinic
acid resistant isolates. Bowser & House (1990) reported an MIC for
enrofloxacin of 100mg/l against a strain of A.salmonicida. However the
present study failed to find such high levels of enrofloxacin resistance in
Scottish isolates. This difference may reflect the different techniques used
to determine MICs (agar- as opposed to broth-dilution). Alternatively, their
strain may have been atypical of quinolone resistant A.salmonicida as
previous studies which determined MICs by broth dilution did not report
such elevated levels ofquinolone resistance (Bragg & Todd, 1988; Tsoumas
etal., 1989).
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Three of the fluoroquinolones tested were considerably more active than
oxolinic acid against both resistant and susceptible isolates. Ro 09-1168,
PD127,391 & PD117,596 were at least 10-15 times more active than
oxolinic acid against resistant and susceptible isolates. In contrast, CI934
was less active than oxolinic acid against oxolinic acid-susceptible isolates
ofA.salmonicida, and not significantly more active than oxolinic acid, in
terms ofMIC, against resistant isolates. Flumequine, was more active than
oxolinic acid against resistant isolates.
With the exception of sarafloxacin, the quinolones were less active in terms
of MIC at 10°C than at 22°C. This is in agreement with recent work by
Martinsen etal. (1992), who reported that theMICs ofquinolones at4°Cwere
1.3-1.5 times higher than those recorded at 15°C. As some of the quinolones
evaluated in the present study were bactericidal against non-dividing cells,
and against cells in which protein and RNA synthesis was inhibited, a
possible explanation of the increased MICs at lower temperatures is reduced
accumulation of the drug within the bacterial cells. These observations may
be significant, as Bowser & Babish (1991) reported that the bioavailability
of enrofloxacin was only 23% at 10°C compared to 43% at 15°C. These two
workers state that a drug must have a bioavailability of >30%, within the
temperature range in which it will be used, before it will be useful in
aquaculture. Unfortunately, they give no indication of how they calculate
this figure. In spite of this, Bowser et al. (1990) reported successful field
trials with enrofloxacin inwater temperatures ranging between 7°C and 10°C.
A method of increasing the bioavailability of quinolones has been reported
in cultured yellowtail and sea bream (Endo et al. 1987a, 1987b). Ultra fine
size reduction of oxolinic acid resulted in uptake of the drug, administered
by admixture with diet, increasing by 1.3 to 1.7 fold.
4.1.2. Effect ofSeawater Ions onAntibacterials. It has been reported that
the quinolones are susceptible to the effects of divalent cations (Smith &
Lewin, 1988). Indeed, in human medicine, the quinolone ciprofloxacin is
prescribed with strict instructions that milk and antacid compounds should
be avoided during therapy. Similarly, uptake ofoxytetracyline has also been
reported to be affected by multivalent ions (Jun & Lee, 1980; Lunestad &
Gokspyr, 1990)
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The sea has a complex and varied ion make-up. However, magnesium ions
may be present in concentrations in excess of 50mM in sea water of 35%o
salinity (Potts & Parry, 1964). The effect of this concentration of ions on
aquaculture antibacterials was therefore investigated. Not surprisingly the
MICs of the quinolones and oxytetracycline were increased by 20 to 30 fold
on Bacto marine agar, which contains 50mM magnesium chloride. This
effect appeared to result almost entirely from the presence of Mg2+, as
addition of 50mM MgCl2 to TSA had a similar effect, whereas addition of
340mM NaCl (concentration in Bacto marine agar) to TSA had no effect on
the MICs of the quinolones or oxytetracycline. Amoxycillin, and the
components of the potentiated sulphonamide Romet, ormetoprim and
sulphadimethoxine, were not affected by these concentrations ofMg2+ orNa+.
These observations may be clinically relevant. When sea water fish are
medicated with oxytetracycline or a quinolone, contact with sea water
cations is unavoidable. This occurs when the surface coated pellet is in the
water or in the gastrointestinal tract, as marine teleost fish are hypo-osmotic
and must continually drink sea water to compensate for water loss. For
example, Atlantic salmon maintained in sea water have been reported to
drink 129ml/kg/day sea water, while those kept in fresh water drink none at
all (Usher et al., 1988). Thus the inside of the gut of marine fish can be
envisaged as modified sea water.
In light of these results, susceptibility testing of marine fish pathogens may
be more accurately undertaken on Bacto marine agar, or medium prepared
with natural or synthetic seawater. Indeed, Lunestad and Gokspyr (1990)
recommended that media be prepared with 70% sea water, as considerable
underestimation of the levels of quinolone and oxytetracycline resistance
may occur when media are prepared without using sea water. Use of sea
water in media for susceptibility testing amoxycillin or potentiated
sulphonamides, however, would appear, from these results, to be less
important.
The problem of drug interaction with cations in sea water prior to entry into
the fish may partially be avoided by encapsulation of the antibiotic in feed
pellets such as aqualets® (Apothokernes LaboratoriumAS, Oslo, Norway).
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However, for the drug to be uptaken from the fishes' gut, it must be in the
liquid phase, thus interactionwith seawater ions at this stage is unavoidable.
4.1.3. Bactericidal Activity. In human medicine, it is often necessary
merely to inhibit the multiplication of a pathogen to enable the immune
system to dealwith the infection. Current treatment regimens for furunculosis
with the bacteriostatic drug oxolinic acidmay only save those fish which are
in early stages ofA.salmonicida infection. However, as a result of resistance
to both normal and immune serum (Munn & Tust, 1984), coupled with
cytotoxicity of A.salmonicida to macrophages (Olivier et al., 1992), the
immune system of the fish may be rapidly compromised rendering it unable
to control the diease. Thus a bactericidal antimicrobial may be of benefit
under these circumstances.
The quinolones are rapidly bactericidal against E.coli (Smith, 1984a).
However, it has been demonstrated that oxolinic acid is not bactericidal
against A.salmonicida (Lewin & Hastings, 1990). On the other hand, two
new fluoroquinolones, norfloxacin and ciprofloxacin were shown to be
rapidly bactericidal againstA.salmonicida (Lewin & Hastings, 1990). In the
present study, it was confirmed that oxolinic acid is merely bacteriostatic
against A.salmonicida after 6h exposure. However, the normal therapeutic
period for treatment with oxolinic acid is 10 days, during which the level of
oxolinic acid in the tissues should remain in excess of the MIC for sensitive
isolates, provided the treatment regimen is adhered to. It would be interesting,
therefore, to study the bactericidal activity of oxolinic acid over a longer
period of time.
Flumequine, a fluoroquinolonewhich was initially developed over 20 years
ago, was able to kill A.salmonicida in vitro after 3hours exposure.With the
exception of CI934, the remaining fluoroquinolones tested, sarafloxacin,
enrofloxacin, PD127,391, PD117,596 and Ro 09-1168, were rapidly
bactericidal against both oxolinic acid-susceptible and resistant isolates of
A.salmonicida, the activity being detected at concentrations just above the
MIC after 1 hour exposure. This bactericidal activity may be of use in
eliminating the asyptomatic carrier status ofA.salmonicida. In this context,
it is interesting to note that Scallan & Smith (1985) obtained promising
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results with flumequine in reducing carriers in salmon and trout, and
Markwardt & Klontz (1989b) had similar encouraging results with
sarafloxacin. It should be noted, however, that in the study ofMarkwardt &
Klontz (1989b), an artificial carrier status was induced by gastric intubation
(Markwardt & Klontz, 1989a). It is questionable how well this reflects the
carrier state in the natural situation.
MIC (mg/1) OBC (mg/1) Ratio
Antibacterial (a) (b) (b/a)
CI934 0.40 1.50 3.75
PD127,391 0.0075 0.03 4.00
PD117,596 0.015 0.05 3.33
Enrofloxacin 0.02 0.90 45.00
Sarafloxacin 0.05 1.50 30.00
Ro 09-1168 0.01 0.30 30.00
Table 36. Ratio of MICs and OBCs for fluoroquinolones against A.salmonicida
MT363 (oxolinic acid-susceptible).
4.1.4. Optimum Bactericidal Concentrations (OBCs). Optimum
bactericidal concentrations ranged from approximately three times theMIC
to as much as 45 times the MIC (table 36). OBCs have not been determined
against A.salmonicida previously, thus few comparisons can be drawn.
However, the ratio of OBC/MIC for the three Parke-Davis compounds,
PD127,391, PD117,596 and CI934, was very low compared to the other
fluoroquinolones tested here, and low compared with 4-quinolones tested
against other bacterial species (Smith, 1984a).
Optimum bactericidal concentrations could not be determined in every case
because of the nature of the technique used to assess bactericidal activity.
With extremely active compounds, even after dilution of the sample aliquots,
a sufficient concentration of antibiotic is carried onto the viable count plates
such as to continue killing the bacteria. Thus the curves can only be drawn
to a certain concentration above the MIC and the biphasic pattern is not
established.
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4.1.5. Mechanism of Action. The three fluoroquinolones investigated,
sarafloxacin, enrofloxacin and Ro 09-1168, were all active against a) non-
dividing bacteria, b) bacteria in which protein synthesis was inhibited, and
c) bacteria in which RNA synthesis was inhibited. This suggests that these
three antibiotics act through mechanism B in addition to mechanismA, the
latter being common to all quinolones. Mechanisms A and B appear to be
very closely related. MechanismApossibly represents reversible binding of
the drug to the DNA-DNA gyrase complex, while mechanism B may
represent irreversible binding of the drug to this complex (Lewinetal., 1991).
4.2. RESISTANCE TO THE QUINOLONES.
Almost half the isolates tested were resistant to oxolinic acid according to
the criteria used. Resistance to the quinolones was stable, as repeated
passage on drug-free TSAhad little effect on the MICs, any reduction being
less than that required to render the organism susceptible. This is in
agreement with the findings of Tsoumas et al. (1989), who reported that
MICs could be reduced by up to 2.5 fold by serial passages on drug free
medium. However, Tsoumas et al. (1989) concluded from their
observations that quinolone resistance was unstable, in spite of the fact that
the decrease in MIC did not render the isolates susceptible according their
own criteria.
Resistance to one quinolone tends to lead to a biochemical resistance, ie
elevatedMIC, to other quinolones as they all have a similar mode of action.
In this study, A.salmonicida isolates with elevated MICs of oxolinic acid
tended to have elevated MICs to the other fluoroquinolones. In practical
terms the significance of this phenomenon may be limited, as a slightly
elevatedMIC ofahighly active quinolonemay be insufficient to compromise
its therapeutic efficacy.
4.2.1. Frequency ofChromosomalMutation to Resistance.A.salmonicida
exposed to the fluoroquinolones tested at 5 times their respective MICs all
developed resistance at lower frequencies than to oxolinic acid. A previous
study by Stamm (1989) did not find this difference in mutation frequency
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between sarafloxacin and oxolinic acid. This discrepancy in results may be
explained by the 7-day incubation period employed in the present study
compared with only 48 hours incubation in the study by Stamm (1989), as
mutants resistant to oxolinic acid were rarely seen after 48 hours incubation.
The lower mutation frequencies of the fluoroquinolones combined with
their increased activity against A.salmonicida suggests that resistance to
these drugs may be less likely to developduring clinical use than to oxolinic
acid.
4.2.2. Resistance Resulting from Alterations in Outer Membrane
Proteins. Although there was some apparent variation in the relative
concentrations ofminor OMPs as revealed by SDS-PAGE, both quinolone-
sensitive and highly quinolone-resistant isolates ofA.salmonicida appeared
to have very similar major OMP profiles. However, the OMP profiles of
mutant strains exhibiting low-level resistance to quinolones, coupled with
cross resistance to oxytetracycline, had markedly different major OMPs.
The two cross resistant mutants isolated in this study had differing MIC
profiles: the oxolinic acid MIC ofAB174 was increased 30-fold compared
to its parent strain (MT363), while the oxolinic acid MIC ofAB 176 was only
increased 3-fold compared to its parent (MT744). Both of these mutants
were found to express an additional protein, molecular mass 37 kDa, which
was not present in the parent strains. However, AB174 did not express a 43
kDa protein which was expressed in its parent (MT363), in AB176, and in
all the highly resistant or susceptible isolates examined. The complete
absence of this protein inAB 174may explain why resistance to oxolinic acid
and oxytetracycline in this strain was higher than in mutant AB176 (See
below).
Both the 37 kDa and the 43kDa proteins were non-covalently associated
with peptidoglycan suggesting that they may function as porins (Darveau et
al. 1983). Indeed, Darveau et al. (1983) reported that a peptidoglycan
associated protein of approximately 42kDa functions as a porin in
A.salmonicida. The porin model is supported by the the observation that
hydrophilic antibiotics such as oxolinic acid and nalidixic acid, which rely
almost entirely on porins for their uptake, were affected to a greater extent
by the OMP changes than the more hydrophobic antibiotics sarafloxacin,
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enrofloxacin, amoxycillin and oxytetracycline, which may be taken across
the membrane barrier by other routes. It would therefore appear that these
two outermembrane proteins possibly play a role in antibiotic uptake in this
species, as this and other studies (Wood et al., 1986; Griffiths & Lynch,
1989) have found that alterations in these two proteins are associated with
changes in susceptibility to a wide range of drugs. These two porins may
operate in a similar manner to OmpF and OmpC mutants of E.coli K12.
Mutants lacking the OmpF porin (which possesses slightly larger pores),
retain the OmpC with its narrower channel, thereby decreasing the outer
membrane permeability (Nikaido, 1989). It is also intriguing to speculate
that, as these changes are pleiotropic, amutation in a regulatory gene similar
tomarAinE.coli (George & Levy, 1983; Cohen etal., 1988; Nikaido, 1989)
may be involved, rather than a gene encoding a specific porin.
This phenomenon of OMP associated cross-resistance is not solely a
laboratory phenomenon. Awild type isolate ofA.salmonicida, MT464, also
exhibited increased expression of the 37kDa protein. However, this is
probably not the sole cause ofoxytetracycline or quinolone resistance in this
isolate. The oxytetracycline MIC of 40mg/l is 40 fold higher than the
laboratorymutant (AB176) carrying the same mutation. Such high levels of
oxytetracycline resistance are likely to be plasmid mediated (Aoki, 1988;
Hedges et al., 1985b). Furthermore, the MIC of oxolinic acid for MT464
(1.50mg/l), although similar to that of AB174, is 15 times greater than that
ofAB176, themutant carrying the sameOMPalteration. Therefore, MT464
may also contain an alteration in DNA gyrase. This is supported by the
observation that, in other Gram-negative bacteria, resistance to the 4-
quinolones is often associated with alterations in both OMPs and DNA
gyrase (Aoyamaetal., 1987; Lewin, Allen & Amyes, 1990). Furthermore,
it has been shown in E.coli that mar mutants exhibiting reduced drug
accumulation can then mutate relatively easily to higher, clinically relevant
levels of quinolone resistance (Cohen et al., 1989).
Griffiths & Lynch (1989) reported that these outermembrane alterations are
often associated with a loss of protease activity. One may speculate,
therefore, that such isolates may be avirulent, as loss of virulence has been
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associatedwith protease deficiency (Sakai, 1985). However, the isolation of
a wild type A.salmonicida exhibiting such OMP changes from a clinical
outbreak of furunculosis in Scotland suggests that some of these isolates
may retain, or regain, their virulence.
The significance of this cross resistance phenomenon in the aquaculture
industry is considerable. In an industry where relatively few antibiotics are
licensed, a single mutation giving rise to resistance to all of them could have
serious implications.
4.2.3. Probing forAlterations in the GyraseA Subunit.Attempts to probe
for mutations in DNA gyrase in A.salmonicida were unsuccessful. It must
be noted however, that purification of plasmid DNA from A.salmonicida
appears to have been unsuccessful in several instances, thus we cannot tell
from figure 32whether the plasmid pBP513 is presentor not. It is impossible
to tell from the data generated in this study whether the problem with the two
gyrA probes was because the plasmids were not introduced into the cell, or
whether the plasmids were introduced but not expressed. Further work is
required to determine which of these two possibilities is the case. Either the
plasmids could be introduced by electroporation, which would determine
whether they were expressed, or, alternatively, the wild type E.coli gyrA
which is incorporated into both of the probes used could be cloned into an
A.salmonicida plasmid and introduced by transformation. Hopefully this
would reveal whether the transformation techniques employed in this study
were successful or not.
4.3. IN VITRO EFFICACY OF ORMETOPRIM AND
SULPHADIMETHOXINE.
4.3.1. MICs of the Two Components Determined Separately. MICs of
ormetoprim against A.salmonicida ranged between 0.5 and 1.0 mg/1. This
differed fromresults determined against Japanese isolates, whereAoki etal.
(1983) reported MICs ranging between 0.1 and 400mg/l in culture pond
isolates, and 1.6-12.5 mg/1 inriverisolates. In thepresent study, concentrations
of trimethoprim required to inhibitA.salmonicida were approximately half
the ormetoprim MICs. MICs of sulphadimethoxine 6.0mg/l and >2048mg/
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1. These values seem remarkably high when compared to theMICs of7 other
sulphonamides determined by McCarthy etal. (1974a). This may, ofcourse,
reflect the regular use of potentiated sulphonamides in Scottish aquaculture
since tribrissen was licensed in 1987.
4.3.2.Ormetoprim and sulphadimethoxine in combination. At the points
of maximum interaction of the two antibacterials, the FIC indices were
lower than 0.7, indicating potentiation of the two antibiotics. However, in
the cases of several of the sulphadimethoxine resistant isolates, the FIC
indices were very close to 0.7 at the point of maximum interaction. In the
case ofMT320, for example, the FIC index was greater than 0.7 ateither side
of the point of maximum interaction. This stresses the importance of
achieving the correct ratio of the drugs in vivo if potentiation of the drugs is
to occur where it is required. An important addition to this series of
experiments, therefore, would be to determine the levels of the two drugs
achieved in vivo when administered at the recommended dose.
4.4. IN VIVO STUDIES
4.4.1. A Laboratory SeaWater Infection ChallengeModel. A laboratory
infection challenge model for furunculosis inAtlantic salmonwas developed
in this study. The model, based on a water borne exposure toA.salmonicida
infection, was capable ofinducing significantmortalities due to furunculosis
in control fish. Exposure of fish toA.salmonicida at 1 x 104, 1 x 105, 1 x 106
cfu/ml resulted in 30%, 65% and 85%mortalities respectively. Our challenge
did not appear to be particularly reproducible, however, as a similar
challenge conducted during the investigation into the clinical efficacy of
Romet 30 did not result in such high mortalities. However, this is likely to
result from lower water temperatures and the use of larger fish in the second
study. A search of the literature has not revealed any other attempts at
furunculosis challenges in Atlantic salmon in seawater. There are, however,
numerous reports of bath challenges in Atlantic salmon, and other species,
in freshwater (Adams et al., 1987; McCarthy, 1983; Michel, 1980).
4.4.2. In Vivo Efficacy of the Potentiated Sulphonamide Romet. In
laboratory trials, a 5-day oral treatment with Romet 30 (50mg/kg/day i.e
15mg active drug/kg day) was found to be highly effective in controlling
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furunculosis in Atlantic salmon held in sea water. This dose rate was lower
than that employed for trout in the USA (50mg active agent/kg/
day)(Maestrone, 1984). There have been anecdotal reports of palatability
problems associated with Romet 30 in trout (D.Love, Pers.Comm). No
palability problems or adverse reactions to Romet 30 medicated feed using
the lower dose rate were observed during the trials inAtlantic salmon. At the
dose rate used, Romet 30 did not appear to be effective at reducing carrier
populations, as the prevalence of asymptomatic A.salmonicida infection
detected by bacteriological sampling among surviving fish was similar in
Romet treated and control (untreated) populations. A possible improvement
to this experiment would be to test the survivors according to the method of
McCarthy (1977). This technique involves intramuscular injection of
prednisolone acetate followed by elevation of thewater temperature to 18°C,
and has been reported to be the most effective means of identifying carrier
fish (McCarthy, 1977).
4.4.3. Efficacy of Iodine as a Sea Water Disinfectant. The in vivo
challenge model, and the clinical efficacy study into Romet 30, were
performed in the summer of 1990 and disinfectionwas effectedby iodination
ofeffluent seawatermixedwith fresh water at a ratio ofapproximately 1:10.
However, site modifications dictated that subsequent infection work be
carried out in a new sea water only quarantine facility. As the effectiveness
of iodination as a method for disinfection of undiluted effluent sea water is
not known, its antibacterial activity in the seawater at Loch Ewe under these
conditions was investigated.
Iodine was bactericidal in sea water, killing >90% of the bacteria at 4ppm
within 20min. However, in infection challenges, cell concentrations of 105
or 106 cfu/ml were used. If ten percent of these survive, then 104 or 105 cfu/
ml of a virulent fish pathogen would be discharged into the marine
environment. Thus a means of improving the disinfection needed to be
found before any further infection work could be undertaken.
Increasing the iodine concentration to 8ppm decreased the number of
survivors to 1%. However, in a challenge experiment, this would still mean
that 103 or 104 cfu/ml would remain viable. The problem did not appear to
result from the organic loading of the sea water as similar results were
obtained in artificial sea water, and effluent sea water with reduced fish
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numbers and lower feed rate. The iodine was therefore likely to be binding
to dissociated ions in the sea water, reducing its bactericidal efficacy.
Reduction of the pH of the sea water is a reasonably inexpensive process,
even on a large scale, by addition ofhydrochloric acid. Although this greatly
increased the bactericidal activity of iodine, 0.003% of the challenge still
remained viable. In the 105cfu/ml sea water challenge model, this would
mean that there was still a possibility of 30 organisms per ml remaining
viable. This may seem insignificant, however, lower numbers of a virulent
isolate of A.salmonicida can cause outbreaks of furunculosis (Dr D I
Mcintosh, personal communication). As a result of these findings, no further
sea water infection work was undertaken.
These experiments may not, however, fully reflect the situation in a
challenge in seawater tanks. Due to the hydrophobic nature ofA.salmonicida
(Munn &Trust, 1984) it is more likely to be associatedwithmicro algae, dirt
on tank or sump walls, in sediments, and in the lipid rich neuston at the
surface of the water. A more thorough approach, therefore, may involve
pumping effluentwater from the disinfectant sump through tanks containing
healthy fish during a challenge. Mortalities due to furunculosis would
indicate incomplete disinfection. Furthermore, surviving fish could be
stressed by the method of McCarthy (1977) to determine the percentage of
carriers. Negative results from such an experiment, coupled with the data
presented in the current study may provide further evidence on the safety of
infection experiments. Future seawater challenges could involve a similar
set up as a control.
Possible alternatives to iodine include chlorine, which is cheaper but there
are handling difficulties associated with its use. Small infection facilities
occasionally employ ozone fordisinfection purposes. This method, however,
is expensive and may not be suited to high rate flow-through conditions.
Bullock and Stuckey (1977) reported that doses ofUV light were capable of
killing 99.99% of bacteria including A.salmonicida in filtered freshwater,
and preventing the transmission of infection to Atlantic salmon. Their
systemwas capable ofhandling 56.8 litres/minofeffluentwater, asufficiently
large capacity to conduct amoderately scaled infection study. This technique
is worth further investigation.
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4.4.4. An in vivo Efficacy Study Not Requiring an Infection Model. A
potential alternative to infection models has been investigated in this study.
A series of pharmacokinetic studies followed by a study into the ability of
the drugs to kill the target pathogen in serum may give an indication of a
drugs potential efficacy in vivo without the necessity of an infection
challenge. Should infection models be required to backup these results, they
may be performed provided adequate dilution of sea water with fresh water
is effected prior to iodination.
The pharmacokinetic study was performed on a small scale, with limited
numbers of fish and only three time periods were sampled. This precluded
the calculation of an absorption rate constant. However, as a pilot study,
some information on the levels of quinolones attained in fish serum
following oral administration ofthe dmgs at certain dose rateswas determined.
Results were determined from serum pooled from several fish, and therefore
do not reflect variations between individual fish. Pooled samples were
employed to provide sufficient volumes for the bactericidal assays.
The highest level of oxolinic acid reached was between 0.8 and 1.0 mg/1
between 3 and5 hours after the final administration of feed. This differs from
previous results (Hustvedt^a/., 1991) which reported peak levels of l-3mg/
1 occuring 9-20 hours after administration. However, since samples were not
taken between 9 and 20 hours post administration in the present study, a peak
may have been missed at this time.
The highest serum concentrations of flumequine in this study ranged
between 1.16 and 1.47 mg/1, attained 25 hours after the final oral dose.
Sarafloxacin was only detectable in one of the serum samples, with a level
of 0.54 mg/1. This level corresponds with those determined by Abbott
Laboratories (L. Brown, Pers.Comm.) who reported levels between 0.3 and
0.5 mg/1 in serum.
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The highest serum levels recorded for the other fluoroquinolones were
varied. One of the pooled samples of serum from the fish treated with
enrofloxacin had 2.2 mg/1 of the drug present, however the level recorded
in the other pool sampled at the same time was less than half this amount.
In contrast, the serum concentration attained with Ro 09-1168 was very
much lower, peaking at 0.24 mg/1 after 24h 15min. The serum samples
obtained from the Ro 09-1168 medicated fish were sent to F. Hoffmann La-
Roche in Basle, Switzerland for validation byHPLC. The levels recorded by
HPLC were close to the results determined by bioassay in the present study,
supporting the validity of these results.
In this study, a level of enrofloxacin in excess of 2mg/l was detected in
serum. In a studyperformed in rainbow trout fingerling (Bowser etal. 1992),
apeak serum level of0.35 mg/1 was attained at the same dose rate (5mg/Kg/
day). Thismay reflectpooreruptake ofthe drug in rainbow trout.Alternatively,
as fewer fish were employed in this study, the results may not reflect the
general situation in a large population of fish. The serum concentrations
attained with enrofloxacin and Ro 09-1168 were well in excess of the MICs
of most of the isolates examined during this study. This is encouraging as,
at least in humans, quinolones tend to accumulate in the kidneys, urinary
tract and other tissues, rather than the serum (Bergan, 1988). Thus if the
levels in the serum are sufficient to inhibit A.salmonicida, the drug should
be effective in therapy.
As a study into the efficacy of the quinolones in vivo was not possible at this
stage of the study, the antibacterial activity of the serum samples obtained
from the pharmacokinetic study was investigated. The quinolones merely
inhibited the oxolinic acid resistant isolate, MT477. However, with the
exception of oxolinic acid, they were able to reduce significantly viable
numbers of a sensitive isolate ofA.salmonicida, MT363. Enrofloxacin, Ro
09-1168 and sarafloxacin were able to kill >99% of the bacteria within the
6 hour duration of the experiment. This is particularly significant if they are
to be used in the elimination of the asymptomatic carrier state of furunculosis.
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Based on a recent report by Cipriano (1992) which states that the pathogen
is more frequently isolated from the external mucus ofAtlantic salmon than
from the kidney or other internal organs of carrier fish, treatments based on
bathing may be more successful than oral therapy. In this context, O'Grady
et al. (1988) demonstrated that bath administration of flumequine to brown
trout and Atlantic salmon was effective both therapeutically and
prophylactically. This may not be so effective in seawater in light of the
antagonism of fluoroquinolones reported in the present study.
Further work on this technique needs to be undertaken to correlate the results
obtained here with true infection models, in order to verify how these serum
bactericidal assays relate to clinical efficacy. This type of model may have
future potential to reduce the need for infectious disease experiments for
humanitarian reasons, or where lack of suitable containment facilities
precludes the use of infection models.
4.5. AMOXYCILLIN RESISTANCE IN A.SALMONICIDA.
The MICs of amoxycillin against all theA.salmonicida subsp. salmonicida
isolates testedwere less than or equal to 1,5mg/l, whereas theA.salmonicida
subsp. achromogenes isolates tested were resistant, having MICs in excess
of 500mg/l.
Resistance to amoxycillin in the subsp. achromogenes appeared to result
from the production of a p-lactamase enzyme with a major band of pi 8.0.
This pi seems to be common amongst B-lactamases of the Aeromonas
species, as Bakken et al. (1988) reported three enzymes with this pi isolated
from A.sobria, three isolated from A.hydrophila, and one fromA.veronii.
In common with the enzymes isolated in the study Bakken et al. (1988), the
(^-lactamase in the present studywas highly inducible, hydrolysing nitrocefin
163 times faster when induced with cefoxitin, suggesting the enzyme is
chromosomally mediated. In contrast, however, the (3-lactamase activity
isolated in the present study was susceptible to clavulanic acid, as MICs of
amoxycillinwere greatly reduced in the presenceofthis compound. Although
this is characteristic of enzymes of plasmid origin, ASE-1 is likely to be
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chromosomally mediated as production of the enzyme was not affected by
ethidium bromide, a plasmid curing agent (Bouanchaud et al., 1969).
Chromosomal locationis supported by the inducibility, which is characteristic
ofchromosomally mediatedB-lactamase enzymes inGram-negative bacteria.
The substrate profile ofASE-1 was similar, within the limits ofexperimental
error, to SHV-1. A number of SHV enzymes have been identified, but all of
them have extended-spectrum activity against cefotaxime and ceftazidime
(Payne & Amyes, 1991). None of them match the pi or substrate profile of
ASE-1, thus this enzme is believed to be novel.
The existence of amoxycillin resistant strains ofA.salmonicida is cause for
concern in view of the recent introduction of this antibiotic for control of
furunculosis. However, resistance was only detected in the achromogenes
subspecies which has seldom, ifever, been associatedwith disease in farmed
salmonids in Scotland; nevertheless, this subspecies has caused outbreaks
of furunculosis at Canadian (Harmon etal., 1991) and Finnish salmon farm
sites (Rintamaki & Yaltonen, 1991). Furthermore, the (3-lactamase enzyme
responsible for resistance appears to be chromosomally mediated and is thus
unlikely to be transferred to the more prevalent salmonicida subsp., unless
it is borne on a transposon. This is unlikely as ASE-1 could not be mobilised
with the IncP plasmid R702. Itmust be stressd that further experimentation
involving alterations in the transfer protocol is required, as this route of
transfer is not completely ruled out in the limited scope of this experiment.
However, the use of amoxycillin may promote the selection of an increased
numberofoutbreaks ofdisease resulting from infection by the achromogenes
subsp. In addition, bearing in mind the plethora of transferable (3-lactamase
genes in environmental bacteria, caution should be excercised when using
amoxycillin in furunculosis therapy as the potential for selecting (3-
lactamase producing strains is still present.
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4.6 CONCLUDING OBSERVATIONS.
Aquaculture is an essential industry in Scotland, both as a source of
employment in rural areas, and as a valuable source of revenue. Furthermore,
the demand for high quality fish meat cannot continue to be fulfilled from
wild fish stocks. Indeed, severe measures are being imposed on most EEC
fisheries to limit the over-fishing of coastal and deep-sea fish stocks. Thus
the demand for fish must be supplied, at least in part, by farming.
The rapid growth of the farming industry has brought with it the problems
of disease. In Scottish salmon farming, a major problem is the bacterial
disease furunculosis. Effective commercial furunculosis vaccines are not
yet available thus the control of this disease is still largely dependent upon
the use of antibacterial compounds. Currently, Scottish salmon farmers are
faced with falling profits, increased disease problems, and an extremely
limited arsenal of chemicals with which to combat furunculosis.
This study has investigated the potential of a range of new drugs which are
being considered, or have recently been introduced for aquaculture use. In
vitro the quinolones are very active in terms ofMIC and bactericidal activity
against the causative agent of furunculosis, A.salmonicida . However, they
are adversely affected by the cations found in sea water, and to a lesser
degree by the low temperatures associated with Scottish sea lochs.
Nevertheless, reasonable levels can be attained in the serum, and these levels
were found to be bactericidal against susceptible isolates ofA.salmonicida
and inhibitory against a resistant isolate.
Resistance to the quinolones may develop by spontaneous chromosomal
mutation, which leads to either high level (possibly gyrA mediated)
resistance, or lower levelmultiple antibiotic resistancemediatedby alterations
in outer membrane proteins. The frequency of spontaneous mutation to
resistance to the fluoroquinolones, however, is much lower than that for
oxolinic acid.
Of the quinolones tested in this study, PD117,596, PD127,391 and CI934
have been withdrawn for potential human use. Enrofloxacin has been
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withdrawnbyBayer as themajormetabolite ofthe compound is ciprofloxacin
(Vancutsem et al., 1990), currently the largest selling quinolone in human
medicine. It is possible that the manufacturers are concerned about the
spread of resistance to ciprofloxacin into human pathogens, as there has
been a report of ciprofloxacin resistant Campylobacterjejeuni infections in
humans resulting fromchickens treatedwith enrofloxacin in the Netherlands
(Endtz et al., 1991).
The Roche quinolone, Ro 09-1168, is currently in the preliminary stages of
investigation and is being investigated for veterinary (this study) or human
(Shimma et al. 1991) use for the time being. Sarafloxacin is at an advanced
stage of the licensing process, and may gain full licensing for use in
aquaculture sometime this year (L. Brown, Pers. Comm.). Sarafloxacin is
potentially a better drug than oxolinic acid, as it is more active in terms of
MIC and bactericidal activity, and retains its activity in the absence of
protein andRNA synthesis, and against non-dividing cells. Furthermore, the
frequency of spontaneous chromosomal mutation to resistance to this
compound is significantly lower than for oxolinic acid. These benefits put
sarafloxacin in astrong position for aquaculture use. A disadvantage,
however, is presentedby the recentwithdrawal oftheAbbott fluoroquinolone
temafloxacin (Teflox) from clinical use in humans due to severe adverse
reactions (Pharmaceutical Journal 248: 768). Side effects included
hypoglycaemia, renal dysfunction, anaphylaxis and death. Although
quinolones have been widely used in human medicine for 25 years with no
severe adverse effects, the withdrawal ofTefloxmay create added difficulties
in the future licensing of fluoroquinolones.
The potentiated sulphonamide, Romet 30, has been used since 1984 in the
USA for the treatment of bacterial infections in salmonids (Meyer &
Schnick, 1989). A study in our laboratory demonstrated that the components
of this compound acted synergistically and were able to inhibit Scottish
isolates ofA.salmonicida in vitro. An in vivo trial conducted in this study
demonstrated that low dose treatment with Romet 30 was effective in
controlling a laboratory induced outbreak of furunculosis inAtlantic salmon
in seawater, though it had little effect on asymptomatic A.salmonicida
infection. It remains to be seen, however, whether this drug will provide an
improved alternative to Tribrissen.
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Amoxycillin was licensed for use in Scottish aquaculture in September
1990. In this study it has been shown that, as yet, high level (3-lactamase
mediated resistance to this compound only occurs in the atypical
A.salmonicida subsp. achromogenes. Although this subspecies causes
destructive fish kills in wild populations, it is rarely reported to cause
outbreaks of furunculosis in farmed fish in Scotland.
This study has evaluated a number ofpotential chemotherapeutic agents for
the control offurunculosis. Furtherwork is required, notmerely in the search
for new compounds, but also into the environmental impacts associatedwith
chemotherapy. Furthermore, to encourage the pharmaceutical companies to
develop their compounds for aquaculture use, agreement needs to be sought
among licensing authorities of fish farming nations to enable companies to
recoup the costs of obtaining product licences. Finally, good husbandry and
management strategies which reduce the prevalence of disease, and thus
minimise the requirement for antibiotics, will become increasingly necessary
if there is to be a future for Scottish aquaculture.
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APPENDIX
Appendix A. Culture collection: Aeromonas salmonicida isolates used in
this study. Appendix lists subspecies, host, year of isolation, and country of
origin. The source of isolates was the SOAFD Marine Laboratory, unless
otherwise stated.
Appendix B. Minimum inhibitory concentrations (MICs)(mg/l) of
antibiotics determined in this study against isolates ofA.salmonicida.
Strain Species Subspecies Year Host Country of Oriain
isolated
\B173 Aeromonas salmonicida salmonicida 1990 Lab mutant (parent
\B174 Aeromonas salmonicida salmonicida 1990 Lab mutant (parent
\B175 Aeromonas salmonicida salmonicida 1990 Lab mutant (parent
\B176 Aeromonas salmonicida salmonicida 1990 Lab mutant (parent
^B177 Aeromonas salmonicida salmonicida 1990 Lab mutant (Parent
\B178 Aeromonas salmonicida salmonicida 1990 Lab mutant (parent
^B179 Aeromonas salmonicida salmonicida 1990 Lab mutant (parent
\B180 Aeromonas salmonicida salmonicida 1990 Lab mutant (parent
^B181 Aeromonas salmonicida salmonicida 1990 Lab mutant (parent
\B182 Aeromonas salmonicida salmonicida 1990 lab mutant (parent MT490)
^B183 Aeromonas salmonicida salmonicida 1990 Lab mutant (parent
\B184 Aeromonas salmonicida salmonicida 1990 Lab mutant (parent
\B185 Aeromonas salmonicida salmonicida 1990 Lab mutant (parent
\B202 Aeromonas salmonicida salmonicida 1990 Lab mutant (parent AB176)
VB222 Aeromonas salmonicida salmonicida 1990 Lab mutant (parent SW Flumequine
\B223 Aeromonas salmonicida salmonicida 1990 Lab mutant (parent 490) SW Flumequine
\B224 Aeromonas salmonicida salmonicida 1990 Lab mutant (parent 740) sw flumequine
VB225 Aeromonas salmonicida salmonicida 1990 Lab mutant (parent 744) sw flumequine
Isolate C Aeromonas salmonicida salmonicida 1989 Atlantic salmon Abbott (UK)
Isolate C Aeromonas salmonicida salmonicida 1992 Passaged thro' Salmon Abbott (UK)
VIT004 Aeromonas salmonicida salmonicida 1978 Atlantic salmon, sea water Scotland (Unilever
MT1010 Aeromonas salmonicida salmonicida 1990 Atlantic salmon Norway
V1T1011 Aeromonas salmonicida salmonicida 1990 Atlantic salmon Norway
MT1012 Aeromonas salmonicida salmonicida 1990 Atlantic salmon Norway
V1T1013 Aeromonas salmonicida salmonicida 1990 Atlantic salmon Norway
WT1014 Aeromonas salmonicida salmonicida 1990 Atlantic salmon Norway
V1T1015 Aeromonas salmonicida salmonicida 1990 Atlantic salmon Norway
MT1016 Aeromonas salmonicida salmonicida 1990 Atlantic salmon Norway
VIT1017 Aeromonas salmonicida salmonicida 1990 Atlantic salmon Norway
MT1018 Aeromonas salmonicida salmonicida 1990 Atlantic salmon Norway
V4T1019 Aeromonas salmonicida salmonicida 1990 Atlantic salmon Norway
HT194 Aeromonas salmonicida achromogenes 1985 Atlantic salmon, seawater Scotland
HT199 Aeromonas salmonicida salmonicida 1985 Rainbow trout, freshwater Scotland
MT273 Aeromonas salmonicida achromogenes 1989 unknown Scotland
HT320 Aeromonas salmonicida salmonicida 1986 Atlantic salmon, seawater Scotland
HT321 Aeromonas salmonicida salmonicida 1986 Atlantic salmon, seawater Scotland
HT324 Aeromonas salmonicida salmonicida 1986 Atlantic salmon, seawater Scotland
tfT326 Aeromonas salmonicida salmonicida 1986 Atlantic salmon Scotland
Species Subspecies Year Host Country of Origin
isolated
MT328 Aeromonas salmonicida salmonicida 1986 Atlantic salmon Scotland
MT329 Aeromonas salmonicida salmonicida 1986 Atlantic salmon, Seawater Scotland
MT335 Aeromonas salmonicida salmonicida 1986 Atlantic salmon, seawater Scotland
MT336 Aeromonas salmonicida salmonicida 1986 unknown unknown
MT337 Aeromonas salmonicida salmonicida 1986 Unknown Scotland
MT340 Aeromonas salmonicida salmonicida 1987 Atlantic salmon Scotland
MT350 Aeromonas salmonicida salmonicada 1987 Atlantic salmon Scotland
MT361 Aeromonas salmonicida salmonicida 1987 Atlantic salmon Scotland
MT362 Aeromonas salmonicida Salmonicida 1987 Atlantic salmon, seawater Scotland
MT363 Aeromonas salmonicida salmonicida 1987 Atlantic salmon Scotland
MT364 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, sea water Scotland
MT366 Aeromonas salmonicida salmonicida 1986 Atlantic salmon, Seawater Scotland
MT367 Aeromonas salmonicida salmonicida 1987 Atlantic salmon, seawater Scotland
MT368 Aeromonas salmonicida salmonicida 1987 Atlantic salmon, seawater Scotland
MT404 Aeromonas salmonicida salmonicida 1987 Atlantic salmon Scotland
MT427 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT429 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT431 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT438 Aeromonas salmonicida salmonicida 1988 salmon parr Scotland
MT446 Aeromonas salmonicida salmonicida 1988 Salmon parr, freshwater Scotland
MT448 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT455 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT456 Aeromonas salmonicida salmonicida 1988 Atlantic salmon Scotland
MT458 Aeromonas salmonicida salmonicida 1988 Salmon pan- Scotland
MT459 Aeromonas salmonicida salmonicida 1988 Salmon pan- Scotland
MT460 Aeromonas salmonicida achromogenes 1988 Sea trout Scotland
MT461 Aeromonas salmonicida salmonicida 1988 salmon smolt Scotland
MT462 Aeromonas salmonicida salmonicida 1988 Salmon pan- Scotland
MT463 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT464 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT466 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT469 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT471 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT472 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT473 Aeromonas salmonicida achromogenes 1988 Atlantic salmon, seawater Scotland
MT474 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT475 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT476 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
Species Subspecies Year Host Country of Origin
isolated
MT477 Aeromonas salmonicida salmonicida 1987 Atlantic salmon, seawater Scotland
MT478 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT479 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT479 Aeromonas salmonicida achromogenes 1988 mature salmon, freshwater Scotland
MT481 Aeromonas salmonicida salmonicida 1988 Atlantic salmon Scotland
MT482 Aeromonas salmonicida achromogenes 1988 Mature salmon, freshwater Scotland
MT487 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT488 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT489 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT490 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT491 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, Sea Scotland
MT492 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT493 Aeromonas salmonicida salmonicida 1988 Atlantic salmon,seawater Scotland
MT494 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT495 Aeromonas salmonicida salmonicida 1988 Atlantic salmon, seawater Scotland
MT529 Aeromonas salmonicida achromogenes 1989 Atlantic salmon, sea water Scotland
MT533 Aeromonas salmonicida achromogenes(EL 1980 Atlantic salmon, seawater Iceland (B.
MT596 Aeromonas salmonicida unknown 1989 Mature salmon, freshwater Scotland
MT600 Aeromonas salmonicida salmonicida 1989 salmon pair Scotland
MT616 Aeromonas salmonicida salmonicida 152 6G 1 986 unknown:A -, no high Mw (D. Evenberg)
MT674 Aeromonas salmonicida salmonicida 1989 Salmon fry Scotland
MT675 Aeromonas salmonicida achromogenes 1989 Sea Trout, freshwater Scotland
MT728 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT729 Aeromonas salmonicida salmonicida 1989 Isolated from an unusual
MT730 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT731 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT732 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT733 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT736 Aeromonas salmonicida salmonicida 1989 Atlantic salmon,seawater Scotland
MT737 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT738 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT739 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT740 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, sea water Scotland
MT743 Aeromonas salmonicida salmonicida 1989 Salmon pan- Scotland
MT744 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT746 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, Seawater Scotland
MT747 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT748 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
Strain Species Subspecies Year Host Country of Origin
isolated
MT750 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT752 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT753 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT754 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT755 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT756 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland
MT757 Aeromonas salmonicida salmonicida 1989 Atlantic salmon, seawater Scotland














c v c 1 i n e
i A m o x
ciiiin
AB174 1.00 NT 0.40 0.15 NT 0.10 0.15 2.0 1.50 0.75
AB175 0.075 NT 0.20 0.075 NT 0.05 0.075 2.00 0.75 NT
AB176 0.10 NT 0.20 0.10 NT 0.05 0.15 2.00 1.00 1.00
AB177 1.00 NT 1.00 0.15 NT 0.05 0.15 2.00 0.50 NT
AB178 1.00 NT 1.00 0.15 NT 0.05 0.15 2.00 0.40 NT
AB179 0.04 NT 0.075 0.04 NT 0.075 0.075 1.00 1.50 NT
AB180 0.10 NT 0.30 0.15 NT 0.10 0.15 3.00 0.75 NT
AB181 0.10 NT 0.30 0.15 NT 0.10 0.15 2.00 0.75 NT
AB182 0.10 NT 0.30 0.15 NT 0.10 0.15 2.00 0.75 NT
AB183 1.00 NT 1.00 0.15 NT 0.05 0.15 3.00 0.40 NT
AB184 0.04 NT 0.075 0.04 NT 0.03 0.04 1.00 1.50 NT
AB185 0.10 NT 0.30 0.15 NT 0.10 0.15 3.00 1.00 NT
AB202 1.50 NT 0.30 0.10 NT NT NT NT 1.00 0.75
AB222 NTNT NT NT NT NT NT NT NT NT NT
AB223 NT NT NT NT NT NT NT NT NT NT
AB224 NT NT NT NT NT NT NT NT NT NT
AB225 NT NT NT NT NT NT NT NT NT NT
MT004 0.075 0.075 0.02 0.02 0.01 0.005 0.015 0.075 0.30 0.50
MT1010 NT NT NT NT NT NT NT NT NT NT
MT1011 NT NT NT NT NT NT NT NT NT NT
MT1012 NT NT NT NT NT NT NT NT NT NT
MT1013 NT NT NT NT NT NT NT NT NT NT
MT1014 NT NT NT NT NT NT NT NT NT NT
MT1015 NT NT NT NT NT NT NT NT NT NT
MT1016 NT NT NT NT NT NT NT NT NT NT
MT1017 NT NT NT NT NT NT NT NT NT NT
MT1018 NT NT NT NT NT NT NT NT NT NT
MT1019 NT NT NT NT NT NT NT NT NT NT
MT194 0.03 NT 0.01 0.005 0.01 0.002 0.004 0.20 0.30 >500.00
MT199 0.20 0.075 0.15 0.15 0.01 0.03 0.075 1.00 0.30 0.50
MT273 NT 0.075 NT NT NT NT NT NT 0.30 >500.00
MT320 7.50 0.75 1.50 0.40 NT 0.10 0.20 3.00 40.00 0.075
MT321 0.04 0.15 0.075 0.03 0.10 0.0075 0.015 0.50 40.00 0.50

















MT326 0.03 NT 0.075 0.02 NT 0.01 0.01 0.40 NT NT
MT328 7.50 NT 4.00 1.00 0.20 0.15 0.40 7.50 0.30 0.40
MT329 0.03 0.075 0.05 0.03 0.01 0.0075 0.015 0.50 50.00 0.50
MT335 5.00 NT 4.00 1.50 0.10 0.75 0.75 3.00 50.00 0.75
MT336 NT NT NT NT NT NT NT NT NT NT
MT337 NT 0.075 NT NT 0.01 NT NT NT 0.30 0.50
MT340 0.75 NT 0.50 0.15 NT 0.04 0.075 1.50 NT NT
MT350 0.04 0.075 0.05 0.02 0.01 0.0075 0.015 0.40 40.00 0.50
MT361 2.00 NT 0.75 0.20 0.10 0.04 0.075 4.00 150 0.50
MT362 5.00 NT 2.00 0.75 0.40 0.150 0.30 4.00 0.30 0.30
MT363 0.03 0.10 0.05 0.02 0.01 0.0075 0.015 0.40 0.20 0.30
MT364 7.50 0.75 3.00 1.00 0.01 0.10 0.30 3.00 0.30 0.50
MT366 0.03 NT 0.075 0.05 0.01 0.015 0.015 0.40 NT 0.30
MT367 NT NT NT NT NT NT NT NT NT NT
MT368 5.00 NT 4.00 1.50 NT 0.30 0.50 10.00 NT NT
MT404 NT 0.10 NT NT 0.01 NT NT NT 40.00 0.50
MT427 NT NT NT NT 0.075 NT NT NT 40.00 0.40
MT429 3.00 NT 2.00 0.50 0.01 0.10 0.20 7.50 30.00 0.40
MT431 5.00 2.00 2.00 1.00 0.20 0.15 0.30 3.00 0.30 0.40
MT438 1.50 NT 1.00 0.20 0.20 0.04 0.075 3.00 0.30 0.50
MT446 2.0 NT 0.20 0.05 NT 0.015 0.05 0.40 NT NT
MT448 NT 0.075 NT NT NT NT NT NT 40.00 0.50
MT455 0.03 0.10 0.075 0.02 0.01 0.01 0.01 0.40 30.00 0.75
MT456 0.03 0.10 0.075 0.03 0.01 0.01 0.015 0.50 40.0 0.50
MT458 1.00 NT 0.75 0.30 0.075 0.075 0.015 1.50 50.00 0.50
MT459 2.00 NT 1.50 0.30 0.10 0.075 0.10 2.00 0.30 0.50
MT460 0.40 0.075 0.30 0.04 0.01 0.015 0.05 1.50 0.30 >500.00
MT461 0.03 0.075 0.075 0.03 0.01 0.01 0.015 0.50 0.30 0.30
MT462 2.0 NT 1.00 0.20 0.075 0.04 0.075 3.00 100.00 0.30
MT463 10.00 NT 4.00 1.50 0.20 0.20 0.75 10.00 0.30 0.75
MT464 1.50 1.00 1.00 0.20 0.10 0.05 0.10 3.00 40.00 0.30
MT466 2.00 NT 0.75 0.20 0.075 0.04 0.10 3.00 75.0 0.50
MT469 NT 0.10 NT NT 0.01 NT NT NT 0.30 0.50











PD117. CI934 Oxvtetra Amox
596 cvcline cillin
MT472 3.00 NT 2.00 1.00 0.20 0.10 0.20 2.00 0.30 0.30
MT473 0.40 NT 0.20 0.15 0.01 0.075 0.05 0.75 0.30 >500.00
MT474 NT 0.075 NT NT NT NT NT NT 0.30 1.50
MT475 3.00 NT 2.00 0.75 NT 0.10 0.15 3.00 NT NT
MT476 2.00 NT 0.75 0.20 0.075 0.04 0.10 3.00 0.30 0.50
MT477 1.50 0.50 0.75 0.20 0.10 0.04 0.075 3.00 0.30 0.50
MT478 NT NT NT NT 0.01 NT NT NT NT NT
MT479 10.00 NT 4.00 1.00 0.20 0.10 0.75 7.50 0.30 0.40
MT479 NT 0.075 NT NT NT NT NT NT 0.30 >500.00
MT481 3.00 NT 2.00 0.75 NT 0.10 0.15 3.00 NT NT
MT482 0.01 0.075 0.02 0.003 NT 0.0075 0.015 0.15 0.30 >500.00
MT487 5.00 NT 2.00 1.00 0.10 0.10 0.20 2.00 0.30 0.50
MT488 NT 0.50 NT NT 0.075 NT NT NT 0.30 0.50
MT489 3.00 NT 1.50 0.30 0.20 0.10 0.15 3.00 0.30 0.50
MT490 0.03 0.075 0.04 0.02 0.01 0.0075 0.015 0.40 0.30 0.30
MT491 0.04 0.075 0.075 0.05 0.01 0.015 0.015 0.40 0.30 0.75
MT492 0.03 NT 0.075 0.02 NT 0.0075 0.0075 0.40 0.30 1.50
MT493 3.00 0.75 1.50 0.50 1.00 0.15 0.30 3.00 0.30 1.00
MT494 0.03 0.075 0.05 0.02 0.01 0.0075 0.015 0.40 30.00 0.30
MT495 0.03 0.075 0.04 0.02 0.01 0.0075 0.015 0.50 0.30 0.40
MT529 0.03 NT 0.015 0.0075 0.01 0.0075 0.003 0.15 NT >500.00
MT533 NT 0.075 NT NT 0.01 NT NT NT 0.30 >500.00
MT596 0.03 0.075 0.03 0.015 0.01 0.0075 0.015 0.40 0.30 0.40
MT600 0.03 NT 0.05 0.02 NT 0.01 0.01 0.40 NT NT
MT616 0.015 0.075 0.0075 0.004 NT 0.003 0.004 0.04 0.30 1.00
MT674 7.50 5.00 3.00 1.00 0.10 0.10 0.20 10.00 50.00 0.40
MT675 0.015 0.10 0.01 0.005 NT 0.005 0.005 0.30 0.30 >500.00
MT728 0.03 0.10 0.05 0.02 0.01 0.0075 0.015 0.40 0.30 0.50
MT729 0.40 NT 0.20 0.075 0.01 0.015 0.04 1.50 NT NT
MT730 0.04 0.075 0.05 0.02 0.01 0.0075 0.015 0.30 0.30 0.30
MT731 0.015 NT 0.03 0.03 0.01 0.0075 0.015 0.15 30.00 0.30
MT732 0.015 0.100 0.200 0.15 0.01 0.03 0.03 0.15 0.30 0.50
MT733 15.00 NT 1.00 0.50 0.50 0.15 0.20 3.00 40.00 0.30

















MT737 3.00 NT 2.00 0.75 NT 0.15 0.20 3.00 NT NT
MT738 0.03 0.10 0.075 0.02 NT 0.01 0.01 0.40 0.30 0.30
MT739 3.00 NT 1.50 0.50 0.30 0.10 0.15 3.00 0.30 0.30
MT740 1.50 NT 1.00 0.20 0.10 0.03 0.075 3.00 NT NT
MT743 0.03 0.075 0.075 0.02 0.01 0.01 0.01 0.40 75.0 0.50
MT744 0.03 0.075 0.05 0.015 0.01 0.0075 0.015 0.40 0.30 0.30
MT746 3.00 NT 2.00 0.75 NT 0.15 0.20 3.00 0.30 1.00
MT747 0.03 0.075 0.075 0.02 0.01 0.0075 0.015 0.40 0.30 0.50
MT748 0.03 0.10 0.03 0.02 0.01 0.0075 0.015 0.40 40.00 0.75
MT750 0.03 NT 0.05 0.02 0.01 0.0075 0.015 0.400 NT 0.40
MT752 NT NT NT NT NT NT NT NT 0.30 1.50
MT753 0.03 NT 0.05 0.02 NT 0.0075 0.01 0.40 NT NT
MT754 0.03 0.075 0.075 0.02 NT 0.01 , 0.01 0.40 40.00 0.30
MT755 4.00 NT 2.00 0.75 0.15 0.075 0.10 3.00 40.00 1.50
MT756 0.03 NT 0.04 0.02 0.01 0.0075 0.0075 0.30 NT 0.30
MT757 0.04 0.075 0.05 0.03 0.01 0.0075 0.015 0.50 30.00 0.40
MT879 7.50 5.00 5.00 0.50 0.10 NT NT NT NT NT
